<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td></td><td></td></tr>
<tr><td>Johnson & Johnson (NYSE:JNJ) Q3 2025 Earnings Call October 14, 2025 8:30 AM EDT<br><br>Company Participants<br><br>Darren Snellgrove - Vice President of Investor Relations<br>Joaquin Duato - CEO & Chairman<br>Joseph Wolk - Executive VP & CFO<br>Tim Schmid - Executive VP & Worldwide Chairman of MedTech<br>Jennifer Taubert - Executive VP & Worldwide Chairman of Innovative Medicine<br>John Reed - Executive Vice President of Innovative Medicine, R&D<br><br>Conference Call Participants<br><br>Alexandria Hammond - Wolfe Research, LLC<br>Danielle Antalffy - UBS Investment Bank, Research Division<br>Christopher Schott - JPMorgan Chase & Co, Research Division<br>Larry Biegelsen - Wells Fargo Securities, LLC, Research Division<br>Asad Haider - Goldman Sachs Group, Inc., Research Division<br>Shagun Singh Chadha - RBC Capital Markets, Research Division<br>Terence Flynn - Morgan Stanley, Research Division<br>Jayson Bedford - Raymond James & Associates, Inc., Research Division<br>Vamil Divan - Guggenheim Securities, LLC, Research Division<br>Matthew Miksic - Barclays Bank PLC, Research Division<br>David Risinger - Leerink Partners LLC, Research Division<br><br>Presentation<br><br>Operator<br><br>Good morning, and welcome to Johnson & Johnson's Third Quarter 2025 Earnings Conference Call.</td><td>ì¡´ìŠ¨ì•¤ë“œì¡´ìŠ¨(NYSE:JNJ) 2025ë…„ 3ë¶„ê¸° ì‹¤ì ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ 2025ë…„ 10ì›” 14ì¼ ì˜¤ì „ 8ì‹œ 30ë¶„ EDT<br><br>íšŒì‚¬ ì°¸ì„ì<br><br>ëŒ€ëŸ° ìŠ¤ë„¬ê·¸ë¡œë¸Œ - íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ë¶€ì‚¬ì¥<br>í˜¸ì•„í‚¨ ë‘ì•„í†  - CEO ê²¸ íšŒì¥<br>ì¡°ì…‰ ë³¼í¬ - ì „ë¬´ì´ì‚¬ ê²¸ CFO<br>íŒ€ ìŠˆë¯¸ë“œ - ì „ë¬´ì´ì‚¬ ê²¸ ë©”ë“œí…Œí¬ ì‚¬ì—…ë¶€ ê¸€ë¡œë²Œ íšŒì¥<br>ì œë‹ˆí¼ íƒ€ìš°ë²„íŠ¸ - ì „ë¬´ì´ì‚¬ ê²¸ í˜ì‹ ì˜ì•½í’ˆ ì‚¬ì—…ë¶€ ê¸€ë¡œë²Œ íšŒì¥<br>ì¡´ ë¦¬ë“œ - í˜ì‹ ì˜ì•½í’ˆ ì‚¬ì—…ë¶€ R&D ì „ë¬´ì´ì‚¬<br><br>ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ì„ì<br><br>ì•Œë ‰ì‚°ë“œë¦¬ì•„ í•´ë¨¼ë“œ - ìš¸í”„ ë¦¬ì„œì¹˜<br>ë‹¤ë‹ˆì—˜ ì•ˆíƒˆí”¼ - UBS ì¸ë² ìŠ¤íŠ¸ë¨¼íŠ¸ ë±…í¬, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>í¬ë¦¬ìŠ¤í† í¼ ì‡¼íŠ¸ - JPëª¨ê±´ ì²´ì´ìŠ¤, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë˜ë¦¬ ë¹„ê²”ì„¼ - ì›°ìŠ¤íŒŒê³  ì‹œíë¦¬í‹°ì¦ˆ, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì•„ì‚¬ë“œ í•˜ì´ë” - ê³¨ë“œë§Œì‚­ìŠ¤ ê·¸ë£¹, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ìƒ¤êµ° ì‹± ì°¨ë‹¤ - RBC ìºí”¼í„¸ ë§ˆì¼“ì¸ , ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>í…Œë ŒìŠ¤ í”Œë¦° - ëª¨ê±´ìŠ¤íƒ ë¦¬, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì œì´ìŠ¨ ë² ë“œí¬ë“œ - ë ˆì´ëª¬ë“œ ì œì„ìŠ¤ ì–´ì†Œì‹œì—ì´ì¸ , ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë°”ë°€ ë””ë°˜ - êµ¬ê²í•˜ì„ ì‹œíë¦¬í‹°ì¦ˆ, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë§¤íŠœ ë¯¹ì‹ - ë°”í´ë ˆì´ì¦ˆ ë±…í¬, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë°ì´ë¹„ë“œ ë¦¬ì‹±ì–´ - ë¦¬ë§í¬ íŒŒíŠ¸ë„ˆìŠ¤, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br><br>ë°œí‘œ<br><br>ì˜¤í¼ë ˆì´í„°<br><br>ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ. ì¡´ìŠ¨ì•¤ë“œì¡´ìŠ¨ì˜ 2025ë…„ 3ë¶„ê¸° ì‹¤ì ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤.</td></tr>
<tr><td>[Operator Instructions] This call is being recorded. [Operator Instructions]<br><br>I will now turn the conference call over to Johnson & Johnson. You may begin. Darren Snellgrove<br>Vice President of Investor Relations<br><br>Hello, everyone. This is Darren Snellgrove, Vice President of Investor Relations for Johnson & Johnson. Welcome to our 2025 third quarter review of business results and updated financial outlook. First, a few logistics. As a reminder, today's presentation and associated schedules are available on the Investor Relations section of the Johnson & Johnson website at investor.jnj.com.</td><td>[ìš´ì˜ì ì•ˆë‚´] ì´ í†µí™”ëŠ” ë…¹ìŒë˜ê³  ìˆìŠµë‹ˆë‹¤. [ìš´ì˜ì ì•ˆë‚´]<br><br>ì´ì œ ì»¨í¼ëŸ°ìŠ¤ ì½œì„ Johnson & Johnsonìœ¼ë¡œ ë„˜ê²¨ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì‹œì‘í•˜ì…”ë„ ë©ë‹ˆë‹¤.<br><br>ëŒ€ëŸ° ìŠ¤ë„¬ê·¸ë¡œë¸Œ(Darren Snellgrove)<br>íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ë¶€ì‚¬ì¥<br><br>ì•ˆë…•í•˜ì„¸ìš”, ì—¬ëŸ¬ë¶„. ì €ëŠ” Johnson & Johnsonì˜ íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ë¶€ì‚¬ì¥ ëŒ€ëŸ° ìŠ¤ë„¬ê·¸ë¡œë¸Œì…ë‹ˆë‹¤. 2025ë…„ 3ë¶„ê¸° ì‚¬ì—… ì‹¤ì  ê²€í†  ë° ì—…ë°ì´íŠ¸ëœ ì¬ë¬´ ì „ë§ì— ëŒ€í•œ ë°œí‘œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. ë¨¼ì € ëª‡ ê°€ì§€ ì•ˆë‚´ì‚¬í•­ì„ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì°¸ê³ ë¡œ ì˜¤ëŠ˜ì˜ í”„ë ˆì  í…Œì´ì…˜ê³¼ ê´€ë ¨ ìë£Œë“¤ì€ Johnson & Johnson ì›¹ì‚¬ì´íŠ¸ì˜ íˆ¬ìì ê´€ê³„ ì„¹ì…˜ì¸ investor.jnj.comì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Please note that this presentation contains forward-looking statements regarding, among other things, the company's future operating and financial performance, market position and business strategy. You are cautioned not to rely on these forward-looking statements, which are based on the current expectations of future events using the information available as of the date of this recording and are subject to certain risks and uncertainties that may cause the company's actual results to differ materially from those projected.</td><td>ë³¸ ë°œí‘œì—ëŠ” íšŒì‚¬ì˜ í–¥í›„ ì˜ì—… ë° ì¬ë¬´ ì„±ê³¼, ì‹œì¥ ì§€ìœ„, ì‚¬ì—… ì „ëµ ë“±ì— ê´€í•œ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì´ í¬í•¨ë˜ì–´ ìˆìŒì„ ì•Œë ¤ë“œë¦½ë‹ˆë‹¤. ì´ëŸ¬í•œ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì€ ë³¸ ë…¹ì·¨ë¡ ì‘ì„±ì¼ í˜„ì¬ ì´ìš© ê°€ëŠ¥í•œ ì •ë³´ë¥¼ ë°”íƒ•ìœ¼ë¡œ í–¥í›„ ì‚¬ê±´ì— ëŒ€í•œ í˜„ì¬ì˜ ê¸°ëŒ€ì— ê·¼ê±°í•œ ê²ƒìœ¼ë¡œ, íšŒì‚¬ì˜ ì‹¤ì œ ê²°ê³¼ê°€ ì˜ˆìƒê³¼ í¬ê²Œ ë‹¤ë¥¼ ìˆ˜ ìˆëŠ” íŠ¹ì • ìœ„í—˜ê³¼ ë¶ˆí™•ì‹¤ì„±ì´ ì¡´ì¬í•˜ë¯€ë¡œ ì´ëŸ¬í•œ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì— ì˜ì¡´í•˜ì§€ ë§ˆì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>A description of these risks, uncertainties and other factors can be found in our SEC filings, including our 2024 Form 10-K, which is available at investor.jnj.com and on the SEC's website. Additionally, several of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges those relationships. Moving to today's agenda. Joaquin Duato, our Chairman and CEO, will discuss our business performance and growth drivers. I will then review the third quarter sales and P&L results.</td><td>ì´ëŸ¬í•œ ìœ„í—˜ìš”ì†Œ, ë¶ˆí™•ì‹¤ì„± ë° ê¸°íƒ€ ìš”ì¸ë“¤ì— ëŒ€í•œ ì„¤ëª…ì€ investor.jnj.comê³¼ SEC ì›¹ì‚¬ì´íŠ¸ì—ì„œ í™•ì¸í•  ìˆ˜ ìˆëŠ” 2024ë…„ Form 10-Kë¥¼ í¬í•¨í•œ ë‹¹ì‚¬ì˜ SEC ì œì¶œì„œë¥˜ì—ì„œ ì°¾ì•„ë³´ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë˜í•œ ì˜¤ëŠ˜ ë…¼ì˜ë˜ëŠ” ì—¬ëŸ¬ ì œí’ˆê³¼ í™”í•©ë¬¼ë“¤ì€ ì „ëµì  íŒŒíŠ¸ë„ˆì™€ì˜ í˜‘ë ¥ì„ í†µí•´ ê°œë°œë˜ê±°ë‚˜ ë‹¤ë¥¸ íšŒì‚¬ë¡œë¶€í„° ë¼ì´ì„ ìŠ¤ë¥¼ ë°›ì€ ê²ƒë“¤ì…ë‹ˆë‹¤. ì´ ìŠ¬ë¼ì´ë“œëŠ” ê·¸ëŸ¬í•œ ê´€ê³„ë“¤ì„ ëª…ì‹œí•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì˜¤ëŠ˜ì˜ ì•ˆê±´ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ë‹¹ì‚¬ì˜ íšŒì¥ ê²¸ CEOì¸ í˜¸ì•„í‚¨ ë‘ì•„í† (Joaquin Duato)ê°€ ì‚¬ì—… ì„±ê³¼ì™€ ì„±ì¥ ë™ë ¥ì— ëŒ€í•´ ë§ì”€ë“œë¦´ ì˜ˆì •ì´ë©°, ì´í›„ ì œê°€ 3ë¶„ê¸° ë§¤ì¶œ ë° ì†ìµê³„ì‚°ì„œ ê²°ê³¼ë¥¼ ê²€í† í•´ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Joe Wolk, our CFO, will then close by sharing an overview of our cash position and capital allocation priorities, followed by additional details on our intended separation of the Orthopaedics business. He will also provide an update on 2025 guidance, key milestones and qualitative considerations for 2026. Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine; John Reed, Executive Vice President, Innovative Medicine Research and Development; and Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech, will be joining us for Q&A. To ensure we provide enough time to address your questions, we anticipate the webcast will last approximately 60 minutes.</td><td>ì €í¬ CFOì¸ Joe WolkëŠ” í˜„ê¸ˆ í¬ì§€ì…˜ê³¼ ìë³¸ ë°°ë¶„ ìš°ì„ ìˆœìœ„ì— ëŒ€í•œ ê°œìš”ë¥¼ ê³µìœ í•˜ë©° ë§ˆë¬´ë¦¬í•˜ê³ , ì´ì–´ì„œ ì •í˜•ì™¸ê³¼ ì‚¬ì—…ë¶€ ë¶„ë¦¬ ê³„íšì— ëŒ€í•œ ì¶”ê°€ ì„¸ë¶€ì‚¬í•­ì„ ì œê³µí•  ì˜ˆì •ì…ë‹ˆë‹¤. ë˜í•œ 2025ë…„ ê°€ì´ë˜ìŠ¤, ì£¼ìš” ë§ˆì¼ìŠ¤í†¤ ë° 2026ë…„ ì •ì„±ì  ê³ ë ¤ì‚¬í•­ì— ëŒ€í•œ ì—…ë°ì´íŠ¸ë„ ì œê³µí•  ê²ƒì…ë‹ˆë‹¤. í˜ì‹ ì˜ì•½í’ˆ ì‚¬ì—…ë¶€ ì „ì„¸ê³„ íšŒì¥ ê²¸ ë¶€ì‚¬ì¥ì¸ Jennifer Taubert, í˜ì‹ ì˜ì•½í’ˆ ì—°êµ¬ê°œë°œ ë¶€ì‚¬ì¥ì¸ John Reed, ê·¸ë¦¬ê³  ë©”ë“œí…Œí¬ ì‚¬ì—…ë¶€ ì „ì„¸ê³„ íšŒì¥ ê²¸ ë¶€ì‚¬ì¥ì¸ Tim Schmidê°€ Q&A ì„¸ì…˜ì— í•¨ê»˜ ì°¸ì—¬í•  ì˜ˆì •ì…ë‹ˆë‹¤. ì—¬ëŸ¬ë¶„ì˜ ì§ˆë¬¸ì„ ì¶©ë¶„íˆ ë‹¤ë£° ìˆ˜ ìˆëŠ” ì‹œê°„ì„ í™•ë³´í•˜ê¸° ìœ„í•´ ì›¹ìºìŠ¤íŠ¸ëŠ” ì•½ 60ë¶„ê°„ ì§„í–‰ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤.</td></tr>
<tr><td>With that, I will now turn the call over to Joaquin. Joaquin Duato<br>CEO & Chairman<br><br>Thank you, Darren, and hello, everyone. We are looking forward to sharing our very strong third quarter results with you. They are a clear sign Johnson & Johnson is in a powerful new era of growth. The success of our portfolio and pipeline is proof that our relentless focus on innovation is doing more than fueling progress. It is accelerating it. In the third quarter, we delivered operational sales growth of 5.4% across our business. In Innovative Medicine, we reported 5.3% operational sales growth and a second consecutive quarter of sales of more than $15 billion.</td><td>ì´ì œ í˜¸ì•„í‚¨ì—ê²Œ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>í˜¸ì•„í‚¨ ë‘ì•„í† <br>CEO ê²¸ íšŒì¥<br><br>ëŒ€ëŸ°, ê°ì‚¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—¬ëŸ¬ë¶„ ì•ˆë…•í•˜ì„¸ìš”. ë§¤ìš° ê°•ë ¥í•œ 3ë¶„ê¸° ì‹¤ì ì„ ì—¬ëŸ¬ë¶„ê³¼ ê³µìœ í•˜ê²Œ ë˜ì–´ ê¸°ëŒ€ê°€ í½ë‹ˆë‹¤. ì´ë²ˆ ì‹¤ì ì€ Johnson & Johnsonì´ ê°•ë ¥í•œ ìƒˆë¡œìš´ ì„±ì¥ ì‹œëŒ€ì— ì§„ì…í–ˆë‹¤ëŠ” ëª…í™•í•œ ì‹ í˜¸ì…ë‹ˆë‹¤. ìš°ë¦¬ í¬íŠ¸í´ë¦¬ì˜¤ì™€ íŒŒì´í”„ë¼ì¸ì˜ ì„±ê³µì€ í˜ì‹ ì— ëŒ€í•œ ìš°ë¦¬ì˜ ëŠì„ì—†ëŠ” ì§‘ì¤‘ì´ ë‹¨ìˆœíˆ ì§„ì „ì„ ì´‰ì§„í•˜ëŠ” ê²ƒ ì´ìƒì˜ ì—­í• ì„ í•˜ê³  ìˆë‹¤ëŠ” ì¦ê±°ì…ë‹ˆë‹¤. ì´ëŠ” ì„±ì¥ì„ ê°€ì†í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>3ë¶„ê¸°ì— ìš°ë¦¬ëŠ” ì „ì²´ ì‚¬ì—…ì—ì„œ 5.4%ì˜ ìš´ì˜ ë§¤ì¶œ ì„±ì¥ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. í˜ì‹ ì˜ì•½í’ˆ ë¶€ë¬¸ì—ì„œëŠ” 5.3%ì˜ ìš´ì˜ ë§¤ì¶œ ì„±ì¥ì„ ê¸°ë¡í–ˆìœ¼ë©°, 150ì–µ ë‹¬ëŸ¬ë¥¼ ë„˜ëŠ” ë§¤ì¶œì„ ì—°ì† 2ë¶„ê¸°ì§¸ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Some were not convinced we could grow through the loss of exclusivity of STELARA, but we were confident, and we have now unequivocally answered that question. How did we accomplish that when other companies have failed? In Q3, we did it by delivering double-digit growth across 11 brands, including DARZALEX, CARVYKTI, TALVEY, TECVAYLI, ERLEADA, RYBREVANT, LAZCLUZE, CAPLYTA, SPRAVATO, SIMPONI, REMICADE and remarkable growth of 40% in TREMFYA. In MedTech, operational sales growth was even stronger, accelerating to 5.6% with improvements across all businesses. And as you have seen from this morning's news, we have announced the planned separation of our Orthopaedics business.</td><td>ì¼ë¶€ì—ì„œëŠ” STELARAì˜ ë…ì ê¶Œ ìƒì‹¤ì„ ê²ªìœ¼ë©´ì„œë„ ì„±ì¥í•  ìˆ˜ ìˆì„ì§€ í™•ì‹ í•˜ì§€ ëª»í–ˆì§€ë§Œ, ì €í¬ëŠ” ìì‹ ì´ ìˆì—ˆê³ , ì´ì œ ê·¸ ì§ˆë¬¸ì— ëª…í™•í•˜ê²Œ ë‹µë³€ì„ ì œì‹œí–ˆìŠµë‹ˆë‹¤. ë‹¤ë¥¸ íšŒì‚¬ë“¤ì´ ì‹¤íŒ¨í•œ ìƒí™©ì—ì„œ ì €í¬ëŠ” ì–´ë–»ê²Œ ì´ë¥¼ ë‹¬ì„±í–ˆì„ê¹Œìš”? 3ë¶„ê¸°ì— ì €í¬ëŠ” DARZALEX, CARVYKTI, TALVEY, TECVAYLI, ERLEADA, RYBREVANT, LAZCLUZE, CAPLYTA, SPRAVATO, SIMPONI, REMICADEë¥¼ í¬í•¨í•œ 11ê°œ ë¸Œëœë“œì—ì„œ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ë‹¬ì„±í–ˆê³ , TREMFYAëŠ” 40%ë¼ëŠ” ë†€ë¼ìš´ ì„±ì¥ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ë©”ë“œí…Œí¬ ë¶€ë¬¸ì—ì„œëŠ” ìš´ì˜ ë§¤ì¶œ ì„±ì¥ë¥ ì´ ë”ìš± ê°•ë ¥í•´ì ¸ 5.6%ë¡œ ê°€ì†í™”ë˜ì—ˆìœ¼ë©°, ëª¨ë“  ì‚¬ì—… ë¶€ë¬¸ì—ì„œ ê°œì„ ì„ ë³´ì˜€ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì˜¤ëŠ˜ ì•„ì¹¨ ë‰´ìŠ¤ì—ì„œ ë³´ì…¨ë“¯ì´, ì €í¬ëŠ” ì •í˜•ì™¸ê³¼ ì‚¬ì—…ë¶€ì˜ ë¶„ì‚¬ ê³„íšì„ ë°œí‘œí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This decision further sharpens our focus as a health care innovation leader and accelerates the shift of our MedTech portfolio to areas of greatest unmet need and higher growth, which includes cardiovascular and robotic surgery. I will touch more on this later, but one thing is clear, Johnson & Johnson's momentum is strong and our achievements are multiplying. I will now focus on the progress we are making across our 6 priority areas: oncology, immunology, neuroscience, cardiovascular, surgery and vision. These are areas where we have deep expertise and clear leadership positions. First, oncology, where Q3 operational sales grew nearly 20%.</td><td>ì´ëŸ¬í•œ ê²°ì •ì€ í—¬ìŠ¤ì¼€ì–´ í˜ì‹  ë¦¬ë”ë¡œì„œì˜ ìš°ë¦¬ì˜ ì§‘ì¤‘ë„ë¥¼ ë”ìš± ë†’ì´ê³ , MedTech í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ë¯¸ì¶©ì¡± ì˜ë£Œ ìˆ˜ìš”ê°€ ê°€ì¥ í° ê³ ì„±ì¥ ì˜ì—­ì¸ ì‹¬í˜ˆê´€ ë° ë¡œë´‡ ìˆ˜ìˆ  ë¶„ì•¼ë¡œ ì „í™˜í•˜ëŠ” ê²ƒì„ ê°€ì†í™”í•©ë‹ˆë‹¤. ì´ì— ëŒ€í•´ì„œëŠ” ë‚˜ì¤‘ì— ë” ìì„¸íˆ ë§ì”€ë“œë¦¬ê² ì§€ë§Œ, í•œ ê°€ì§€ ë¶„ëª…í•œ ê²ƒì€ Johnson & Johnsonì˜ ëª¨ë©˜í…€ì´ ê°•ë ¥í•˜ê³  ìš°ë¦¬ì˜ ì„±ê³¼ê°€ ë°°ê°€ë˜ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ì œ ìš°ë¦¬ê°€ ê¹Šì€ ì „ë¬¸ì„±ê³¼ ëª…í™•í•œ ë¦¬ë”ì‹­ ì§€ìœ„ë¥¼ ë³´ìœ í•œ 6ê°œ ìš°ì„  ë¶„ì•¼ì¸ ì¢…ì–‘í•™, ë©´ì—­í•™, ì‹ ê²½ê³¼í•™, ì‹¬í˜ˆê´€, ìˆ˜ìˆ  ë° ì‹œë ¥ ë¶„ì•¼ì—ì„œ ì´ë£¨ê³  ìˆëŠ” ì§„ì „ì— ëŒ€í•´ ì§‘ì¤‘ì ìœ¼ë¡œ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¨¼ì € ì¢…ì–‘í•™ ë¶„ì•¼ì—ì„œëŠ” 3ë¶„ê¸° ìš´ì˜ ë§¤ì¶œì´ ê±°ì˜ 20% ì„±ì¥í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>You have heard me say before that we are much more than a one-shot company, and our expertise in blood cancers and solid tumors in our oncology portfolio is a great example. Take multiple myeloma, where our competitiveness is unrivaled. No other company has the expertise or success in multiple myeloma that we do. We have treatments in every line of therapy, and DARZALEX is the gold standard with more than 50% market share across all lines of therapy.</td><td>ì´ì „ì— ì €í¬ê°€ ì¼íšŒì„± íšŒì‚¬ê°€ ì•„ë‹ˆë¼ëŠ” ë§ì”€ì„ ë“œë¦° ë°” ìˆëŠ”ë°, ì €í¬ ì¢…ì–‘í•™ í¬íŠ¸í´ë¦¬ì˜¤ì—ì„œ í˜ˆì•¡ì•”ê³¼ ê³ í˜•ì•”ì— ëŒ€í•œ ì „ë¬¸ì„±ì´ ê·¸ ì¢‹ì€ ì˜ˆì…ë‹ˆë‹¤. ë‹¤ë°œì„± ê³¨ìˆ˜ì¢…ì„ ë³´ë©´, ì €í¬ì˜ ê²½ìŸë ¥ì€ íƒ€ì˜ ì¶”ì¢…ì„ ë¶ˆí—ˆí•©ë‹ˆë‹¤. ì €í¬ë§Œí¼ ë‹¤ë°œì„± ê³¨ìˆ˜ì¢…ì—ì„œ ì „ë¬¸ì„±ê³¼ ì„±ê³µì„ ê±°ë‘” íšŒì‚¬ëŠ” ì—†ìŠµë‹ˆë‹¤. ì €í¬ëŠ” ëª¨ë“  ì¹˜ë£Œ ë¼ì¸ì—ì„œ ì¹˜ë£Œì œë¥¼ ë³´ìœ í•˜ê³  ìˆìœ¼ë©°, DARZALEXëŠ” ëª¨ë“  ì¹˜ë£Œ ë¼ì¸ì—ì„œ 50% ì´ìƒì˜ ì‹œì¥ ì ìœ ìœ¨ì„ ì°¨ì§€í•˜ëŠ” ê³¨ë“œ ìŠ¤íƒ ë‹¤ë“œì…ë‹ˆë‹¤.</td></tr>
<tr><td>Q3 operational sales of DARZALEX grew by 20%, and its potential continues to build with the approval this quarter in Europe as a treatment for high-risk smoldering multiple myeloma as well as promising new studies of DARZALEX FASPRO in combination with TECVAYLI. I also want to say a word about CARVYKTI, our CAR-T treatment for multiple myeloma. We have now treated more than 8,500 patients globally, making CARVYKTI the most successful CAR-T launch ever. With operational sales growing by more than 80% this quarter, we are increasingly confident in CARVYKTI's $5 billion peak year sales potential. Turning to solid tumors.</td><td>3ë¶„ê¸° DARZALEXì˜ ìš´ì˜ ë§¤ì¶œì€ 20% ì„±ì¥í–ˆìœ¼ë©°, ì´ë²ˆ ë¶„ê¸° ìœ ëŸ½ì—ì„œ ê³ ìœ„í—˜ ë¬´ì¦ìƒ ë‹¤ë°œì„± ê³¨ìˆ˜ì¢… ì¹˜ë£Œì œë¡œ ìŠ¹ì¸ë°›ì€ ê²ƒê³¼ ë”ë¶ˆì–´ TECVAYLIì™€ì˜ ë³‘ìš©ìš”ë²•ì—ì„œ DARZALEX FASPROì˜ ìœ ë§í•œ ìƒˆë¡œìš´ ì—°êµ¬ë“¤ì„ í†µí•´ ê·¸ ì ì¬ë ¥ì´ ê³„ì† í™•ëŒ€ë˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ë‹¤ë°œì„± ê³¨ìˆ˜ì¢…ì— ëŒ€í•œ CAR-T ì¹˜ë£Œì œì¸ CARVYKTIì— ëŒ€í•´ì„œë„ ë§ì”€ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. í˜„ì¬ê¹Œì§€ ì „ ì„¸ê³„ì ìœ¼ë¡œ 8,500ëª… ì´ìƒì˜ í™˜ìë¥¼ ì¹˜ë£Œí–ˆìœ¼ë©°, ì´ë¡œì¨ CARVYKTIëŠ” ê°€ì¥ ì„±ê³µì ì¸ CAR-T ì¶œì‹œ ì‚¬ë¡€ê°€ ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸° ìš´ì˜ ë§¤ì¶œì´ 80% ì´ìƒ ì„±ì¥í•˜ë©´ì„œ, CARVYKTIì˜ ì—°ê°„ ìµœëŒ€ ë§¤ì¶œ 50ì–µ ë‹¬ëŸ¬ ì ì¬ë ¥ì— ëŒ€í•œ í™•ì‹ ì´ ë”ìš± ì»¤ì§€ê³  ìˆìŠµë‹ˆë‹¤. ê³ í˜•ì•”ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We were thrilled to receive FDA approval for our bladder cancer treatment INLEXZO last month. INLEXZO highlights what is unique about Johnson & Johnson, building on our unmatched capabilities in both Innovative Medicine and MedTech, it is the first and only drug releasing system to provide sustained local delivery of a cancer treatment directly into the bladder. It is transformative for patients, and it is transformative for doctors. It will also contribute significantly to future growth with a targeted release platform projected to be another blockbuster treatment with at least $5 billion in annual peak year sales.</td><td>ì§€ë‚œë‹¬ ë°©ê´‘ì•” ì¹˜ë£Œì œ INLEXZOì— ëŒ€í•œ FDA ìŠ¹ì¸ì„ ë°›ê²Œ ë˜ì–´ ë§¤ìš° ê¸°ì©ë‹ˆë‹¤. INLEXZOëŠ” Johnson & Johnsonë§Œì˜ ë…íŠ¹í•¨ì„ ë³´ì—¬ì£¼ëŠ” ì œí’ˆìœ¼ë¡œ, í˜ì‹  ì˜ì•½í’ˆê³¼ ì˜ë£Œê¸°ê¸° ë¶„ì•¼ì—ì„œì˜ íƒ€ì˜ ì¶”ì¢…ì„ ë¶ˆí—ˆí•˜ëŠ” ì—­ëŸ‰ì„ ë°”íƒ•ìœ¼ë¡œ ê°œë°œë˜ì—ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì•” ì¹˜ë£Œì œë¥¼ ë°©ê´‘ ë‚´ë¡œ ì§ì ‘ ì§€ì†ì ìœ¼ë¡œ êµ­ì†Œ ì „ë‹¬í•˜ëŠ” ìµœì´ˆì´ì ìœ ì¼í•œ ì•½ë¬¼ ë°©ì¶œ ì‹œìŠ¤í…œì…ë‹ˆë‹¤. ì´ëŠ” í™˜ìë“¤ì—ê²Œ í˜ì‹ ì ì´ë©°, ì˜ì‚¬ë“¤ì—ê²Œë„ í˜ì‹ ì ì…ë‹ˆë‹¤. ë˜í•œ ì—°ê°„ ìµœê³  ë§¤ì¶œ 50ì–µ ë‹¬ëŸ¬ ì´ìƒì„ ë‹¬ì„±í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ëŠ” ë˜ ë‹¤ë¥¸ ë¸”ë¡ë²„ìŠ¤í„° ì¹˜ë£Œì œì¸ í‘œì  ë°©ì¶œ í”Œë«í¼ì„ í†µí•´ í–¥í›„ ì„±ì¥ì—ë„ í¬ê²Œ ê¸°ì—¬í•  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Sourced through an early-stage deal, INLEXZO is also an example of our outstanding business development model. In fact, in the last 18 months alone, we have completed more than 60 deals of this kind. And in lung cancer, we recently published results in the New England Journal of Medicine for RYBREVANT plus LAZCLUZE, showing a statistically significant reduction in the risk of death compared to osimertinib. We are now seeing the potential for patients to live significantly longer than anyone thought possible. The combination of RYBREVANT plus LAZCLUZE is another of our $5 billion peak year sales assets. Next, I want to talk about immunology, where we have been leaders for 25 years.</td><td>ì´ˆê¸° ë‹¨ê³„ ë”œì„ í†µí•´ í™•ë³´í•œ INLEXZOëŠ” ë˜í•œ ì €í¬ì˜ ë›°ì–´ë‚œ ì‚¬ì—…ê°œë°œ ëª¨ë¸ì˜ ì‚¬ë¡€ì´ê¸°ë„ í•©ë‹ˆë‹¤. ì‹¤ì œë¡œ ì§€ë‚œ 18ê°œì›” ë™ì•ˆë§Œ ì €í¬ëŠ” ì´ëŸ° ì¢…ë¥˜ì˜ ê±°ë˜ë¥¼ 60ê±´ ì´ìƒ ì™„ë£Œí–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  íì•” ë¶„ì•¼ì—ì„œëŠ” ìµœê·¼ New England Journal of Medicineì— RYBREVANTì™€ LAZCLUZE ë³‘ìš©ìš”ë²•ì— ëŒ€í•œ ê²°ê³¼ë¥¼ ë°œí‘œí–ˆëŠ”ë°, ì˜¤ì‹œë¨¸í‹°ë‹™ ëŒ€ë¹„ ì‚¬ë§ ìœ„í—˜ì„ í†µê³„ì ìœ¼ë¡œ ìœ ì˜í•˜ê²Œ ê°ì†Œì‹œí‚¤ëŠ” ê²ƒìœ¼ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ì´ì œ í™˜ìë“¤ì´ ëˆ„êµ¬ë„ ê°€ëŠ¥í•˜ë‹¤ê³  ìƒê°í–ˆë˜ ê²ƒë³´ë‹¤ í›¨ì”¬ ë” ì˜¤ë˜ ì‚´ ìˆ˜ ìˆëŠ” ì ì¬ë ¥ì„ ë³´ê³  ìˆìŠµë‹ˆë‹¤. RYBREVANTì™€ LAZCLUZEì˜ ë³‘ìš©ìš”ë²•ì€ ì €í¬ì˜ ë˜ ë‹¤ë¥¸ ì—°ê°„ ìµœëŒ€ ë§¤ì¶œ 50ì–µ ë‹¬ëŸ¬ ìì‚°ì…ë‹ˆë‹¤. ë‹¤ìŒìœ¼ë¡œ, ì €í¬ê°€ 25ë…„ê°„ ì„ ë„ì  ìœ„ì¹˜ë¥¼ ìœ ì§€í•´ì˜¨ ë©´ì—­í•™ ë¶„ì•¼ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê³ ì í•©ë‹ˆë‹¤.</td></tr>
<tr><td>From REMICADE to SIMPONI and STELARA to TREMFYA, some of our biggest blockbusters have come from our immunology portfolio. We have long talked about TREMFYA as the next big innovation to follow the success of STELARA. Based on this quarter's performance, it looks like it could be both bigger and better, having delivered operational sales growth of 40%, driven by new indications in inflammatory bowel disease. TREMFYA is the only IL-23 inhibitor to offer a fully subcutaneous regimen across ulcerative colitis and Crohn's disease.</td><td>REMICADEë¶€í„° SIMPONI, STELARA, TREMFYAì— ì´ë¥´ê¸°ê¹Œì§€, ì €í¬ì˜ ê°€ì¥ í° ë¸”ë¡ë²„ìŠ¤í„° ì˜ì•½í’ˆë“¤ ì¤‘ ì¼ë¶€ëŠ” ë©´ì—­í•™ í¬íŠ¸í´ë¦¬ì˜¤ì—ì„œ ë‚˜ì™”ìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì˜¤ë«ë™ì•ˆ TREMFYAë¥¼ STELARAì˜ ì„±ê³µì„ ì´ì–´ê°ˆ ì°¨ì„¸ëŒ€ í˜ì‹  ì˜ì•½í’ˆìœ¼ë¡œ ì–¸ê¸‰í•´ì™”ìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸° ì‹¤ì ì„ ë°”íƒ•ìœ¼ë¡œ ë³¼ ë•Œ, TREMFYAëŠ” ì—¼ì¦ì„± ì¥ì§ˆí™˜ì˜ ìƒˆë¡œìš´ ì ì‘ì¦ì— í˜ì…ì–´ 40%ì˜ ìš´ì˜ ë§¤ì¶œ ì„±ì¥ì„ ë‹¬ì„±í•˜ë©° ë” í¬ê³  ë” ë‚˜ì€ ì„±ê³¼ë¥¼ ë³´ì¼ ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. TREMFYAëŠ” ê¶¤ì–‘ì„± ëŒ€ì¥ì—¼ê³¼ í¬ë¡ ë³‘ ì „ë°˜ì— ê±¸ì³ ì™„ì „í•œ í”¼í•˜ íˆ¬ì—¬ ìš”ë²•ì„ ì œê³µí•˜ëŠ” ìœ ì¼í•œ IL-23 ì–µì œì œì…ë‹ˆë‹¤.</td></tr>
<tr><td>Even prior to the launch of our subcutaneous formulation, TREMFYA was capturing approximately half of all new patient starts for IL-23 ulcerative colitis treatments in the U.S., which we achieved within 1 year from launch. We are confident TREMFYA will become a more than $10 billion asset. And in typical J&J fashion, we are deep in development of our next immunology innovation, icotrokinra, initially for moderate to severe plaque psoriasis. Historically, the most effective immunology treatments have been injectables. As the first oral peptide to selectively block the IL-23 receptor, icotrokinra has the potential to revolutionize the treatment of plaque psoriasis with a once-a-day pill.</td><td>í”¼í•˜ì£¼ì‚¬ ì œí˜• ì¶œì‹œ ì´ì „ì—ë„ TREMFYAëŠ” ë¯¸êµ­ ë‚´ IL-23 ê¶¤ì–‘ì„± ëŒ€ì¥ì—¼ ì¹˜ë£Œì œì˜ ëª¨ë“  ì‹ ê·œ í™˜ì ì‹œì‘ ì¤‘ ì•½ ì ˆë°˜ì„ ì°¨ì§€í•˜ê³  ìˆì—ˆìœ¼ë©°, ì´ëŠ” ì¶œì‹œ í›„ 1ë…„ ì´ë‚´ì— ë‹¬ì„±í•œ ì„±ê³¼ì…ë‹ˆë‹¤. ì €í¬ëŠ” TREMFYAê°€ 100ì–µ ë‹¬ëŸ¬ ì´ìƒì˜ ìì‚°ì´ ë  ê²ƒì´ë¼ê³  í™•ì‹ í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì „í˜•ì ì¸ J&J ë°©ì‹ìœ¼ë¡œ, ì €í¬ëŠ” ì°¨ì„¸ëŒ€ ë©´ì—­í•™ í˜ì‹  ê¸°ìˆ ì¸ icotrokinraì˜ ê°œë°œì— ê¹Šì´ ëª°ë‘í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ì´ˆê¸°ì— ì¤‘ë“±ë„ì—ì„œ ì¤‘ì¦ íŒìƒ ê±´ì„ ì„ ëŒ€ìƒìœ¼ë¡œ í•©ë‹ˆë‹¤. ì—­ì‚¬ì ìœ¼ë¡œ ê°€ì¥ íš¨ê³¼ì ì¸ ë©´ì—­í•™ ì¹˜ë£Œì œë“¤ì€ ì£¼ì‚¬ì œì˜€ìŠµë‹ˆë‹¤. IL-23 ìˆ˜ìš©ì²´ë¥¼ ì„ íƒì ìœ¼ë¡œ ì°¨ë‹¨í•˜ëŠ” ìµœì´ˆì˜ ê²½êµ¬ í©íƒ€ì´ë“œë¡œì„œ, icotrokinraëŠ” 1ì¼ 1íšŒ ë³µìš©í•˜ëŠ” ì•Œì•½ìœ¼ë¡œ íŒìƒ ê±´ì„  ì¹˜ë£Œì— í˜ëª…ì„ ì¼ìœ¼í‚¬ ì ì¬ë ¥ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We submitted icotrokinra for plaque psoriasis to the FDA in July. And you know this is just the beginning as we have already presented data from our Phase II trials in ulcerative colitis. Let's now turn to neuroscience with SPRAVATO operational sales growing an impressive 61% in Q3. SPRAVATO remains the only approved stand-alone therapy for treatment-resistant depression, a major depressive disorder with suicidal ideation. Through Q3, we have now treated more than 180,000 patients, and I could not be prouder of the impact this team is having.</td><td>7ì›”ì— íŒìƒ ê±´ì„ ì— ëŒ€í•œ icotrokinraë¥¼ FDAì— ì œì¶œí–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ë¯¸ ê¶¤ì–‘ì„± ëŒ€ì¥ì—¼ì— ëŒ€í•œ 2ìƒ ì„ìƒì‹œí—˜ ë°ì´í„°ë¥¼ ë°œí‘œí•œ ë°”ì™€ ê°™ì´, ì´ëŠ” ì‹œì‘ì— ë¶ˆê³¼í•©ë‹ˆë‹¤. <br><br>ì´ì œ ì‹ ê²½ê³¼í•™ ë¶„ì•¼ë¡œ ë„˜ì–´ê°€ì„œ, SPRAVATOì˜ ìš´ì˜ ë§¤ì¶œì´ 3ë¶„ê¸°ì— ì¸ìƒì ì¸ 61% ì„±ì¥ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. SPRAVATOëŠ” ì¹˜ë£Œ ì €í•­ì„± ìš°ìš¸ì¦ê³¼ ìì‚´ ê´€ë…ì„ ë™ë°˜í•œ ì£¼ìš” ìš°ìš¸ ì¥ì• ì— ëŒ€í•œ ìœ ì¼í•œ ìŠ¹ì¸ëœ ë‹¨ë… ì¹˜ë£Œì œë¡œ ë‚¨ì•„ ìˆìŠµë‹ˆë‹¤. 3ë¶„ê¸°ê¹Œì§€ í˜„ì¬ 180,000ëª… ì´ìƒì˜ í™˜ìë¥¼ ì¹˜ë£Œí–ˆìœ¼ë©°, ì´ íŒ€ì´ ë¯¸ì¹˜ê³  ìˆëŠ” ì˜í–¥ì— ëŒ€í•´ ë”í•  ë‚˜ìœ„ ì—†ì´ ìë‘ìŠ¤ëŸ½ê²Œ ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Our leadership in neuropsychiatry was also strengthened by this year's acquisition of intracellular therapies with FDA approval for CAPLYTA in major depressive disorder anticipated soon. CAPLYTA is already FDA approved for the treatment of schizophrenia as well as depressive episodes associated with bipolar disorder I and II. We project CAPLYTA to reach $5 billion annually. Now let's turn to MedTech, starting with our cardiovascular portfolio. In Q3, cardiovascular operational sales increased by approximately 12% as we fortify our leadership in the fastest-growing cardiovascular intervention segment.</td><td>ì €í¬ì˜ ì‹ ê²½ì •ì‹ ì˜í•™ ë¶„ì•¼ ë¦¬ë”ì‹­ì€ ì˜¬í•´ ì¸íŠ¸ë¼ì…€ë£°ëŸ¬ í…Œë¼í”¼ìŠ¤(Intracellular Therapies) ì¸ìˆ˜ë¥¼ í†µí•´ ë”ìš± ê°•í™”ë˜ì—ˆìœ¼ë©°, CAPLYTAì˜ ì£¼ìš”ìš°ìš¸ì¥ì• ì— ëŒ€í•œ FDA ìŠ¹ì¸ì´ ê³§ ì˜ˆìƒë©ë‹ˆë‹¤. CAPLYTAëŠ” ì´ë¯¸ ì¡°í˜„ë³‘ ì¹˜ë£Œë¿ë§Œ ì•„ë‹ˆë¼ ì–‘ê·¹ì„± ì¥ì•  Ií˜• ë° IIí˜•ê³¼ ê´€ë ¨ëœ ìš°ìš¸ ì‚½í™” ì¹˜ë£Œì— ëŒ€í•´ FDA ìŠ¹ì¸ì„ ë°›ì•˜ìŠµë‹ˆë‹¤. ì €í¬ëŠ” CAPLYTAê°€ ì—°ê°„ 50ì–µ ë‹¬ëŸ¬ì— ë„ë‹¬í•  ê²ƒìœ¼ë¡œ ì „ë§í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì´ì œ ë©”ë“œí…Œí¬ë¡œ ë„˜ì–´ê°€ì„œ ì‹¬í˜ˆê´€ í¬íŠ¸í´ë¦¬ì˜¤ë¶€í„° ì‚´í´ë³´ê² ìŠµë‹ˆë‹¤. 3ë¶„ê¸°ì— ì‹¬í˜ˆê´€ ìš´ì˜ ë§¤ì¶œì€ ì•½ 12% ì¦ê°€í–ˆìœ¼ë©°, ì´ëŠ” ê°€ì¥ ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠ” ì‹¬í˜ˆê´€ ì¤‘ì¬ì‹œìˆ  ë¶„ì•¼ì—ì„œ ì €í¬ì˜ ë¦¬ë”ì‹­ì„ ê°•í™”í•˜ê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>With operational sales growth of over 20%, Shockwave's unique intravascular lithotripsy technology is helping treat more atherosclerotic cardiovascular patients than ever before. In fact, in the last quarter, Shockwave supported their 1 millionth patient. And with the recent European approval of the Javelin Peripheral Intravascular Lithotripsy Catheter, we expect strong momentum moving forward. We anticipate Shockwave becoming our $13 billion MedTech platform by year-end. In electrophysiology, we are industry leaders and with the strength of our mapping technology, that continues.</td><td>ìš´ì˜ ë§¤ì¶œì´ 20% ì´ìƒ ì„±ì¥í•˜ë©´ì„œ, Shockwaveì˜ ë…íŠ¹í•œ í˜ˆê´€ë‚´ ì‡„ì„ìˆ  ê¸°ìˆ ì€ ê·¸ ì–´ëŠ ë•Œë³´ë‹¤ ë§ì€ ì£½ìƒë™ë§¥ê²½í™”ì„± ì‹¬í˜ˆê´€ í™˜ìë“¤ì˜ ì¹˜ë£Œë¥¼ ë•ê³  ìˆìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ ì§€ë‚œ ë¶„ê¸°ì— ShockwaveëŠ” 100ë§Œ ë²ˆì§¸ í™˜ìë¥¼ ì§€ì›í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìµœê·¼ Javelin ë§ì´ˆ í˜ˆê´€ë‚´ ì‡„ì„ìˆ  ì¹´í…Œí„°ì˜ ìœ ëŸ½ ìŠ¹ì¸ê³¼ í•¨ê»˜, ì•ìœ¼ë¡œ ê°•ë ¥í•œ ëª¨ë©˜í…€ì„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” Shockwaveê°€ ì—°ë§ê¹Œì§€ 130ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ MedTech í”Œë«í¼ì´ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì „ê¸°ìƒë¦¬í•™ ë¶„ì•¼ì—ì„œ ìš°ë¦¬ëŠ” ì—…ê³„ ì„ ë‘ì£¼ìì´ë©°, ìš°ë¦¬ì˜ ë§¤í•‘ ê¸°ìˆ ì˜ ê°•ì ìœ¼ë¡œ ì´ëŠ” ê³„ì†ë˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In Q3, we again delivered close to 10% operational sales growth, and our position was further strengthened with real-world data showing VARIPULSE achieved 99.7% acute effectiveness in nearly 800 patients with strong safety and no incidence of stroke. Our Abiomed business also continues to perform strongly with more than 15% operational sales growth in the quarter. Our success reflects the impact that our Impella CP Heart Pump is having on the lives of patients, which you could see in the long-term survival data that was published in the New England Journal of Medicine this quarter.</td><td>3ë¶„ê¸°ì— ìš°ë¦¬ëŠ” ë‹¤ì‹œ í•œë²ˆ ì•½ 10%ì— ê°€ê¹Œìš´ ìš´ì˜ ë§¤ì¶œ ì„±ì¥ì„ ë‹¬ì„±í–ˆìœ¼ë©°, VARIPULSEê°€ ì•½ 800ëª…ì˜ í™˜ìì—ì„œ 99.7%ì˜ ê¸‰ì„± ìœ íš¨ì„±ì„ ë³´ì´ê³  ê°•ë ¥í•œ ì•ˆì „ì„±ê³¼ ë‡Œì¡¸ì¤‘ ë°œìƒë¥  0%ë¥¼ ê¸°ë¡í•œ ì‹¤ì œ ì„ìƒ ë°ì´í„°ë¥¼ í†µí•´ ìš°ë¦¬ì˜ ì…ì§€ê°€ ë”ìš± ê°•í™”ë˜ì—ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ Abiomed ì‚¬ì—… ë˜í•œ ì´ë²ˆ ë¶„ê¸°ì— 15% ì´ìƒì˜ ìš´ì˜ ë§¤ì¶œ ì„±ì¥ì„ ê¸°ë¡í•˜ë©° ì§€ì†ì ìœ¼ë¡œ ê°•ë ¥í•œ ì„±ê³¼ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì„±ê³µì€ ìš°ë¦¬ì˜ Impella CP ì‹¬ì¥ íŒí”„ê°€ í™˜ìë“¤ì˜ ì‚¶ì— ë¯¸ì¹˜ê³  ìˆëŠ” ì˜í–¥ì„ ë°˜ì˜í•˜ëŠ” ê²ƒìœ¼ë¡œ, ì´ëŠ” ì´ë²ˆ ë¶„ê¸° ë‰´ì‰ê¸€ëœë“œ ì˜í•™ì €ë„ì— ë°œí‘œëœ ì¥ê¸° ìƒì¡´ ë°ì´í„°ì—ì„œ í™•ì¸í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In the 10-year DanGer Shock study, routine use of Impella CP in patients who have had a heart attack with cardiogenic shock reduced mortality by 16.3% compared to the standard of care with patients gaining an average of 600 additional days alive. It is a perfect example of what we mean when we say Johnson & Johnson is delivering groundbreaking innovation. In surgery, we are making progress on multiple fronts. Our surgical technologies are used in most operating rooms globally. And in Q3, we delivered more than 9% growth in biosurgery and almost 7% in wound closure, driven by accelerating adoption of our latest innovations.</td><td>10ë…„ê°„ ì§„í–‰ëœ DanGer Shock ì—°êµ¬ì—ì„œ, ì‹¬ê·¼ê²½ìƒ‰ìœ¼ë¡œ ì¸í•œ ì‹¬ì¸ì„± ì‡¼í¬ í™˜ìì—ê²Œ Impella CPë¥¼ ì¼ìƒì ìœ¼ë¡œ ì‚¬ìš©í•œ ê²°ê³¼, í‘œì¤€ ì¹˜ë£Œë²• ëŒ€ë¹„ ì‚¬ë§ë¥ ì´ 16.3% ê°ì†Œí–ˆìœ¼ë©°, í™˜ìë“¤ì€ í‰ê·  600ì¼ì˜ ì¶”ê°€ ìƒì¡´ ê¸°ê°„ì„ ì–»ì—ˆìŠµë‹ˆë‹¤. ì´ëŠ” Johnson & Johnsonì´ íšê¸°ì ì¸ í˜ì‹ ì„ ì œê³µí•œë‹¤ê³  ë§í•  ë•Œì˜ ì™„ë²½í•œ ì‚¬ë¡€ì…ë‹ˆë‹¤. ìˆ˜ìˆ  ë¶„ì•¼ì—ì„œëŠ” ì—¬ëŸ¬ ë°©ë©´ì—ì„œ ì§„ì „ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ë‹¹ì‚¬ì˜ ìˆ˜ìˆ  ê¸°ìˆ ì€ ì „ ì„¸ê³„ ëŒ€ë¶€ë¶„ì˜ ìˆ˜ìˆ ì‹¤ì—ì„œ ì‚¬ìš©ë˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  3ë¶„ê¸°ì—ëŠ” ìµœì‹  í˜ì‹  ê¸°ìˆ ì˜ ë„ì… ê°€ì†í™”ì— í˜ì…ì–´ ë°”ì´ì˜¤ìˆ˜ìˆ  ë¶€ë¬¸ì—ì„œ 9% ì´ìƒ, ì°½ìƒ ë´‰í•© ë¶€ë¬¸ì—ì„œ ê±°ì˜ 7%ì˜ ì„±ì¥ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We also continue to make positive progress with OTTAVA as we anticipate FDA de novo submission in early 2026. And now to vision, where we grew more than 6% last quarter. Our TECNIS intraocular lenses are the fastest growing in the markets where we have launched, fueling our 13.8% operational sales growth in surgical vision. And after launching the world's first multifocal contact lens for people with astigmatism in the U.S. last quarter, we brought this latest member of the ACUVUE OASYS MAX 1-Day family to Europe and Korea in Q3, further strengthening our momentum. And finally, to this morning's Orthopaedics news.</td><td>ë˜í•œ 2026ë…„ ì´ˆ FDA de novo ì œì¶œì„ ì˜ˆìƒí•˜ê³  ìˆëŠ” OTTAVAì™€ ê´€ë ¨í•´ì„œë„ ì§€ì†ì ìœ¼ë¡œ ê¸ì •ì ì¸ ì§„ì „ì„ ì´ë£¨ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ ì§€ë‚œ ë¶„ê¸° 6% ì´ìƒ ì„±ì¥í•œ ë¹„ì „ ì‚¬ì—…ë¶€ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ë‹¹ì‚¬ì˜ TECNIS ì¸ê³µìˆ˜ì •ì²´ëŠ” ì¶œì‹œí•œ ì‹œì¥ì—ì„œ ê°€ì¥ ë¹ ë¥¸ ì„±ì¥ì„¸ë¥¼ ë³´ì´ê³  ìˆìœ¼ë©°, ì´ëŠ” ìˆ˜ìˆ ìš© ë¹„ì „ ë¶€ë¬¸ì—ì„œ 13.8%ì˜ ìš´ì˜ ë§¤ì¶œ ì„±ì¥ì„ ê²¬ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì§€ë‚œ ë¶„ê¸° ë¯¸êµ­ì—ì„œ ë‚œì‹œìš© ì„¸ê³„ ìµœì´ˆì˜ ë‹¤ì´ˆì  ì½˜íƒíŠ¸ë Œì¦ˆë¥¼ ì¶œì‹œí•œ ì´í›„, 3ë¶„ê¸°ì—ëŠ” ACUVUE OASYS MAX 1-Day ì œí’ˆêµ°ì˜ ìµœì‹  ì œí’ˆì„ ìœ ëŸ½ê³¼ í•œêµ­ì— ì¶œì‹œí•˜ì—¬ ë‹¹ì‚¬ì˜ ëª¨ë©˜í…€ì„ ë”ìš± ê°•í™”í–ˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ ì˜¤ëŠ˜ ì•„ì¹¨ ë°œí‘œëœ ì •í˜•ì™¸ê³¼ ê´€ë ¨ ì†Œì‹ì…ë‹ˆë‹¤.</td></tr>
<tr><td>As you know, the health care industry continues to evolve rapidly, and we are constantly evaluating our overall business and portfolio to ensure Johnson & Johnson remains best positioned to truly lead where health care is going. We continue to invest at industry-leading levels in our pipeline and portfolio while making disciplined decisions to exit businesses that we believe will be better able to thrive outside of Johnson & Johnson. For our Orthopaedics business, the planned separation creates new opportunities.</td><td>ì•„ì‹œë‹¤ì‹œí”¼, í—¬ìŠ¤ì¼€ì–´ ì‚°ì—…ì€ ê³„ì†í•´ì„œ ë¹ ë¥´ê²Œ ì§„í™”í•˜ê³  ìˆìœ¼ë©°, ì €í¬ëŠ” Johnson & Johnsonì´ í—¬ìŠ¤ì¼€ì–´ì˜ ë¯¸ë˜ë¥¼ ì§„ì •ìœ¼ë¡œ ì„ ë„í•  ìˆ˜ ìˆëŠ” ìµœì ì˜ ìœ„ì¹˜ë¥¼ ìœ ì§€í•  ìˆ˜ ìˆë„ë¡ ì „ì²´ ì‚¬ì—…ê³¼ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì§€ì†ì ìœ¼ë¡œ í‰ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” íŒŒì´í”„ë¼ì¸ê³¼ í¬íŠ¸í´ë¦¬ì˜¤ì— ì—…ê³„ ìµœê³  ìˆ˜ì¤€ì˜ íˆ¬ìë¥¼ ì§€ì†í•˜ëŠ” ë™ì‹œì—, Johnson & Johnson ì™¸ë¶€ì—ì„œ ë” ì˜ ì„±ì¥í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ íŒë‹¨ë˜ëŠ” ì‚¬ì—…ë“¤ì—ì„œëŠ” ê·œìœ¨ ìˆëŠ” ì² ìˆ˜ ê²°ì •ì„ ë‚´ë¦¬ê³  ìˆìŠµë‹ˆë‹¤. ì •í˜•ì™¸ê³¼ ì‚¬ì—…ì˜ ê²½ìš°, ê³„íšëœ ë¶„ì‚¬ë¥¼ í†µí•´ ìƒˆë¡œìš´ ê¸°íšŒê°€ ì°½ì¶œë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operating as DePuy Synthes and led by Namal Nawana, it will be the largest, most comprehensive orthopaedics company with leading market share positions across major categories and addressing a more than $50 billion and growing market opportunity. We expect DePuy Synthes to benefit from a more focused business model with greater flexibility to extend its market leadership, invest in its commercial capabilities and capitalize on profitable growth opportunities.</td><td>DePuy Synthesë¡œ ìš´ì˜ë˜ë©° Namal Nawanaê°€ ì´ë„ëŠ” ì´ íšŒì‚¬ëŠ” ì£¼ìš” ì¹´í…Œê³ ë¦¬ ì „ë°˜ì— ê±¸ì³ ì„ ë„ì ì¸ ì‹œì¥ ì ìœ ìœ¨ì„ ë³´ìœ í•˜ê³  500ì–µ ë‹¬ëŸ¬ ì´ìƒì˜ ì„±ì¥í•˜ëŠ” ì‹œì¥ ê¸°íšŒë¥¼ ë‹¤ë£¨ëŠ” ê°€ì¥ í¬ê³  í¬ê´„ì ì¸ ì •í˜•ì™¸ê³¼ íšŒì‚¬ê°€ ë  ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” DePuy Synthesê°€ ë³´ë‹¤ ì§‘ì¤‘ëœ ì‚¬ì—… ëª¨ë¸ì„ í†µí•´ ì‹œì¥ ë¦¬ë”ì‹­ì„ í™•ì¥í•˜ê³ , ìƒì—…ì  ì—­ëŸ‰ì— íˆ¬ìí•˜ë©°, ìˆ˜ìµì„± ìˆëŠ” ì„±ì¥ ê¸°íšŒë¥¼ í™œìš©í•  ìˆ˜ ìˆëŠ” ë” í° ìœ ì—°ì„±ì˜ í˜œíƒì„ ë°›ì„ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Following the completion of the planned separation, Johnson & Johnson will retain a leadership position in our 6 core growth areas across Innovative Medicine and MedTech, oncology, immunology, neuroscience, cardiovascular, surgery and vision and be able to place even greater focus in our investment towards higher-growth areas where we can meaningfully extend and improve lives. We are positioning each business to win and deliver for our stakeholders. As we move forward in the separation process, we will provide additional information as appropriate, and Joe will share more details shortly. As I said at the start of the call, we are in a new era of accelerated growth at Johnson & Johnson.</td><td>ê³„íšëœ ë¶„í•  ì™„ë£Œì— ë”°ë¼ Johnson & Johnsonì€ í˜ì‹ ì˜ì•½í’ˆê³¼ ë©”ë“œí…Œí¬ ë¶€ë¬¸ì˜ 6ê°œ í•µì‹¬ ì„±ì¥ ì˜ì—­ì¸ ì¢…ì–‘í•™, ë©´ì—­í•™, ì‹ ê²½ê³¼í•™, ì‹¬í˜ˆê´€, ìˆ˜ìˆ  ë° ì‹œë ¥ ë¶„ì•¼ì—ì„œ ì„ ë„ì  ì§€ìœ„ë¥¼ ìœ ì§€í•˜ê²Œ ë  ê²ƒì´ë©°, ìƒëª…ì„ ì˜ë¯¸ ìˆê²Œ ì—°ì¥í•˜ê³  ê°œì„ í•  ìˆ˜ ìˆëŠ” ê³ ì„±ì¥ ì˜ì—­ì— ëŒ€í•œ íˆ¬ìì— ë”ìš± ì§‘ì¤‘í•  ìˆ˜ ìˆê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê° ì‚¬ì—…ë¶€ê°€ ìŠ¹ë¦¬í•˜ê³  ì´í•´ê´€ê³„ìë“¤ì—ê²Œ ì„±ê³¼ë¥¼ ì œê³µí•  ìˆ˜ ìˆë„ë¡ í¬ì§€ì…”ë‹í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¶„í•  ê³¼ì •ì„ ì§„í–‰í•˜ë©´ì„œ ì ì ˆí•œ ì‹œì ì— ì¶”ê°€ ì •ë³´ë¥¼ ì œê³µí•  ì˜ˆì •ì´ë©°, Joeê°€ ê³§ ë” ìì„¸í•œ ë‚´ìš©ì„ ê³µìœ í•  ê²ƒì…ë‹ˆë‹¤. í†µí™” ì‹œì‘ ì‹œ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ìš°ë¦¬ëŠ” Johnson & Johnsonì˜ ê°€ì†í™”ëœ ì„±ì¥ì˜ ìƒˆë¡œìš´ ì‹œëŒ€ì— ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This is more than just another strong quarter. It is proof that our momentum is building and that our impact is accelerating. Thank you very much, and I will now turn the call back over to Darren. Darren Snellgrove<br>Vice President of Investor Relations<br><br>Thank you, Joaquin. Moving to our financial results. Unless otherwise stated, the percentages quoted represent operational results and therefore, exclude the impact of currency translation. Starting with Q3 2025 sales results. Worldwide sales were $24 billion for the quarter. Sales increased 5.4% despite an approximate 640 basis point headwind from STELARA. Growth in the U.S. was 6.2% and 4.4% outside of the U.S.</td><td>ì´ëŠ” ë‹¨ìˆœíˆ ë˜ ë‹¤ë¥¸ ê°•ë ¥í•œ ë¶„ê¸° ì‹¤ì  ê·¸ ì´ìƒì…ë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ì˜ ëª¨ë©˜í…€ì´ êµ¬ì¶•ë˜ê³  ìˆìœ¼ë©° ìš°ë¦¬ì˜ ì˜í–¥ë ¥ì´ ê°€ì†í™”ë˜ê³  ìˆë‹¤ëŠ” ì¦ê±°ì…ë‹ˆë‹¤. ëŒ€ë‹¨íˆ ê°ì‚¬í•©ë‹ˆë‹¤. ì´ì œ ë‹¤ë Œì—ê²Œ ë‹¤ì‹œ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>ë‹¤ë Œ ìŠ¤ë„¬ê·¸ë¡œë¸Œ<br>íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ë¶€ì‚¬ì¥<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, í˜¸ì•„í‚¨. ì¬ë¬´ ì‹¤ì ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ë³„ë„ë¡œ ëª…ì‹œë˜ì§€ ì•ŠëŠ” í•œ, ì¸ìš©ëœ ë°±ë¶„ìœ¨ì€ ìš´ì˜ ì‹¤ì ì„ ë‚˜íƒ€ë‚´ë©° ë”°ë¼ì„œ í™˜ìœ¨ ë³€ë™ì˜ ì˜í–¥ì€ ì œì™¸ë©ë‹ˆë‹¤. 2025ë…„ 3ë¶„ê¸° ë§¤ì¶œ ì‹¤ì ë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. ë¶„ê¸° ì „ ì„¸ê³„ ë§¤ì¶œì€ 240ì–µ ë‹¬ëŸ¬ì˜€ìŠµë‹ˆë‹¤. STELARAë¡œ ì¸í•œ ì•½ 640 ë² ì´ì‹œìŠ¤ í¬ì¸íŠ¸ì˜ ì—­í’ì—ë„ ë¶ˆêµ¬í•˜ê³  ë§¤ì¶œì€ 5.4% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ë¯¸êµ­ ë‚´ ì„±ì¥ë¥ ì€ 6.2%ì˜€ê³  ë¯¸êµ­ ì™¸ ì§€ì—­ì€ 4.4%ì˜€ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Acquisitions and divestitures had a net positive impact on worldwide growth of 100 basis points, primarily driven by the Intra-Cellular acquisition. Turning now to earnings. For the quarter, net earnings were $5.2 billion with diluted earnings per share of $2.12 versus diluted earnings per share of $1.11 a year ago. Adjusted net earnings for the quarter were $6.8 billion with adjusted diluted earnings per share of $2.80, both representing an increase of 15.7% compared to the third quarter of 2024. As a reminder, results in the third quarter of 2024 were impacted by the acquired IPR&D expense of $1.25 billion associated with the NM26 bispecific antibody.</td><td>ì¸ìˆ˜í•©ë³‘ ë° ë§¤ê°ì€ ì „ ì„¸ê³„ ì„±ì¥ë¥ ì— 100ë² ì´ì‹œìŠ¤í¬ì¸íŠ¸ì˜ ìˆœê¸ì •ì  ì˜í–¥ì„ ë¯¸ì³¤ìœ¼ë©°, ì´ëŠ” ì£¼ë¡œ Intra-Cellular ì¸ìˆ˜ì— ì˜í•œ ê²ƒì…ë‹ˆë‹¤. ì´ì œ ìˆ˜ìµìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸° ìˆœì´ìµì€ 52ì–µ ë‹¬ëŸ¬ì˜€ìœ¼ë©°, í¬ì„ì£¼ë‹¹ìˆœì´ìµì€ 2.12ë‹¬ëŸ¬ë¡œ ì „ë…„ ë™ê¸° í¬ì„ì£¼ë‹¹ìˆœì´ìµ 1.11ë‹¬ëŸ¬ ëŒ€ë¹„ ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸° ì¡°ì •ìˆœì´ìµì€ 68ì–µ ë‹¬ëŸ¬ì˜€ìœ¼ë©°, ì¡°ì •í¬ì„ì£¼ë‹¹ìˆœì´ìµì€ 2.80ë‹¬ëŸ¬ë¡œ, ë‘˜ ë‹¤ 2024ë…„ 3ë¶„ê¸° ëŒ€ë¹„ 15.7% ì¦ê°€ë¥¼ ë‚˜íƒ€ëƒˆìŠµë‹ˆë‹¤. ì°¸ê³ ë¡œ 2024ë…„ 3ë¶„ê¸° ì‹¤ì ì€ NM26 ì´ì¤‘íŠ¹ì´í•­ì²´ì™€ ê´€ë ¨ëœ 12ì–µ 5ì²œë§Œ ë‹¬ëŸ¬ì˜ ì·¨ë“ IPR&D ë¹„ìš©ì˜ ì˜í–¥ì„ ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>I will now comment on business sales performance in the quarter, focusing on the 6 key areas where meaningful innovation is driving our performance and fueling long-term growth. Beginning with Innovative Medicine, where our results demonstrate the depth of our expertise across oncology, immunology and neuroscience. Worldwide sales of $15.6 billion increased 5.3% despite an approximate 1,070 basis point headwind from STELARA, illustrating the continued strength of our key brands and new launches. Growth in the U.S. was 6% and 4.3% outside of the U.S. Acquisitions and divestitures had a net positive impact of 160 basis points on worldwide growth due to the Intra-Cellular acquisition.</td><td>ì´ì œ ë¶„ê¸° ì‹¤ì ì„ ê²¬ì¸í•˜ê³  ì¥ê¸° ì„±ì¥ì„ ì´‰ì§„í•˜ëŠ” ì˜ë¯¸ ìˆëŠ” í˜ì‹ ì´ ì´ë£¨ì–´ì§€ê³  ìˆëŠ” 6ê°œ í•µì‹¬ ì˜ì—­ì„ ì¤‘ì‹¬ìœ¼ë¡œ ì‚¬ì—…ë¶€ë³„ ë§¤ì¶œ ì„±ê³¼ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¨¼ì € í˜ì‹ ì˜ì•½í’ˆ ë¶€ë¬¸ë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. ì´ ë¶€ë¬¸ì˜ ì‹¤ì ì€ ì¢…ì–‘í•™, ë©´ì—­í•™, ì‹ ê²½ê³¼í•™ ì „ë°˜ì— ê±¸ì¹œ ë‹¹ì‚¬ì˜ ì „ë¬¸ì„± ê¹Šì´ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤. ì „ ì„¸ê³„ ë§¤ì¶œì€ 156ì–µ ë‹¬ëŸ¬ë¡œ STELARAë¡œ ì¸í•œ ì•½ 1,070 ë² ì´ì‹œìŠ¤ í¬ì¸íŠ¸ì˜ ì—­í’ì—ë„ ë¶ˆêµ¬í•˜ê³  5.3% ì¦ê°€í–ˆìœ¼ë©°, ì´ëŠ” ì£¼ìš” ë¸Œëœë“œë“¤ê³¼ ì‹ ê·œ ì¶œì‹œ ì œí’ˆë“¤ì˜ ì§€ì†ì ì¸ ê°•ì„¸ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤. ë¯¸êµ­ì—ì„œëŠ” 6% ì„±ì¥í–ˆê³ , ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œëŠ” 4.3% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ì¸ìˆ˜í•©ë³‘ ë° ë§¤ê°ì€ Intra-Cellular ì¸ìˆ˜ë¡œ ì¸í•´ ì „ ì„¸ê³„ ì„±ì¥ë¥ ì— 160 ë² ì´ì‹œìŠ¤ í¬ì¸íŠ¸ì˜ ìˆœê¸ì •ì  ì˜í–¥ì„ ë¯¸ì³¤ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In oncology, starting with multiple myeloma, DARZALEX growth was 19.9%, primarily driven by continued strong share gains of approximately 5.7 points across all lines of therapy with nearly 9 points in the frontline setting as well as market growth. CARVYKTI achieved sales of $524 million with growth of 81.4%, driven by share gains and site expansion. This reflects continued strong sequential growth of 18.5% as our expansion outside the U.S. progresses. TECVAYLI and TALVEY growth was 29.9% and 59.1%, respectively, bolstered by continued expansion into the community setting.</td><td>ì¢…ì–‘í•™ ë¶„ì•¼ì—ì„œ ë‹¤ë°œì„± ê³¨ìˆ˜ì¢…ë¶€í„° ì‚´í´ë³´ë©´, DARZALEXì˜ ì„±ì¥ë¥ ì€ 19.9%ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” ì£¼ë¡œ ëª¨ë“  ì¹˜ë£Œ ë‹¨ê³„ì—ì„œ ì•½ 5.7í¬ì¸íŠ¸ì˜ ì§€ì†ì ì´ê³  ê°•ë ¥í•œ ì ìœ ìœ¨ ì¦ê°€ì— ê¸°ì¸í•˜ë©°, íŠ¹íˆ 1ì°¨ ì¹˜ë£Œ í™˜ê²½ì—ì„œëŠ” ê±°ì˜ 9í¬ì¸íŠ¸ì˜ ì¦ê°€ì™€ ì‹œì¥ ì„±ì¥ì´ ì£¼ìš” ë™ë ¥ì´ì—ˆìŠµë‹ˆë‹¤. CARVYKTIëŠ” 5ì–µ 2,400ë§Œ ë‹¬ëŸ¬ì˜ ë§¤ì¶œì„ ë‹¬ì„±í•˜ë©° 81.4%ì˜ ì„±ì¥ë¥ ì„ ê¸°ë¡í–ˆëŠ”ë°, ì´ëŠ” ì ìœ ìœ¨ ì¦ê°€ì™€ ì‚¬ì´íŠ¸ í™•ì¥ì— ì˜í•œ ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ë¯¸êµ­ ì™¸ ì§€ì—­ìœ¼ë¡œì˜ í™•ì¥ì´ ì§„í–‰ë˜ë©´ì„œ 18.5%ì˜ ê°•ë ¥í•œ ì—°ì† ì„±ì¥ì„ ì§€ì†í•˜ê³  ìˆìŒì„ ë°˜ì˜í•©ë‹ˆë‹¤. TECVAYLIì™€ TALVEYëŠ” ê°ê° 29.9%ì™€ 59.1%ì˜ ì„±ì¥ë¥ ì„ ë³´ì˜€ìœ¼ë©°, ì´ëŠ” ì§€ì—­ì‚¬íšŒ ì˜ë£Œê¸°ê´€ìœ¼ë¡œì˜ ì§€ì†ì ì¸ í™•ì¥ì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>In prostate cancer, ERLEADA delivered strong growth of 15.3% due to market growth and continued share gains, partially offset by the impact of Part D redesign. In lung cancer, RYBREVANT plus LAZCLUZE delivered sales of $198 million and growth over 100%, driven by continued strong launch uptake. We continue to see share gains in both first and second lines of therapy. Within immunology, TREMFYA delivered very strong growth of 40.1%. We continue to see share gains across all indications with particularly robust momentum from our IBD launch. STELARA declined by 42%, driven by the impact of biosimilar competition and Part D redesign, which is in line with our expectations.</td><td>ì „ë¦½ì„ ì•” ë¶„ì•¼ì—ì„œ ERLEADAëŠ” ì‹œì¥ ì„±ì¥ê³¼ ì§€ì†ì ì¸ ì ìœ ìœ¨ í™•ëŒ€ì— í˜ì…ì–´ 15.3%ì˜ ê²¬ê³ í•œ ì„±ì¥ì„ ë‹¬ì„±í–ˆìœ¼ë‚˜, Part D ì¬ì„¤ê³„ì˜ ì˜í–¥ìœ¼ë¡œ ì¼ë¶€ ìƒì‡„ë˜ì—ˆìŠµë‹ˆë‹¤. íì•” ë¶„ì•¼ì—ì„œëŠ” RYBREVANTì™€ LAZCLUZE ë³‘ìš©ìš”ë²•ì´ 1ì–µ 9,800ë§Œ ë‹¬ëŸ¬ì˜ ë§¤ì¶œì„ ê¸°ë¡í•˜ë©° 100%ë¥¼ ë„˜ëŠ” ì„±ì¥ë¥ ì„ ë³´ì˜€ëŠ”ë°, ì´ëŠ” ì§€ì†ì ìœ¼ë¡œ ê°•ë ¥í•œ ì¶œì‹œ í›„ ìˆ˜ìš” ì¦ê°€ì— ê¸°ì¸í•©ë‹ˆë‹¤. 1ì°¨ ë° 2ì°¨ ì¹˜ë£Œ ë¼ì¸ ëª¨ë‘ì—ì„œ ì ìœ ìœ¨ í™•ëŒ€ë¥¼ ì§€ì†í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë©´ì—­í•™ ë¶„ì•¼ì—ì„œëŠ” TREMFYAê°€ 40.1%ì˜ ë§¤ìš° ê°•ë ¥í•œ ì„±ì¥ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ëª¨ë“  ì ì‘ì¦ì—ì„œ ì ìœ ìœ¨ í™•ëŒ€ë¥¼ ì§€ì†í•˜ê³  ìˆìœ¼ë©°, íŠ¹íˆ IBD ì¶œì‹œë¡œë¶€í„° ê²¬ê³ í•œ ëª¨ë©˜í…€ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. STELARAëŠ” ë°”ì´ì˜¤ì‹œë°€ëŸ¬ ê²½ìŸê³¼ Part D ì¬ì„¤ê³„ì˜ ì˜í–¥ìœ¼ë¡œ 42% ê°ì†Œí–ˆìœ¼ë©°, ì´ëŠ” ë‹¹ì‚¬ì˜ ì˜ˆìƒê³¼ ì¼ì¹˜í•©ë‹ˆë‹¤.</td></tr>
<tr><td>In neuroscience, SPRAVATO grew an impressive 60.8%, driven by continued strong demand from physicians and patients. CAPLYTA, which was acquired in Q2 as part of the Intra-Cellular acquisition, delivered sales of $240 million and reflects healthy sequential growth of 13.4%. Now moving to MedTech. Worldwide sales of $8.4 billion increased 5.6%, with growth of 6.6% in the U.S. and 4.5% outside the U.S., driven by strong performance in our 3 focus areas: Cardiovascular, Surgery and Vision. Acquisitions and divestitures had a net negative impact of 10 basis points on worldwide growth.</td><td>ì‹ ê²½ê³¼í•™ ë¶„ì•¼ì—ì„œ SPRAVATOëŠ” ì˜ì‚¬ì™€ í™˜ìë“¤ì˜ ì§€ì†ì ì¸ ê°•í•œ ìˆ˜ìš”ì— í˜ì…ì–´ 60.8%ë¼ëŠ” ì¸ìƒì ì¸ ì„±ì¥ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. 2ë¶„ê¸° Intra-Cellular ì¸ìˆ˜ì˜ ì¼í™˜ìœ¼ë¡œ ì·¨ë“í•œ CAPLYTAëŠ” 2ì–µ 4ì²œë§Œ ë‹¬ëŸ¬ì˜ ë§¤ì¶œì„ ë‹¬ì„±í–ˆìœ¼ë©°, ì´ëŠ” 13.4%ì˜ ê±´ì „í•œ ìˆœì°¨ ì„±ì¥ì„ ë°˜ì˜í•©ë‹ˆë‹¤. <br><br>ì´ì œ ë©”ë“œí…Œí¬ ë¶€ë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì „ ì„¸ê³„ ë§¤ì¶œì€ 84ì–µ ë‹¬ëŸ¬ë¡œ 5.6% ì¦ê°€í–ˆìœ¼ë©°, ë¯¸êµ­ì—ì„œ 6.6%, ë¯¸êµ­ ì™¸ ì§€ì—­ì—ì„œ 4.5% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ì˜ 3ëŒ€ ì¤‘ì  ë¶„ì•¼ì¸ ì‹¬í˜ˆê´€, ìˆ˜ìˆ , ê·¸ë¦¬ê³  ì‹œë ¥ ë¶„ì•¼ì˜ ê°•ë ¥í•œ ì„±ê³¼ì— ê¸°ì¸í•©ë‹ˆë‹¤. ì¸ìˆ˜í•©ë³‘ ë° ë§¤ê°ì€ ì „ ì„¸ê³„ ì„±ì¥ë¥ ì— 10ë² ì´ì‹œìŠ¤í¬ì¸íŠ¸ì˜ ìˆœ ë§ˆì´ë„ˆìŠ¤ ì˜í–¥ì„ ë¯¸ì³¤ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In Cardiovascular, electrophysiology delivered growth of 9.7% versus prior year, driven by procedure growth, commercial execution, VARIPULSE and other new products and strength in competitive mapping. Abiomed delivered growth of 15.6% with continued strong adoption of Impella technology and Shockwave increased 20.9%, driven by double-digit growth globally in both coronary and peripheral. Surgery grew 3.3% despite divestitures negatively impacting results by approximately 50 basis points. Performance was primarily driven by technology penetration in wound closure, the strength of the portfolio and commercial execution in biosurgery as well as a onetime reserve adjustment in the quarter.</td><td>ì‹¬í˜ˆê´€ ë¶€ë¬¸ì—ì„œ ì „ê¸°ìƒë¦¬í•™ì€ ì „ë…„ ëŒ€ë¹„ 9.7% ì„±ì¥ì„ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” ì‹œìˆ  ì¦ê°€, ìƒì—…ì  ì‹¤í–‰ë ¥, VARIPULSE ë° ê¸°íƒ€ ì‹ ì œí’ˆ, ê·¸ë¦¬ê³  ê²½ìŸë ¥ ìˆëŠ” ë§¤í•‘ ë¶„ì•¼ì˜ ê°•ì„¸ì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤. AbiomedëŠ” Impella ê¸°ìˆ ì˜ ì§€ì†ì ì¸ ê°•ë ¥í•œ ì±„íƒìœ¼ë¡œ 15.6% ì„±ì¥ì„ ë‹¬ì„±í–ˆê³ , ShockwaveëŠ” ê´€ìƒë™ë§¥ê³¼ ë§ì´ˆí˜ˆê´€ ëª¨ë‘ì—ì„œ ì „ ì„¸ê³„ì ìœ¼ë¡œ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ê¸°ë¡í•˜ë©° 20.9% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ìˆ˜ìˆ  ë¶€ë¬¸ì€ ë§¤ê°ì´ ì‹¤ì ì— ì•½ 50ë² ì´ì‹œìŠ¤í¬ì¸íŠ¸ì˜ ë¶€ì •ì  ì˜í–¥ì„ ë¯¸ì³¤ìŒì—ë„ ë¶ˆêµ¬í•˜ê³  3.3% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì„±ê³¼ëŠ” ì£¼ë¡œ ìƒì²˜ ë´‰í•© ë¶„ì•¼ì˜ ê¸°ìˆ  ì¹¨íˆ¬ìœ¨ ì¦ê°€, ë°”ì´ì˜¤ìˆ˜ìˆ  í¬íŠ¸í´ë¦¬ì˜¤ì˜ ê°•ì ê³¼ ìƒì—…ì  ì‹¤í–‰ë ¥, ê·¸ë¦¬ê³  í•´ë‹¹ ë¶„ê¸°ì˜ ì¼íšŒì„± ì¶©ë‹¹ê¸ˆ ì¡°ì •ì— ê¸°ì¸í•œ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Growth was partially offset by competitive pressures in energy and the negative impact of China VBP across the portfolio. In Vision, contact lenses and other products grew 3.5%, driven by market growth, strong performance in the ACUVUE OASYS 1-day family of contact lenses. This includes the recent launches of OASYS MAX 1-day multifocal for astigmatism and MAX 1-day for astigmatism as well as continued strategic price actions. Surgical Vision had another strong quarter with growth of 13.8%, driven by new product innovations such as TECNIS PureSee, Odyssey and Eyhance, robust demand and strong commercial execution. These results further solidify our leadership positions in Vision.</td><td>ì„±ì¥ì€ ì—ë„ˆì§€ ë¶€ë¬¸ì˜ ê²½ìŸ ì••ë ¥ê³¼ í¬íŠ¸í´ë¦¬ì˜¤ ì „ë°˜ì— ê±¸ì¹œ ì¤‘êµ­ VBPì˜ ë¶€ì •ì  ì˜í–¥ìœ¼ë¡œ ë¶€ë¶„ì ìœ¼ë¡œ ìƒì‡„ë˜ì—ˆìŠµë‹ˆë‹¤. ë¹„ì „ ë¶€ë¬¸ì—ì„œëŠ” ì½˜íƒíŠ¸ë Œì¦ˆ ë° ê¸°íƒ€ ì œí’ˆì´ 3.5% ì„±ì¥í–ˆìœ¼ë©°, ì´ëŠ” ì‹œì¥ ì„±ì¥ê³¼ ACUVUE OASYS 1-day ì½˜íƒíŠ¸ë Œì¦ˆ ì œí’ˆêµ°ì˜ ê°•ë ¥í•œ ì„±ê³¼ì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ìµœê·¼ ì¶œì‹œëœ OASYS MAX 1-day ë‚œì‹œìš© ë©€í‹°í¬ì»¬ê³¼ MAX 1-day ë‚œì‹œìš© ì œí’ˆ, ê·¸ë¦¬ê³  ì§€ì†ì ì¸ ì „ëµì  ê°€ê²© ì¡°ì¹˜ê°€ í¬í•¨ë©ë‹ˆë‹¤. ìˆ˜ìˆ ìš© ë¹„ì „ ë¶€ë¬¸ì€ TECNIS PureSee, Odyssey, Eyhanceì™€ ê°™ì€ ì‹ ì œí’ˆ í˜ì‹ , ê²¬ê³ í•œ ìˆ˜ìš”, ê·¸ë¦¬ê³  ê°•ë ¥í•œ ìƒì—…ì  ì‹¤í–‰ë ¥ì— í˜ì…ì–´ 13.8% ì„±ì¥í•˜ë©° ë˜ ë‹¤ë¥¸ ê°•ë ¥í•œ ë¶„ê¸°ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê²°ê³¼ëŠ” ë¹„ì „ ë¶€ë¬¸ì—ì„œ ìš°ë¦¬ì˜ ì„ ë„ì  ì§€ìœ„ë¥¼ ë”ìš± ê³µê³ íˆ í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>As Joaquin noted, we have today announced our intent to separate the Orthopaedic business. Orthopaedic growth this quarter is gaining momentum and increased to 2.4% Importantly, hips and knees returned to growth this quarter, delivering 5.1% and 5.6% growth, respectively. Now turning to our consolidated statement of earnings for the third quarter of 2025. I'd like to highlight a few noteworthy items that have changed compared to the same quarter a year ago.</td><td>í˜¸ì•„í‚¨ì´ ì–¸ê¸‰í•œ ë°”ì™€ ê°™ì´, ì €í¬ëŠ” ì˜¤ëŠ˜ ì •í˜•ì™¸ê³¼ ì‚¬ì—…ë¶€ ë¶„ë¦¬ ê³„íšì„ ë°œí‘œí–ˆìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸° ì •í˜•ì™¸ê³¼ ì‚¬ì—…ì˜ ì„±ì¥ì„¸ê°€ íƒ„ë ¥ì„ ë°›ìœ¼ë©° 2.4% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. íŠ¹íˆ ì¤‘ìš”í•œ ì ì€ ê³ ê´€ì ˆê³¼ ë¬´ë¦ ì œí’ˆì´ ì´ë²ˆ ë¶„ê¸°ì— ì„±ì¥ì„¸ë¡œ ëŒì•„ì„œë©° ê°ê° 5.1%ì™€ 5.6%ì˜ ì„±ì¥ì„ ê¸°ë¡í–ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. <br><br>ì´ì œ 2025ë…„ 3ë¶„ê¸° ì—°ê²°ì†ìµê³„ì‚°ì„œë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì „ë…„ ë™ê¸° ëŒ€ë¹„ ë³€í™”ëœ ëª‡ ê°€ì§€ ì£¼ëª©í•  ë§Œí•œ í•­ëª©ë“¤ì„ ê°•ì¡°í•˜ê³ ì í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Cost of products sold leveraged by 60 basis points, driven by a reduction in amortization expense and favorable currency in the Innovative Medicine business as well as the nonrecurring fair value inventory step-up related to Shockwave in 2024. This was partially offset by unfavorable product mix in Innovative Medicine, along with MedTech macroeconomic factors. Selling, marketing and administrative expenses deleveraged by 40 basis points, driven by increased investment in the recent Intra-Cellular acquisition for CAPLYTA and promotional spend across the Innovative Medicine business, partially offset by expense leveraging in MedTech.</td><td>ì œí’ˆ ë§¤ì¶œì›ê°€ëŠ” 60bp ê°œì„ ë˜ì—ˆëŠ”ë°, ì´ëŠ” í˜ì‹ ì˜ì•½í’ˆ ì‚¬ì—…ë¶€ë¬¸ì˜ ìƒê°ë¹„ ê°ì†Œì™€ ìœ ë¦¬í•œ í™˜ìœ¨ íš¨ê³¼, ê·¸ë¦¬ê³  2024ë…„ Shockwave ê´€ë ¨ ë¹„ê²½ìƒì ì¸ ê³µì •ê°€ì¹˜ ì¬ê³ ìì‚° ë‹¨ê³„ì  ì¦ê°€ê°€ ì£¼ìš” ìš”ì¸ì´ì—ˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ í˜ì‹ ì˜ì•½í’ˆ ì‚¬ì—…ë¶€ë¬¸ì˜ ë¶ˆë¦¬í•œ ì œí’ˆ ë¯¹ìŠ¤ì™€ MedTech ê±°ì‹œê²½ì œì  ìš”ì¸ë“¤ì´ ì´ë¥¼ ì¼ë¶€ ìƒì‡„í–ˆìŠµë‹ˆë‹¤. íŒë§¤ê´€ë¦¬ë¹„ëŠ” 40bp ì•…í™”ë˜ì—ˆëŠ”ë°, ìµœê·¼ ì¸ìˆ˜í•œ Intra-Cellularì˜ CAPLYTAì— ëŒ€í•œ íˆ¬ì ì¦ê°€ì™€ í˜ì‹ ì˜ì•½í’ˆ ì‚¬ì—…ë¶€ë¬¸ ì „ë°˜ì˜ í”„ë¡œëª¨ì…˜ ë¹„ìš© ì¦ê°€ê°€ ì£¼ìš” ìš”ì¸ì´ì—ˆìœ¼ë©°, MedTech ë¶€ë¬¸ì˜ ë¹„ìš© ë ˆë²„ë¦¬ì§€ íš¨ê³¼ê°€ ì´ë¥¼ ì¼ë¶€ ìƒì‡„í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Research and development expenses leveraged by 670 basis points, primarily driven by the expense of $1.25 billion to secure the global rights to the NM26 bispecific antibody recorded in 2024. We continued our strong investment in research and development with $3.7 billion or approximately 15% of sales in Q3. Interest income and expense was a net expense of $18 million as compared to $99 million of income in the third quarter of 2024, primarily driven by a higher average debt balance and a lower average cash balance.</td><td>ì—°êµ¬ê°œë°œë¹„ëŠ” 670 ë² ì´ì‹œìŠ¤ í¬ì¸íŠ¸ ë ˆë²„ë¦¬ì§€ë˜ì—ˆìœ¼ë©°, ì´ëŠ” ì£¼ë¡œ 2024ë…„ì— ê¸°ë¡ëœ NM26 ì´ì¤‘íŠ¹ì´í•­ì²´ì˜ ê¸€ë¡œë²Œ ê¶Œë¦¬ í™•ë³´ë¥¼ ìœ„í•œ 12ì–µ 5ì²œë§Œ ë‹¬ëŸ¬ ë¹„ìš©ì— ì˜í•´ ì£¼ë„ë˜ì—ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” 3ë¶„ê¸°ì— 37ì–µ ë‹¬ëŸ¬ ë˜ëŠ” ë§¤ì¶œì˜ ì•½ 15%ë¡œ ì—°êµ¬ê°œë°œì— ëŒ€í•œ ê°•ë ¥í•œ íˆ¬ìë¥¼ ì§€ì†í–ˆìŠµë‹ˆë‹¤. ì´ììˆ˜ìµê³¼ ì´ìë¹„ìš©ì€ ìˆœ 1,800ë§Œ ë‹¬ëŸ¬ì˜ ë¹„ìš©ìœ¼ë¡œ, 2024ë…„ 3ë¶„ê¸°ì˜ 9,900ë§Œ ë‹¬ëŸ¬ ìˆ˜ìµê³¼ ë¹„êµë©ë‹ˆë‹¤. ì´ëŠ” ì£¼ë¡œ í‰ê·  ë¶€ì±„ ì”ì•¡ ì¦ê°€ì™€ í‰ê·  í˜„ê¸ˆ ì”ì•¡ ê°ì†Œì— ê¸°ì¸í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Other income and expense was net income of $0.5 billion compared to an expense of $1.8 billion in the prior year, primarily driven by a talc litigation charge in 2024 and higher gains on the sales of securities in 2025, partially offset by the monetization of royalty rights recorded in 2024. Regarding taxes in the quarter, our effective tax rate was 31.2% compared to 19.3% in the same period last year. The increase is primarily driven by the onetime $1 billion remeasurement of deferred tax balances, which are required to reflect the changes in statutory tax rates associated with the enactment of the One Big Beautiful Bill Act in the third quarter.</td><td>ê¸°íƒ€ ìˆ˜ìµ ë° ë¹„ìš©ì€ 5ì–µ ë‹¬ëŸ¬ì˜ ìˆœìˆ˜ìµì„ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” ì „ë…„ ë™ê¸° 18ì–µ ë‹¬ëŸ¬ì˜ ë¹„ìš©ê³¼ ë¹„êµë©ë‹ˆë‹¤. ì´ëŠ” ì£¼ë¡œ 2024ë…„ íƒˆí¬ ì†Œì†¡ ê´€ë ¨ ë¹„ìš©ê³¼ 2025ë…„ ìœ ê°€ì¦ê¶Œ ë§¤ê°ìœ¼ë¡œ ì¸í•œ ë†’ì€ ì´ìµì— ê¸°ì¸í•˜ë©°, 2024ë…„ì— ê¸°ë¡ëœ ë¡œì—´í‹° ê¶Œë¦¬ í˜„ê¸ˆí™”ë¡œ ì¼ë¶€ ìƒì‡„ë˜ì—ˆìŠµë‹ˆë‹¤. ë¶„ê¸° ì„¸ê¸ˆê³¼ ê´€ë ¨í•˜ì—¬, ë‹¹ì‚¬ì˜ ì‹¤íš¨ì„¸ìœ¨ì€ 31.2%ë¡œ ì‘ë…„ ë™ê¸° 19.3%ì™€ ë¹„êµë©ë‹ˆë‹¤. ì´ëŸ¬í•œ ì¦ê°€ëŠ” ì£¼ë¡œ 3ë¶„ê¸°ì— ì œì •ëœ ì› ë¹… ë·°í‹°í’€ ë¹Œ ë²•ì•ˆ(One Big Beautiful Bill Act)ê³¼ ê´€ë ¨ëœ ë²•ì •ì„¸ìœ¨ ë³€ê²½ì„ ë°˜ì˜í•˜ê¸° ìœ„í•´ ìš”êµ¬ë˜ëŠ” ì´ì—°ë²•ì¸ì„¸ ì”ì•¡ì˜ ì¼íšŒì„± 10ì–µ ë‹¬ëŸ¬ ì¬ì¸¡ì •ì— ê¸°ì¸í•©ë‹ˆë‹¤.</td></tr>
<tr><td>More information can be found in the company's Form 10-Q. Lastly, I'll direct your attention to the box section of the slide, where we have also provided the company's income before tax, net earnings and earnings per share adjusted to exclude the impact of intangible amortization expense and special items. Now let's look at adjusted income before tax by segment for the quarter.</td><td>ë” ìì„¸í•œ ì •ë³´ëŠ” íšŒì‚¬ì˜ Form 10-Qì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ìŠ¬ë¼ì´ë“œì˜ ë°•ìŠ¤ ì„¹ì…˜ì„ ì£¼ëª©í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ë¬´í˜•ìì‚° ìƒê°ë¹„ìš©ê³¼ íŠ¹ë³„í•­ëª©ì˜ ì˜í–¥ì„ ì œì™¸í•˜ê³  ì¡°ì •ëœ íšŒì‚¬ì˜ ì„¸ì „ì´ìµ, ìˆœì´ìµ, ê·¸ë¦¬ê³  ì£¼ë‹¹ìˆœì´ìµì„ ì œê³µí•˜ì˜€ìŠµë‹ˆë‹¤. ì´ì œ ë¶„ê¸°ë³„ ë¶€ë¬¸ë³„ ì¡°ì • ì„¸ì „ì´ìµì„ ì‚´í´ë³´ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Innovative Medicine margin improved from 37.9% to 44.3%, primarily driven by the onetime expense of $1.25 billion to secure the global rights of the NM26 bispecific antibody recorded in 2024, partially offset by increased investment in commercial spend in 2025 and the nonrecurring monetization of royalty rights in 2024. MedTech margin declined from 24.1% to 21%, driven by macroeconomic factors and cost of products sold, partially offset by expense leveraging in SM&A. This concludes the sales and earnings portion of the call, and I will now turn the call over to Joe. Joseph Wolk<br>Executive VP & CFO<br><br>Thanks, Darren. Hello, everyone, and thank you for joining us today.</td><td>í˜ì‹ ì˜ì•½í’ˆ ë§ˆì§„ì€ 37.9%ì—ì„œ 44.3%ë¡œ ê°œì„ ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì£¼ë¡œ 2024ë…„ì— ê¸°ë¡ëœ NM26 ì´ì¤‘íŠ¹ì´í•­ì²´ì˜ ê¸€ë¡œë²Œ ê¶Œë¦¬ í™•ë³´ë¥¼ ìœ„í•œ 12ì–µ 5ì²œë§Œ ë‹¬ëŸ¬ì˜ ì¼íšŒì„± ë¹„ìš©ì— ì˜í•´ ì£¼ë„ë˜ì—ˆìœ¼ë©°, 2025ë…„ ìƒì—…ì  ì§€ì¶œ íˆ¬ì ì¦ê°€ì™€ 2024ë…„ ë¡œì—´í‹° ê¶Œë¦¬ì˜ ë¹„ê²½ìƒì  ìˆ˜ìµí™”ë¡œ ë¶€ë¶„ì ìœ¼ë¡œ ìƒì‡„ë˜ì—ˆìŠµë‹ˆë‹¤. ë©”ë“œí…Œí¬ ë§ˆì§„ì€ 24.1%ì—ì„œ 21%ë¡œ ê°ì†Œí–ˆëŠ”ë°, ì´ëŠ” ê±°ì‹œê²½ì œì  ìš”ì¸ê³¼ ì œí’ˆ ë§¤ì¶œì›ê°€ì— ì˜í•´ ì£¼ë„ë˜ì—ˆìœ¼ë©°, íŒë§¤ê´€ë¦¬ë¹„ì˜ ë¹„ìš© ë ˆë²„ë¦¬ì§€ íš¨ê³¼ë¡œ ë¶€ë¶„ì ìœ¼ë¡œ ìƒì‡„ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ê²ƒìœ¼ë¡œ ë§¤ì¶œ ë° ìˆ˜ìµ ë¶€ë¶„ì˜ ë°œí‘œë¥¼ ë§ˆì¹˜ê² ìœ¼ë©°, ì´ì œ ì¡°ì—ê²Œ ë°œí‘œë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>ì¡°ì…‰ ì›”í¬<br>ë¶€ì‚¬ì¥ ê²¸ CFO<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, ëŒ€ëŸ°. ì•ˆë…•í•˜ì„¸ìš”, ì—¬ëŸ¬ë¶„. ì˜¤ëŠ˜ ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>In the third quarter, we sustained momentum across our in-market portfolio, delivering upon the heightened financial expectations we guided to last quarter. In Innovative Medicine, we continue to grow through the STELARA loss of exclusivity as we said we would. The progression of our pipeline, evidenced by significant regulatory milestones, adds further depth to our 3 focus areas of oncology, immunology and neuroscience. We are well positioned for the balance of the decade. In MedTech, we improved adjusted operational sales across key areas of the business.</td><td>3ë¶„ê¸°ì—ëŠ” ì‹œì¥ ë‚´ í¬íŠ¸í´ë¦¬ì˜¤ ì „ë°˜ì—ì„œ ëª¨ë©˜í…€ì„ ì§€ì†í•˜ë©°, ì§€ë‚œ ë¶„ê¸°ì— ê°€ì´ë˜ìŠ¤ë¡œ ì œì‹œí–ˆë˜ ë†’ì•„ì§„ ì¬ë¬´ì  ê¸°ëŒ€ì¹˜ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. í˜ì‹ ì˜ì•½í’ˆ ë¶€ë¬¸ì—ì„œëŠ” ì €í¬ê°€ ì˜ˆìƒí–ˆë˜ ëŒ€ë¡œ STELARAì˜ ë…ì ê¶Œ ë§Œë£Œì—ë„ ë¶ˆêµ¬í•˜ê³  ì§€ì†ì ì¸ ì„±ì¥ì„ ì´ì–´ê°€ê³  ìˆìŠµë‹ˆë‹¤. ì¤‘ìš”í•œ ê·œì œ ìŠ¹ì¸ ì´ì •í‘œë¡œ ì…ì¦ëœ íŒŒì´í”„ë¼ì¸ì˜ ì§„ì „ì€ ì¢…ì–‘í•™, ë©´ì—­í•™, ì‹ ê²½ê³¼í•™ì´ë¼ëŠ” ì €í¬ì˜ 3ëŒ€ í•µì‹¬ ì˜ì—­ì— ë”ìš± ê¹Šì´ë¥¼ ë”í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” í–¥í›„ 10ë…„ê°„ì˜ ë‚˜ë¨¸ì§€ ê¸°ê°„ì— ëŒ€í•´ ìœ ë¦¬í•œ ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤. ë©”ë“œí…Œí¬ ë¶€ë¬¸ì—ì„œëŠ” ì‚¬ì—…ì˜ í•µì‹¬ ì˜ì—­ ì „ë°˜ì—ì„œ ì¡°ì • ìš´ì˜ ë§¤ì¶œì„ ê°œì„ í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>As Joaquin mentioned, we are sharpening our focus on high-growth, high-margin markets where we can improve patient outcomes as this morning's announcement regarding the DePuy Synthes business indicates. In a moment, I will build upon Joaquin's comments regarding that announcement. The foundation we have set, combined with the progression of our pipeline, strongly position the company for accelerated growth. It also reinforces our conviction to deliver on the upper end of our long-term growth targets. Let me provide a brief update on the Daubert motions pending in the talc litigation.</td><td>í˜¸ì•„í‚¨ì´ ì–¸ê¸‰í–ˆë“¯ì´, ì˜¤ëŠ˜ ì•„ì¹¨ DePuy Synthes ì‚¬ì—… ê´€ë ¨ ë°œí‘œì—ì„œ ì•Œ ìˆ˜ ìˆë“¯ì´ ì €í¬ëŠ” í™˜ì ì¹˜ë£Œ ê²°ê³¼ë¥¼ ê°œì„ í•  ìˆ˜ ìˆëŠ” ê³ ì„±ì¥, ê³ ë§ˆì§„ ì‹œì¥ì— ì§‘ì¤‘ì„ ê°•í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì ì‹œ í›„ í•´ë‹¹ ë°œí‘œì— ëŒ€í•œ í˜¸ì•„í‚¨ì˜ ì½”ë©˜íŠ¸ë¥¼ ë³´ì™„í•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì €í¬ê°€ êµ¬ì¶•í•œ ê¸°ë°˜ê³¼ íŒŒì´í”„ë¼ì¸ì˜ ì§„ì „ì€ íšŒì‚¬ì˜ ê°€ì†í™”ëœ ì„±ì¥ì„ ìœ„í•œ ê°•ë ¥í•œ í¬ì§€ì…”ë‹ì„ ì œê³µí•©ë‹ˆë‹¤. ì´ëŠ” ë˜í•œ ì¥ê¸° ì„±ì¥ ëª©í‘œì˜ ìƒë‹¨ì„ ë‹¬ì„±í•˜ê² ë‹¤ëŠ” ì €í¬ì˜ í™•ì‹ ì„ ë”ìš± ê°•í™”ì‹œì¼œ ì¤ë‹ˆë‹¤. íƒˆí¬ ì†Œì†¡ì—ì„œ ê³„ë¥˜ ì¤‘ì¸ ë„ë²„íŠ¸ ì‹ ì²­ì— ëŒ€í•´ ê°„ëµíˆ ì—…ë°ì´íŠ¸í•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>As you are aware, this is the judicial process by which the court will reexamine the junk science that the mass tort plaintiffs bar can Cox to fuel baseless claims against Johnson & Johnson as well as many American businesses. We look forward to and expect to secure favorable rulings on the Daubert motions, which should be rendered by the first quarter of 2026. Now turning to cash and capital allocation. We generated $14 billion in free cash flow through the first 9 months of the year.</td><td>ì•„ì‹œë‹¤ì‹œí”¼, ì´ëŠ” ì§‘ë‹¨ ë¶ˆë²•í–‰ìœ„ ì›ê³ ì¸¡ ë³€í˜¸ì‚¬ë“¤ì´ ì¡´ìŠ¨ì•¤ë“œì¡´ìŠ¨ê³¼ ë§ì€ ë¯¸êµ­ ê¸°ì—…ë“¤ì„ ìƒëŒ€ë¡œ ê·¼ê±° ì—†ëŠ” ì†Œì†¡ì„ ì œê¸°í•˜ê¸° ìœ„í•´ ì´ìš©í•œ ì—‰í„°ë¦¬ ê³¼í•™ì„ ë²•ì›ì´ ì¬ê²€í† í•˜ëŠ” ì‚¬ë²• ì ˆì°¨ì…ë‹ˆë‹¤. ì €í¬ëŠ” 2026ë…„ 1ë¶„ê¸°ê¹Œì§€ ë‚´ë ¤ì§ˆ ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ëŠ” ë„ë²„íŠ¸ ì‹ ì²­ì— ëŒ€í•´ ìœ ë¦¬í•œ íŒê²°ì„ í™•ë³´í•  ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì´ì œ í˜„ê¸ˆ ë° ìë³¸ ë°°ë¶„ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì˜¬í•´ ì²« 9ê°œì›” ë™ì•ˆ 140ì–µ ë‹¬ëŸ¬ì˜ ì‰ì—¬í˜„ê¸ˆíë¦„ì„ ì°½ì¶œí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We ended the third quarter with approximately $19 billion in cash and marketable securities and $46 billion of debt for a net debt position of $27 billion versus the $32 billion of net debt reported in the second quarter. We continue to utilize our free cash flow generation and strong balance sheet to invest in innovation and return capital directly to shareholders. We are often asked about our appetite for acquisitions to meet financial targets. I can be very clear on this. We rely on a thoughtful long-term approach to growing through any loss of exclusivity and won't carelessly deploy capital on speculative transactions out of desperation.</td><td>3ë¶„ê¸° ë§ í˜„ì¬ í˜„ê¸ˆ ë° ìœ ê°€ì¦ê¶Œì´ ì•½ 190ì–µ ë‹¬ëŸ¬, ë¶€ì±„ê°€ 460ì–µ ë‹¬ëŸ¬ë¡œ ìˆœë¶€ì±„ í¬ì§€ì…˜ì€ 270ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” 2ë¶„ê¸°ì— ë³´ê³ ëœ ìˆœë¶€ì±„ 320ì–µ ë‹¬ëŸ¬ ëŒ€ë¹„ ê°œì„ ëœ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” ì§€ì†ì ìœ¼ë¡œ ì‰ì—¬í˜„ê¸ˆíë¦„ ì°½ì¶œê³¼ ê²¬ê³ í•œ ì¬ë¬´êµ¬ì¡°ë¥¼ í™œìš©í•˜ì—¬ í˜ì‹ ì— íˆ¬ìí•˜ê³  ì£¼ì£¼ë“¤ì—ê²Œ ì§ì ‘ ìë³¸ì„ í™˜ì›í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¬ë¬´ ëª©í‘œ ë‹¬ì„±ì„ ìœ„í•œ ì¸ìˆ˜í•©ë³‘ì— ëŒ€í•œ ë‹¹ì‚¬ì˜ ì˜ì§€ì— ëŒ€í•´ ìì£¼ ì§ˆë¬¸ì„ ë°›ìŠµë‹ˆë‹¤. ì´ì— ëŒ€í•´ ëª…í™•íˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” ë…ì ê¶Œ ìƒì‹¤ì— ë”°ë¥¸ ì„±ì¥ì„ ìœ„í•´ ì‹ ì¤‘í•˜ê³  ì¥ê¸°ì ì¸ ì ‘ê·¼ ë°©ì‹ì— ì˜ì¡´í•˜ë©°, ì ˆë§ê°ì—ì„œ ë¹„ë¡¯ëœ íˆ¬ê¸°ì  ê±°ë˜ì— ë¬´ë¶„ë³„í•˜ê²Œ ìë³¸ì„ íˆ¬ì…í•˜ì§€ ì•Šì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Our current portfolio and pipeline have momentum and with the STELARA loss of exclusivity increasingly in the rearview mirror, we do not need to rely on large transactions to drive our growth. We intend to remain disciplined, opportunistically pursuing strategic high-value opportunities that utilize our expertise and capabilities that deliver an appropriate return for the risk that we bear on behalf of shareholders. Regarding the planned separation of our Orthopaedics business, as Joaquin noted, the separation is expected to enhance the strategic and operational focus of each company and drive value for our shareholders and other stakeholders.</td><td>í˜„ì¬ ì €í¬ í¬íŠ¸í´ë¦¬ì˜¤ì™€ íŒŒì´í”„ë¼ì¸ì€ ëª¨ë©˜í…€ì„ ë³´ì´ê³  ìˆìœ¼ë©°, STELARAì˜ ë…ì ê¶Œ ë§Œë£Œê°€ ì ì°¨ ê³¼ê±°ì˜ ì¼ì´ ë˜ì–´ê°€ê³  ìˆì–´, ì„±ì¥ì„ ê²¬ì¸í•˜ê¸° ìœ„í•´ ëŒ€ê·œëª¨ ê±°ë˜ì— ì˜ì¡´í•  í•„ìš”ê°€ ì—†ìŠµë‹ˆë‹¤. ì €í¬ëŠ” ê·œìœ¨ì„ ìœ ì§€í•˜ë©´ì„œ, ì €í¬ì˜ ì „ë¬¸ì„±ê³¼ ì—­ëŸ‰ì„ í™œìš©í•˜ê³  ì£¼ì£¼ë“¤ì„ ëŒ€ì‹ í•˜ì—¬ ê°ìˆ˜í•˜ëŠ” ë¦¬ìŠ¤í¬ì— ì ì ˆí•œ ìˆ˜ìµì„ ì œê³µí•˜ëŠ” ì „ëµì  ê³ ë¶€ê°€ê°€ì¹˜ ê¸°íšŒë“¤ì„ ê¸°íšŒì£¼ì˜ì ìœ¼ë¡œ ì¶”ì§„í•  ê³„íšì…ë‹ˆë‹¤. ì •í˜•ì™¸ê³¼ ì‚¬ì—…ë¶€ ë¶„í•  ê³„íšê³¼ ê´€ë ¨í•˜ì—¬, í˜¸ì•„í‚¨ì´ ì–¸ê¸‰í–ˆë“¯ì´, ì´ë²ˆ ë¶„í• ì€ ê° íšŒì‚¬ì˜ ì „ëµì  ë° ìš´ì˜ì  ì§‘ì¤‘ë„ë¥¼ ë†’ì´ê³  ì£¼ì£¼ ë° ê¸°íƒ€ ì´í•´ê´€ê³„ìë“¤ì—ê²Œ ê°€ì¹˜ë¥¼ ì°½ì¶œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤.</td></tr>
<tr><td>Given that we are early in the process, there are limited details available, but we are committed to providing you with information on a timely basis. While we will, of course, communicate material developments, we don't expect to have anything newsworthy to convey until mid-next year. But what can we say at this moment? First, the separation will further strengthen our overall MedTech business and increase Johnson & Johnson's top line growth and margins. To give that some directional context, if we just look at normalized year-to-date 2025 results, MedTech's top line revenue growth and operating margin would both improve by at least 75 basis points.</td><td>ì•„ì§ ì´ˆê¸° ë‹¨ê³„ì´ê¸° ë•Œë¬¸ì— ì œí•œì ì¸ ì„¸ë¶€ì‚¬í•­ë§Œ ì œê³µí•  ìˆ˜ ìˆì§€ë§Œ, ì ì‹œì— ì •ë³´ë¥¼ ì œê³µí•˜ëŠ” ê²ƒì— ìµœì„ ì„ ë‹¤í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ì¤‘ìš”í•œ ì§„ì „ì‚¬í•­ì€ ì†Œí†µí•  ì˜ˆì •ì´ì§€ë§Œ, ë‚´ë…„ ì¤‘ë°˜ê¹Œì§€ëŠ” ì „ë‹¬í•  ë§Œí•œ ë‰´ìŠ¤ê°€ ì—†ì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. í•˜ì§€ë§Œ í˜„ì¬ ì‹œì ì—ì„œ ë§ì”€ë“œë¦´ ìˆ˜ ìˆëŠ” ê²ƒì€ ë¬´ì—‡ì¼ê¹Œìš”? <br><br>ì²«ì§¸, ì´ë²ˆ ë¶„ë¦¬ëŠ” ì „ì²´ ë©”ë“œí…Œí¬ ì‚¬ì—…ì„ ë”ìš± ê°•í™”í•˜ê³  ì¡´ìŠ¨ì•¤ë“œì¡´ìŠ¨ì˜ ë§¤ì¶œ ì„±ì¥ë¥ ê³¼ ë§ˆì§„ì„ ì¦ëŒ€ì‹œí‚¬ ê²ƒì…ë‹ˆë‹¤. ë°©í–¥ì„±ì„ ì œì‹œí•˜ê¸° ìœ„í•´ 2025ë…„ ì—°ì´ˆ ëŒ€ë¹„ ì •ê·œí™”ëœ ì‹¤ì ë§Œ ì‚´í´ë³´ë”ë¼ë„, ë©”ë“œí…Œí¬ì˜ ë§¤ì¶œ ì„±ì¥ë¥ ê³¼ ì˜ì—…ë§ˆì§„ ëª¨ë‘ ìµœì†Œ 75ë² ì´ì‹œìŠ¤í¬ì¸íŠ¸ ê°œì„ ë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Next, we are targeting completion of the separation within 18 to 24 months, subject to the satisfaction of certain conditions. Given it is the most resource-intensive and likely longest duration, we are prioritizing and have begun the separation, assuming a spin-off with the intention for that to qualify as a tax-free separation for U.S. federal income tax purposes. However, we will consider other avenues that optimize shareholder value. We do not expect any change to the Johnson & Johnson dividend and are mindful of any impact from stranded costs that are typically present in these types of transactions.</td><td>ë‹¤ìŒìœ¼ë¡œ, íŠ¹ì • ì¡°ê±´ë“¤ì˜ ì¶©ì¡±ì„ ì „ì œë¡œ 18ê°œì›”ì—ì„œ 24ê°œì›” ë‚´ì— ë¶„ë¦¬ë¥¼ ì™„ë£Œí•˜ëŠ” ê²ƒì„ ëª©í‘œë¡œ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ê°€ì¥ ë§ì€ ìì›ì´ ì†Œìš”ë˜ê³  ê°€ì¥ ê¸´ ê¸°ê°„ì´ ê±¸ë¦´ ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ëŠ” ë§Œí¼, ìš°ë¦¬ëŠ” ë¯¸êµ­ ì—°ë°©ì†Œë“ì„¸ ëª©ì ìƒ ë¹„ê³¼ì„¸ ë¶„ë¦¬ ìê²©ì„ ê°–ì¶”ê³ ì í•˜ëŠ” ì˜ë„ë¡œ ìŠ¤í•€ì˜¤í”„ë¥¼ ê°€ì •í•˜ì—¬ ë¶„ë¦¬ ì‘ì—…ì„ ìš°ì„ ìˆœìœ„ì— ë‘ê³  ì´ë¯¸ ì‹œì‘í–ˆìŠµë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ì£¼ì£¼ê°€ì¹˜ë¥¼ ìµœì í™”í•˜ëŠ” ë‹¤ë¥¸ ë°©ì•ˆë“¤ë„ ê³ ë ¤í•  ê²ƒì…ë‹ˆë‹¤. ì¡´ìŠ¨ì•¤ë“œì¡´ìŠ¨ì˜ ë°°ë‹¹ê¸ˆì—ëŠ” ì–´ë– í•œ ë³€í™”ë„ ì˜ˆìƒí•˜ì§€ ì•Šìœ¼ë©°, ì´ëŸ¬í•œ ìœ í˜•ì˜ ê±°ë˜ì—ì„œ ì¼ë°˜ì ìœ¼ë¡œ ë°œìƒí•˜ëŠ” ê³ ë¦½ë¹„ìš©(stranded costs)ìœ¼ë¡œ ì¸í•œ ì˜í–¥ì„ ì—¼ë‘ì— ë‘ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Finally, following the separation, we would expect DePuy Synthes to have a strong capital structure that would allow the Orthopaedics business to build on its long history of innovation and extend leadership positions through enhanced organic investment and strategic growth accretive M&A. As we pursue this separation, the Orthopaedics unit will operate in alignment with the business' current strategy, continuing to make investments in growth, margin improvement and innovation. Turning now to full year guidance for 2025.</td><td>ë§ˆì§€ë§‰ìœ¼ë¡œ, ë¶„í•  ì´í›„ DePuy SynthesëŠ” ì •í˜•ì™¸ê³¼ ì‚¬ì—…ì´ ì˜¤ëœ í˜ì‹ ì˜ ì—­ì‚¬ë¥¼ ë°”íƒ•ìœ¼ë¡œ ê°•í™”ëœ ìœ ê¸°ì  íˆ¬ìì™€ ì „ëµì  ì„±ì¥ ê¸°ì—¬ M&Aë¥¼ í†µí•´ ë¦¬ë”ì‹­ ì§€ìœ„ë¥¼ í™•ì¥í•  ìˆ˜ ìˆë„ë¡ í•˜ëŠ” ê²¬ê³ í•œ ìë³¸ êµ¬ì¡°ë¥¼ ê°–ì¶œ ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ì´ëŸ¬í•œ ë¶„í• ì„ ì¶”ì§„í•˜ë©´ì„œ ì •í˜•ì™¸ê³¼ ì‚¬ì—…ë¶€ëŠ” í˜„ì¬ ì‚¬ì—… ì „ëµì— ë§ì¶° ìš´ì˜ë˜ë©°, ì„±ì¥, ë§ˆì§„ ê°œì„  ë° í˜ì‹ ì— ëŒ€í•œ íˆ¬ìë¥¼ ì§€ì†í•  ê²ƒì…ë‹ˆë‹¤. ì´ì œ 2025ë…„ ì—°ê°„ ê°€ì´ë˜ìŠ¤ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We are increasing operational sales guidance for the full year by approximately $300 million, resulting in operational sales growth for the full year in the range of 4.8% to 5.3%, with a midpoint of $93.2 billion or 5.1%. Excluding the impact from acquisitions and divestitures, our adjusted operational sales growth is now expected to be in the range of 3.5% to 4.0% compared to 2024. As a reminder, we started the year guiding to a midpoint for 2.5% for adjusted operational sales. As you know, we don't speculate on future currency movements. And last quarter, we utilized the euro spot rate relative to the U.S. dollar of 1.17. The U.S. dollar has stayed relatively flat to the euro spot rate.</td><td>ì €í¬ëŠ” ì—°ê°„ ìš´ì˜ ë§¤ì¶œ ê°€ì´ë˜ìŠ¤ë¥¼ ì•½ 3ì–µ ë‹¬ëŸ¬ ìƒí–¥ ì¡°ì •í•˜ì—¬, ì—°ê°„ ìš´ì˜ ë§¤ì¶œ ì„±ì¥ë¥ ì„ 4.8%ì—ì„œ 5.3% ë²”ìœ„ë¡œ ì „ë§í•˜ê³  ìˆìœ¼ë©°, ì¤‘ê°„ê°’ì€ 932ì–µ ë‹¬ëŸ¬ë¡œ 5.1%ì…ë‹ˆë‹¤. ì¸ìˆ˜í•©ë³‘ ë° ë§¤ê°ì˜ ì˜í–¥ì„ ì œì™¸í•œ ì¡°ì • ìš´ì˜ ë§¤ì¶œ ì„±ì¥ë¥ ì€ 2024ë…„ ëŒ€ë¹„ 3.5%ì—ì„œ 4.0% ë²”ìœ„ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ì°¸ê³ ë¡œ ì €í¬ëŠ” ì—°ì´ˆì— ì¡°ì • ìš´ì˜ ë§¤ì¶œì˜ ì¤‘ê°„ê°’ì„ 2.5%ë¡œ ê°€ì´ë˜ìŠ¤ë¥¼ ì œì‹œí–ˆì—ˆìŠµë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼, ì €í¬ëŠ” í–¥í›„ í™˜ìœ¨ ë³€ë™ì— ëŒ€í•´ì„œëŠ” ì¶”ì¸¡í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ì§€ë‚œ ë¶„ê¸°ì—ëŠ” ë¯¸êµ­ ë‹¬ëŸ¬ ëŒ€ë¹„ ìœ ë¡œ í˜„ë¬¼í™˜ìœ¨ 1.17ì„ ì ìš©í–ˆìŠµë‹ˆë‹¤. ë¯¸êµ­ ë‹¬ëŸ¬ëŠ” ìœ ë¡œ í˜„ë¬¼í™˜ìœ¨ ëŒ€ë¹„ ìƒëŒ€ì ìœ¼ë¡œ ë³´í•©ì„¸ë¥¼ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And as a result, we now expect reported sales growth between 5.4% to 5.9% with a midpoint of $93.7 billion or 5.7%. Turning to other notable items on the P&L. We are reiterating our operating margin guide of an approximate 300 basis point improvement for the full year, assuming what we know today as it relates to tariffs. For net interest expense, we are now projecting between $0 million and $50 million, an improvement from the previous guidance, primarily driven by higher cash balances. We are expecting a higher effective tax rate to be in the range of 17.5% to 18% for the full year, with the increase largely due to the recently enacted One Big Beautiful Bill Act.</td><td>ê·¸ ê²°ê³¼, í˜„ì¬ ë³´ê³ ëœ ë§¤ì¶œ ì„±ì¥ë¥ ì„ 5.4%ì—ì„œ 5.9% ì‚¬ì´ë¡œ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ì¤‘ê°„ê°’ì€ 937ì–µ ë‹¬ëŸ¬ ë˜ëŠ” 5.7%ì…ë‹ˆë‹¤. ì†ìµê³„ì‚°ì„œì˜ ë‹¤ë¥¸ ì£¼ëª©í•  ë§Œí•œ í•­ëª©ë“¤ì„ ì‚´í´ë³´ê² ìŠµë‹ˆë‹¤. í˜„ì¬ ê´€ì„¸ì™€ ê´€ë ¨í•˜ì—¬ ì•Œê³  ìˆëŠ” ìƒí™©ì„ ê°€ì •í•  ë•Œ, ì—°ê°„ ì˜ì—…ì´ìµë¥  ê°€ì´ë˜ìŠ¤ë¥¼ ì•½ 300 ë² ì´ì‹œìŠ¤ í¬ì¸íŠ¸ ê°œì„ ìœ¼ë¡œ ì¬í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìˆœì´ìë¹„ìš©ì˜ ê²½ìš°, ì´ì „ ê°€ì´ë˜ìŠ¤ì—ì„œ ê°œì„ ëœ 0ë‹¬ëŸ¬ì—ì„œ 5ì²œë§Œ ë‹¬ëŸ¬ ì‚¬ì´ë¡œ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ì£¼ë¡œ í˜„ê¸ˆ ì”ê³  ì¦ê°€ì— ê¸°ì¸í•©ë‹ˆë‹¤. ì—°ê°„ ì‹¤íš¨ì„¸ìœ¨ì€ 17.5%ì—ì„œ 18% ë²”ìœ„ë¡œ ë” ë†’ì•„ì§ˆ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ì´ëŸ¬í•œ ì¦ê°€ëŠ” ì£¼ë¡œ ìµœê·¼ ì œì •ëœ ì› ë¹… ë·°í‹°í’€ ë¹Œ ë²•ì•ˆ(One Big Beautiful Bill Act)ì— í¬ê²Œ ê¸°ì¸í•©ë‹ˆë‹¤.</td></tr>
<tr><td>We feel strongly that U.S. tax policy has enabled Johnson & Johnson to increase our manufacturing footprint in the U.S. We have more manufacturing facilities in the United States than in any other country, and we remain committed to investing $55 billion in U.S.-based innovation and manufacturing over the next 4 years. In March, we broke ground at our Wilson, North Carolina facility. And in August, we announced a $2 billion commitment to further increase our presence in North Carolina with a more than 160,000 square foot dedicated manufacturing facility at FUJIFILM's new biopharmaceutical manufacturing site in Holly Springs. Our overall U.S.</td><td>ì €í¬ëŠ” ë¯¸êµ­ ì„¸ì œ ì •ì±…ì´ Johnson & Johnsonì´ ë¯¸êµ­ ë‚´ ì œì¡° ê¸°ë°˜ì„ í™•ëŒ€í•  ìˆ˜ ìˆë„ë¡ ë’·ë°›ì¹¨í•´ ì£¼ì—ˆë‹¤ê³  í™•ì‹ í•©ë‹ˆë‹¤. ì €í¬ëŠ” ë‹¤ë¥¸ ì–´ë–¤ êµ­ê°€ë³´ë‹¤ë„ ë¯¸êµ­ì— ë” ë§ì€ ì œì¡° ì‹œì„¤ì„ ë³´ìœ í•˜ê³  ìˆìœ¼ë©°, í–¥í›„ 4ë…„ê°„ ë¯¸êµ­ ê¸°ë°˜ í˜ì‹  ë° ì œì¡°ì—…ì— 550ì–µ ë‹¬ëŸ¬ë¥¼ íˆ¬ìí•˜ê² ë‹¤ëŠ” ì•½ì†ì„ ì§€ì¼œë‚˜ê°€ê³  ìˆìŠµë‹ˆë‹¤. ì§€ë‚œ 3ì›”ì—ëŠ” ë…¸ìŠ¤ìºë¡¤ë¼ì´ë‚˜ì£¼ ìœŒìŠ¨ ì†Œì¬ ì‹œì„¤ì˜ ê¸°ê³µì‹ì„ ê°€ì¡ŒìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  8ì›”ì—ëŠ” í™€ë¦¬ ìŠ¤í”„ë§ìŠ¤ì— ìœ„ì¹˜í•œ FUJIFILMì˜ ìƒˆë¡œìš´ ë°”ì´ì˜¤ì˜ì•½í’ˆ ì œì¡° ë‹¨ì§€ ë‚´ì— 16ë§Œ í‰ë°©í”¼íŠ¸ ì´ìƒ ê·œëª¨ì˜ ì „ìš© ì œì¡° ì‹œì„¤ì„ êµ¬ì¶•í•˜ì—¬ ë…¸ìŠ¤ìºë¡¤ë¼ì´ë‚˜ì£¼ ë‚´ ì…ì§€ë¥¼ ë”ìš± í™•ëŒ€í•˜ê² ë‹¤ëŠ” 20ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ íˆ¬ì ê³„íšì„ ë°œí‘œí–ˆìŠµë‹ˆë‹¤. ì €í¬ì˜ ì „ë°˜ì ì¸ ë¯¸êµ­ ë‚´</td></tr>
<tr><td>investment plans also include 3 additional new advanced manufacturing facilities as well as the expansion of several existing sites. Turning to earnings per share. You may recall, we started the year guiding to adjusted EPS of $10.60. Today, we stand much higher even after including dilution of $0.25 from the Intra-Cellular acquisition. Today, we are reaffirming our elevated July earnings per share outlook, which also absorbs a higher annual effective tax rate and fourth quarter investments that will further position the business for long-term success. As such, our expected adjusted earnings per share guidance remains $10.85 or 8.7% at the midpoint with a range of $10.80 to $10.90.</td><td>íˆ¬ì ê³„íšì—ëŠ” 3ê°œì˜ ì¶”ê°€ì ì¸ ì‹ ê·œ ì²¨ë‹¨ ì œì¡°ì‹œì„¤ê³¼ ì—¬ëŸ¬ ê¸°ì¡´ ì‚¬ì—…ì¥ì˜ í™•ì¥ë„ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì£¼ë‹¹ìˆœì´ìµìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ê¸°ì–µí•˜ì‹œê² ì§€ë§Œ, ì €í¬ëŠ” ì—°ì´ˆì— ì¡°ì • ì£¼ë‹¹ìˆœì´ìµì„ 10.60ë‹¬ëŸ¬ë¡œ ê°€ì´ë˜ìŠ¤ë¥¼ ì œì‹œí–ˆìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ í˜„ì¬ Intra-Cellular ì¸ìˆ˜ë¡œ ì¸í•œ 0.25ë‹¬ëŸ¬ì˜ í¬ì„íš¨ê³¼ë¥¼ í¬í•¨í•œ í›„ì—ë„ í›¨ì”¬ ë†’ì€ ìˆ˜ì¤€ì— ìˆìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ì €í¬ëŠ” 7ì›”ì— ìƒí–¥ ì¡°ì •í•œ ì£¼ë‹¹ìˆœì´ìµ ì „ë§ì„ ì¬í™•ì¸í•˜ë©°, ì´ëŠ” ë” ë†’ì€ ì—°ê°„ ì‹¤íš¨ì„¸ìœ¨ê³¼ ì¥ê¸°ì  ì„±ê³µì„ ìœ„í•œ ì‚¬ì—… í¬ì§€ì…”ë‹ì„ ìœ„í•œ 4ë¶„ê¸° íˆ¬ìë„ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ì˜ ì¡°ì • ì£¼ë‹¹ìˆœì´ìµ ê°€ì´ë˜ìŠ¤ëŠ” ì¤‘ê°„ê°’ ê¸°ì¤€ 8.7% ì¦ê°€í•œ 10.85ë‹¬ëŸ¬ë¥¼ ìœ ì§€í•˜ë©°, ë²”ìœ„ëŠ” 10.80ë‹¬ëŸ¬ì—ì„œ 10.90ë‹¬ëŸ¬ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Our adjusted operational earnings per share guidance is $10.68 or 7% at the midpoint. Looking beyond our financial commitments for the year, we are on track to add to the already impressive number of milestones that we achieved across our pipeline in 2025. In Innovative Medicine, we anticipate U.S. FDA approval for subcutaneous RYBREVANT for non-small cell lung cancer as well as for CAPLYTA in adjunctive major depressive disorder. We recently filed for a label expansion on TREMFYA in psoriatic arthritis and plan to present data for RYBREVANT in head and neck cancer at ESMO in the coming week.</td><td>ë‹¹ì‚¬ì˜ ì¡°ì • ì˜ì—…ì´ìµ ì£¼ë‹¹ìˆœì´ìµ ê°€ì´ë˜ìŠ¤ëŠ” ì¤‘ê°„ê°’ ê¸°ì¤€ìœ¼ë¡œ 10.68ë‹¬ëŸ¬ ë˜ëŠ” 7%ì…ë‹ˆë‹¤. ì˜¬í•´ ì¬ë¬´ì  ì•½ì†ì„ ë„˜ì–´ì„œ, ë‹¹ì‚¬ëŠ” 2025ë…„ íŒŒì´í”„ë¼ì¸ ì „ë°˜ì— ê±¸ì³ ë‹¬ì„±í•œ ì´ë¯¸ ì¸ìƒì ì¸ ì´ì •í‘œë“¤ì— ì¶”ê°€ë¡œ ì„±ê³¼ë¥¼ ë”í•  ì˜ˆì •ì…ë‹ˆë‹¤. í˜ì‹ ì˜ì•½í’ˆ ë¶€ë¬¸ì—ì„œëŠ” ë¹„ì†Œì„¸í¬íì•”ì— ëŒ€í•œ í”¼í•˜ì£¼ì‚¬ìš© RYBREVANTì™€ ì£¼ìš”ìš°ìš¸ì¥ì•  ë³´ì¡°ìš”ë²•ì—ì„œì˜ CAPLYTAì— ëŒ€í•œ ë¯¸êµ­ FDA ìŠ¹ì¸ì„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìµœê·¼ ê±´ì„ ì„± ê´€ì ˆì—¼ì—ì„œ TREMFYAì˜ ë¼ë²¨ í™•ì¥ì„ ì‹ ì²­í–ˆìœ¼ë©°, ë‹¤ìŒ ì£¼ ESMOì—ì„œ ë‘ê²½ë¶€ì•”ì—ì„œì˜ RYBREVANT ë°ì´í„°ë¥¼ ë°œí‘œí•  ì˜ˆì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>In MedTech, we continue to make progress with our clinical trial for our OTTAVA robotic surgical system. In our cardiovascular portfolio, we are planning regulatory submissions for the dual-energy THERMOCOOL SMARTTOUCH SF Catheter for cardiac arrhythmia in the U.S. and in Vision, we will continue to roll out ACUVUE OASYS MAX for astigmatism. As we are close to year-end and with a strong caveat that we are still finalizing plans for next year and macro factors can change quickly, let me provide some preliminary thoughts to inform your modeling for 2026. For Innovative Medicine, we remain very confident in our ability to deliver accelerated growth despite STELARA loss of exclusivity.</td><td>MedTech ë¶€ë¬¸ì—ì„œëŠ” OTTAVA ë¡œë´‡ ìˆ˜ìˆ  ì‹œìŠ¤í…œì˜ ì„ìƒì‹œí—˜ì„ í†µí•´ ì§€ì†ì ìœ¼ë¡œ ì§„ì „ì„ ì´ë£¨ê³  ìˆìŠµë‹ˆë‹¤. ì‹¬í˜ˆê´€ í¬íŠ¸í´ë¦¬ì˜¤ì—ì„œëŠ” ë¯¸êµ­ ë‚´ ì‹¬ì¥ ë¶€ì •ë§¥ ì¹˜ë£Œìš© ë“€ì–¼ ì—ë„ˆì§€ THERMOCOOL SMARTTOUCH SF ì¹´í…Œí„°ì˜ ê·œì œ ìŠ¹ì¸ ì‹ ì²­ì„ ê³„íší•˜ê³  ìˆìœ¼ë©°, Vision ë¶€ë¬¸ì—ì„œëŠ” ë‚œì‹œìš© ACUVUE OASYS MAXì˜ ì¶œì‹œë¥¼ ì§€ì†ì ìœ¼ë¡œ í™•ëŒ€í•´ ë‚˜ê°ˆ ì˜ˆì •ì…ë‹ˆë‹¤. <br><br>ì—°ë§ì´ ê°€ê¹Œì›Œì§€ê³  ìˆëŠ” ì‹œì ì—ì„œ, ë‚´ë…„ ê³„íšì„ ì•„ì§ ìµœì¢… í™•ì •í•˜ëŠ” ì¤‘ì´ê³  ê±°ì‹œê²½ì œ ìš”ì¸ë“¤ì´ ë¹ ë¥´ê²Œ ë³€í•  ìˆ˜ ìˆë‹¤ëŠ” ì ì„ ê°•í•˜ê²Œ ì „ì œí•˜ë©´ì„œ, 2026ë…„ ëª¨ë¸ë§ì— ì°¸ê³ í•˜ì‹¤ ìˆ˜ ìˆë„ë¡ ëª‡ ê°€ì§€ ì˜ˆë¹„ì ì¸ ê²¬í•´ë¥¼ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. <br><br>Innovative Medicine ë¶€ë¬¸ì˜ ê²½ìš°, STELARAì˜ ë…ì ê¶Œ ìƒì‹¤ì—ë„ ë¶ˆêµ¬í•˜ê³  ê°€ì†í™”ëœ ì„±ì¥ì„ ë‹¬ì„±í•  ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ì— ëŒ€í•´ ì—¬ì „íˆ ë§¤ìš° í™•ì‹ í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This will be driven by our in-market brands and continued progress from our recently launched products, including TREMFYA in inflammatory bowel disease, RYBREVANT plus LAZCLUZE in non-small cell lung cancer and INLEXZO in bladder cancer. We currently anticipate a 2026 approval for icotrokinra in psoriasis. In MedTech, we continue to expect accelerated growth off this year's levels driven by focus on higher-growth markets as well as the continued adoption of newer products across all MedTech platforms. We also anticipate the launch of Shockwave C2 Aero Coronary IVL Catheter, the TECNIS PureSee intraocular lens in the U.S.</td><td>ì´ëŠ” ê¸°ì¡´ ì‹œì¥ ë‚´ ë¸Œëœë“œë“¤ê³¼ ìµœê·¼ ì¶œì‹œëœ ì œí’ˆë“¤ì˜ ì§€ì†ì ì¸ ì„±ê³¼ì— ì˜í•´ ê²¬ì¸ë  ê²ƒì…ë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ì—¼ì¦ì„± ì¥ì§ˆí™˜ ì ì‘ì¦ì˜ TREMFYA, ë¹„ì†Œì„¸í¬íì•” ì ì‘ì¦ì˜ RYBREVANT plus LAZCLUZE, ê·¸ë¦¬ê³  ë°©ê´‘ì•” ì ì‘ì¦ì˜ INLEXZOê°€ í¬í•¨ë©ë‹ˆë‹¤. í˜„ì¬ ê±´ì„  ì ì‘ì¦ì˜ icotrokinraì— ëŒ€í•´ì„œëŠ” 2026ë…„ ìŠ¹ì¸ì„ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>MedTech ë¶€ë¬¸ì—ì„œëŠ” ê³ ì„±ì¥ ì‹œì¥ì— ëŒ€í•œ ì§‘ì¤‘ê³¼ ëª¨ë“  MedTech í”Œë«í¼ì—ì„œ ì‹ ì œí’ˆì˜ ì§€ì†ì ì¸ ë„ì…ì— í˜ì…ì–´ ì˜¬í•´ ìˆ˜ì¤€ ëŒ€ë¹„ ê°€ì†í™”ëœ ì„±ì¥ì„ ì§€ì†ì ìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ Shockwave C2 Aero ê´€ìƒë™ë§¥ IVL ì¹´í…Œí„°ì™€ ë¯¸êµ­ ë‚´ TECNIS PureSee ì¸ê³µìˆ˜ì •ì²´ì˜ ì¶œì‹œë„ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>as well as regulatory submission for the OTTAVA robotic surgical system. Again, while early, I like the way 2026 is shaping up. In fact, based on my last look at your 2026 models, it appears the current revenue consensus of 4.6% growth in your models for 2026 is lower than we project, which we believe in total will exceed 5%. Similarly, with the expectation that adjusted earnings per share is commensurate with sales growth, there appears to be some upside to the current adjusted earnings per share consensus of $11.39, perhaps as much as $0.05.</td><td>ë˜í•œ OTTAVA ë¡œë´‡ ìˆ˜ìˆ  ì‹œìŠ¤í…œì˜ ê·œì œ ìŠ¹ì¸ ì‹ ì²­ë„ í¬í•¨ë©ë‹ˆë‹¤. ì•„ì§ ì´ˆê¸° ë‹¨ê³„ì´ì§€ë§Œ, 2026ë…„ì´ ì–´ë–»ê²Œ êµ¬ì„±ë˜ê³  ìˆëŠ”ì§€ ë§ˆìŒì— ë“­ë‹ˆë‹¤. ì‹¤ì œë¡œ ì—¬ëŸ¬ë¶„ì˜ 2026ë…„ ëª¨ë¸ì„ ë§ˆì§€ë§‰ìœ¼ë¡œ ê²€í† í•œ ê²°ê³¼, í˜„ì¬ ë§¤ì¶œ ì»¨ì„¼ì„œìŠ¤ì¸ 4.6% ì„±ì¥ë¥ ì´ ì—¬ëŸ¬ë¶„ì˜ ëª¨ë¸ì—ì„œ ìš°ë¦¬ê°€ ì˜ˆìƒí•˜ëŠ” ê²ƒë³´ë‹¤ ë‚®ì€ ê²ƒìœ¼ë¡œ ë³´ì´ë©°, ìš°ë¦¬ëŠ” ì „ì²´ì ìœ¼ë¡œ 5%ë¥¼ ì´ˆê³¼í•  ê²ƒìœ¼ë¡œ ë¯¿ê³  ìˆìŠµë‹ˆë‹¤. ë§ˆì°¬ê°€ì§€ë¡œ, ì¡°ì • ì£¼ë‹¹ìˆœì´ìµì´ ë§¤ì¶œ ì„±ì¥ê³¼ ìƒì‘í•  ê²ƒì´ë¼ëŠ” ê¸°ëŒ€ì™€ í•¨ê»˜, í˜„ì¬ ì¡°ì • ì£¼ë‹¹ìˆœì´ìµ ì»¨ì„¼ì„œìŠ¤ì¸ $11.39ì— ìƒìŠ¹ ì—¬ë ¥ì´ ìˆëŠ” ê²ƒìœ¼ë¡œ ë³´ì´ë©°, ì•„ë§ˆë„ $0.05 ì •ë„ì¼ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>This commentary considers investments we will be making behind many of the new product launches I just highlighted, but you can also expect some margin improvement. It also reflects our understanding of the present legislative landscape, tariffs, foreign exchange rates and procedural volumes. We look forward to sharing further details regarding our official guide for 2026 during our Q4 earnings call in January. In summary, the strength of our business model with a focus on where we can have the greatest impact for patients will enable Johnson & Johnson to deliver against our strategic objectives and financial commitments.</td><td>ì´ ë…¼í‰ì€ ì œê°€ ë°©ê¸ˆ ê°•ì¡°í•œ ë§ì€ ì‹ ì œí’ˆ ì¶œì‹œë¥¼ ë’·ë°›ì¹¨í•˜ê¸° ìœ„í•´ ìš°ë¦¬ê°€ íˆ¬ìí•  ë¶€ë¶„ë“¤ì„ ê³ ë ¤í•œ ê²ƒì´ì§€ë§Œ, ì¼ë¶€ ë§ˆì§„ ê°œì„ ë„ ê¸°ëŒ€í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë˜í•œ í˜„ì¬ì˜ ì…ë²• í™˜ê²½, ê´€ì„¸, ì™¸í™˜ í™˜ìœ¨ ë° ì‹œìˆ ëŸ‰ì— ëŒ€í•œ ìš°ë¦¬ì˜ ì´í•´ë¥¼ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. 1ì›” 4ë¶„ê¸° ì‹¤ì  ë°œí‘œì—ì„œ 2026ë…„ ê³µì‹ ê°€ì´ë˜ìŠ¤ì— ëŒ€í•œ ìì„¸í•œ ë‚´ìš©ì„ ê³µìœ í•  ìˆ˜ ìˆê¸°ë¥¼ ê¸°ëŒ€í•©ë‹ˆë‹¤. ìš”ì•½í•˜ìë©´, í™˜ìë“¤ì—ê²Œ ê°€ì¥ í° ì˜í–¥ì„ ë¯¸ì¹  ìˆ˜ ìˆëŠ” ë¶„ì•¼ì— ì§‘ì¤‘í•˜ëŠ” ìš°ë¦¬ ë¹„ì¦ˆë‹ˆìŠ¤ ëª¨ë¸ì˜ ê°•ì ì€ Johnson & Johnsonì´ ì „ëµì  ëª©í‘œì™€ ì¬ë¬´ì  ì•½ì†ì„ ì´í–‰í•  ìˆ˜ ìˆê²Œ í•´ì¤„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>We are as confident as we have been in recent memory about the future. I'd like to end my remarks by thanking our colleagues around the world for their continued hard work and steadfast dedication that serve our patients and who make these financial results possible and sustainable. With that, we are happy to take your questions. Kevin, will you please open the call for Q&A?</td><td>ìµœê·¼ ê¸°ì–µì„ ë”ë“¬ì–´ë´ë„ ë¯¸ë˜ì— ëŒ€í•´ ì´ë§Œí¼ í™•ì‹ ì„ ê°€ì ¸ë³¸ ì ì´ ì—†ìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, í™˜ìë“¤ì„ ìœ„í•´ ë´‰ì‚¬í•˜ê³  ì´ëŸ¬í•œ ì¬ë¬´ ì„±ê³¼ë¥¼ ê°€ëŠ¥í•˜ê²Œ í•˜ê³  ì§€ì†ê°€ëŠ¥í•˜ê²Œ ë§Œë“œëŠ” ì§€ì†ì ì¸ ë…¸ë ¥ê³¼ ë³€í•¨ì—†ëŠ” í—Œì‹ ì„ ë³´ì—¬ì£¼ì‹  ì „ ì„¸ê³„ ë™ë£Œë“¤ì—ê²Œ ê°ì‚¬ì˜ ë§ì”€ì„ ë“œë¦¬ë©° ì œ ë°œì–¸ì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ì´ì œ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ê°–ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. Kevin, Q&A ì„¸ì…˜ì„ ì‹œì‘í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;">Here's a summary of the key points from Johnson & Johnson's Q3 2025 earnings call in Korean:<br><br>â€¢ ì‹¤ì  í•˜ì´ë¼ì´íŠ¸:<br>- 3ë¶„ê¸° ì˜ì—… ë§¤ì¶œ 5.4% ì„±ì¥ (ë§¤ì¶œ 240ì–µ ë‹¬ëŸ¬)<br>- í˜ì‹ ì˜ì•½í’ˆ ë¶€ë¬¸ 5.3% ì„±ì¥, ë©”ë“œí…Œí¬ ë¶€ë¬¸ 5.6% ì„±ì¥<br>- ì¡°ì • EPS 2.80ë‹¬ëŸ¬ (ì „ë…„ ëŒ€ë¹„ 15.7% ì¦ê°€)<br><br>â€¢ ì£¼ìš” ì‚¬ì—… ë™í–¥:<br>- TREMFYA 40% ì„±ì¥ìœ¼ë¡œ ë©´ì—­ì§ˆí™˜ ì¹˜ë£Œì œ ì‹œì¥ì—ì„œ ê°•ì„¸<br>- ì‹¬í˜ˆê´€ ë¶€ë¬¸ 12% ì„±ì¥, íŠ¹íˆ Shockwave ê¸°ìˆ  20% ì´ìƒ ì„±ì¥<br>- ì •í˜•ì™¸ê³¼ ì‚¬ì—…ë¶€ ë¶„ì‚¬ ê³„íš ë°œí‘œ (18-24ê°œì›” ë‚´ ì™„ë£Œ ëª©í‘œ)<br><br>â€¢ 2025ë…„ ê°€ì´ë˜ìŠ¤:<br>- ì—°ê°„ ë§¤ì¶œ ì„±ì¥ë¥  4.8-5.3% ì „ë§ (ê¸°ì¡´ ëŒ€ë¹„ 300ë°±ë§Œ ë‹¬ëŸ¬ ìƒí–¥)<br>- ì¡°ì • EPS 10.80-10.90ë‹¬ëŸ¬ ìœ ì§€<br>- ì˜ì—…ì´ìµë¥  ì•½ 300bp ê°œì„  ì˜ˆìƒ<br><br>â€¢ í–¥í›„ ì „ë§:<br>- 2026ë…„ 5% ì´ìƒì˜ ë§¤ì¶œ ì„±ì¥ ê¸°ëŒ€<br>- ì‹ ì œí’ˆ ì¶œì‹œì™€ íŒŒì´í”„ë¼ì¸ ì§„ì „ìœ¼ë¡œ ì„±ì¥ ëª¨ë©˜í…€ ì§€ì†<br>- ì •í˜•ì™¸ê³¼ ì‚¬ì—… ë¶„ì‚¬ í›„ í•µì‹¬ ì„±ì¥ ë¶„ì•¼ì— ë”ìš± ì§‘ì¤‘ ì˜ˆì •</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Operator: [Operator Instructions] Our first question is coming from Alex Hammond from Wolfe Research.</td><td>**Operator:** [ìš´ì˜ì ì•ˆë‚´] ì²« ë²ˆì§¸ ì§ˆë¬¸ì€ ìš¸í”„ ë¦¬ì„œì¹˜ì˜ ì•Œë ‰ìŠ¤ í•´ë¨¼ë“œë‹˜ê»˜ì„œ ì£¼ì…¨ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Wolfe Research, LLC: On the Orthopaedics spinout, I'd be interested to understand the why now? And also, could we expect similar separations for other divisions in the future? And as a quick follow-up, how should we think about the long-term guidance in light of the separation? Could we expect J&J to revisit these forecasts in the near term?</td><td>**Wolfe Research, LLC:** ì •í˜•ì™¸ê³¼ ì‚¬ì—…ë¶€ ë¶„ì‚¬ì™€ ê´€ë ¨í•´ì„œ, ì™œ ì§€ê¸ˆì¸ì§€ ê·¸ ì´ìœ ë¥¼ ì•Œê³  ì‹¶ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í–¥í›„ ë‹¤ë¥¸ ì‚¬ì—…ë¶€ì—ì„œë„ ë¹„ìŠ·í•œ ë¶„ë¦¬ë¥¼ ê¸°ëŒ€í•  ìˆ˜ ìˆì„ê¹Œìš”? ê°„ë‹¨í•œ í›„ì† ì§ˆë¬¸ìœ¼ë¡œ, ì´ë²ˆ ë¶„ì‚¬ë¥¼ ê³ ë ¤í•  ë•Œ ì¥ê¸° ê°€ì´ë˜ìŠ¤ë¥¼ ì–´ë–»ê²Œ ë´ì•¼ í• ê¹Œìš”? J&Jê°€ ê°€ê¹Œìš´ ì‹œì¼ ë‚´ì— ì´ëŸ¬í•œ ì „ë§ì¹˜ë“¤ì„ ì¬ê²€í† í•  ê°€ëŠ¥ì„±ì´ ìˆì„ê¹Œìš”?</td></tr>
<tr><td>CEO & Chairman: Thank you, Alex. And let me take the first question. Why now, why the Orthopaedic separation. It's been a hallmark of Johnson & Johnson to be a good steward of our capital and to make decisions in our portfolio to prioritize where we think breakthrough innovation can come through. And that's exactly what we are doing. We're moving Johnson & Johnson into high-growth markets with significant unmet medical need. And at the same time, we have the foresight to recognize when a stand-alone company could be better and could be in a better position to drive growth innovation and better margins. That's exactly what we are doing with our Orthopedics separation. We are fueling the innovation within Johnson & Johnson, focus on our 6 priority areas, continue to invest as we are doing in cardiovascular with the acquisitions of Abiomed, Shockwave and also in pharmaceuticals with the acquisition of Intra-Cellular and creating a stand-alone company that is going to be a champion within the context of the Orthopaedics sector. Orthopaedics is a growing market. $50 billion market. It's fueled by the aging of the population, and we have commanding market shares in the most important segments of the Orthopaedics business. The company is going to be called DePuy Synthes. It's going to be led by Namal Nawana, who is an industry veteran. And I have no doubt that they are going to be better positioned to succeed, to drive innovation, to drive growth and to become what they are, the largest Orthopaedics company in the world. Overall, this is a clear move to be able to manage our portfolio, to position Johnson & Johnson to be able to deliver breakthrough innovation. And the results that you are seeing so far with a very, very strong quarter. I want to underline, this is not only a very strong quarter. It's also an indication, a signal that Johnson & Johnson is in an accelerated cycle of growth, which we expect is going to last the balance of the decade. So moving in the right direction. I'm sure investors are going to be happy to see that Johnson & Johnson is an active portfolio manager.</td><td>**CEO & Chairman:** ê°ì‚¬í•©ë‹ˆë‹¤, Alex. ì²« ë²ˆì§¸ ì§ˆë¬¸ë¶€í„° ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì™œ ì§€ê¸ˆ ì •í˜•ì™¸ê³¼ ì‚¬ì—…ë¶€ë¥¼ ë¶„ë¦¬í•˜ëŠ”ì§€ì— ëŒ€í•œ ì§ˆë¬¸ì´êµ°ìš”. ì¡´ìŠ¨ì•¤ì¡´ìŠ¨ì€ í•­ìƒ ìë³¸ì„ íš¨ìœ¨ì ìœ¼ë¡œ ê´€ë¦¬í•˜ê³ , í˜ì‹ ì ì¸ ëŒíŒŒêµ¬ê°€ ë‚˜ì˜¬ ìˆ˜ ìˆëŠ” ë¶„ì•¼ì— ìš°ì„ ìˆœìœ„ë¥¼ ë‘ì–´ í¬íŠ¸í´ë¦¬ì˜¤ ê²°ì •ì„ ë‚´ë¦¬ëŠ” ê²ƒì„ íŠ¹ì§•ìœ¼ë¡œ í•´ì™”ìŠµë‹ˆë‹¤. ì§€ê¸ˆ í•˜ê³  ìˆëŠ” ê²ƒì´ ë°”ë¡œ ê·¸ëŸ° ì¼ì…ë‹ˆë‹¤. ì¡´ìŠ¨ì•¤ì¡´ìŠ¨ì„ ì¶©ì¡±ë˜ì§€ ì•Šì€ ì˜ë£Œ ìˆ˜ìš”ê°€ ìƒë‹¹í•œ ê³ ì„±ì¥ ì‹œì¥ìœ¼ë¡œ ì´ë™ì‹œí‚¤ê³  ìˆìŠµë‹ˆë‹¤. ë™ì‹œì— ë…ë¦½ íšŒì‚¬ê°€ ì„±ì¥ê³¼ í˜ì‹ ì„ ì¶”ì§„í•˜ê³  ë” ë‚˜ì€ ë§ˆì§„ì„ ë‹¬ì„±í•˜ëŠ” ë° ë” ìœ ë¦¬í•œ ìœ„ì¹˜ì— ìˆì„ ìˆ˜ ìˆë‹¤ëŠ” ì ì„ ë¯¸ë¦¬ ì¸ì‹í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì •í˜•ì™¸ê³¼ ì‚¬ì—…ë¶€ ë¶„ë¦¬ë¥¼ í†µí•´ ì •í™•íˆ ê·¸ëŸ° ì¼ì„ í•˜ê³  ìˆëŠ” ê²ƒì…ë‹ˆë‹¤. ì €í¬ëŠ” Johnson & Johnson ë‚´ì—ì„œ í˜ì‹ ì„ ì´‰ì§„í•˜ê³  ìˆìœ¼ë©°, 6ê°œ ìš°ì„  ì˜ì—­ì— ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. Abiomed, Shockwave ì¸ìˆ˜ë¥¼ í†µí•œ ì‹¬í˜ˆê´€ ë¶„ì•¼ì™€ Intra-Cellular ì¸ìˆ˜ë¥¼ í†µí•œ ì œì•½ ë¶„ì•¼ì— ì§€ì†ì ìœ¼ë¡œ íˆ¬ìí•˜ê³  ìˆìœ¼ë©°, ì •í˜•ì™¸ê³¼ ë¶€ë¬¸ì—ì„œ ì„ ë‘ì£¼ìê°€ ë  ë…ë¦½ íšŒì‚¬ë¥¼ ì„¤ë¦½í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì •í˜•ì™¸ê³¼ëŠ” ì„±ì¥í•˜ëŠ” ì‹œì¥ì…ë‹ˆë‹¤. 500ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ì‹œì¥ì´ì£ . ì¸êµ¬ ê³ ë ¹í™”ê°€ ì´ ì„±ì¥ì„ ê²¬ì¸í•˜ê³  ìˆìœ¼ë©°, ì €í¬ëŠ” ì •í˜•ì™¸ê³¼ ì‚¬ì—…ì˜ ê°€ì¥ ì¤‘ìš”í•œ ë¶„ì•¼ë“¤ì—ì„œ ì••ë„ì ì¸ ì‹œì¥ ì ìœ ìœ¨ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ íšŒì‚¬ëŠ” DePuy Synthesë¼ê³  ë¶ˆë¦´ ì˜ˆì •ì´ë©°, ì—…ê³„ ë² í…Œë‘ì¸ Namal Nawanaê°€ ì´ëŒê²Œ ë©ë‹ˆë‹¤. ê·¸ë“¤ì´ ì„±ê³µí•˜ê³ , í˜ì‹ ì„ ì£¼ë„í•˜ë©°, ì„±ì¥ì„ ì´ëŒì–´ ì„¸ê³„ ìµœëŒ€ì˜ ì •í˜•ì™¸ê³¼ íšŒì‚¬ê°€ ë  ìˆ˜ ìˆë„ë¡ ë” ë‚˜ì€ ìœ„ì¹˜ì— ì„œê²Œ ë  ê²ƒì´ë¼ëŠ” ì ì— ëŒ€í•´ì„œëŠ” ì „í˜€ ì˜ì‹¬í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ ì´ëŠ” ìš°ë¦¬ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ê´€ë¦¬í•˜ê³ , ì¡´ìŠ¨ì•¤ë“œì¡´ìŠ¨ì´ íšê¸°ì ì¸ í˜ì‹ ì„ ì œê³µí•  ìˆ˜ ìˆë„ë¡ í¬ì§€ì…”ë‹í•˜ê¸° ìœ„í•œ ëª…í™•í•œ ì›€ì§ì„ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì§€ê¸ˆê¹Œì§€ ë³´ì‹œê³  ê³„ì‹  ê²°ê³¼ë“¤, ë§¤ìš° ê°•ë ¥í•œ ë¶„ê¸° ì‹¤ì ì„ ë§ì”€ë“œë¦¬ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ê°•ì¡°í•˜ê³  ì‹¶ì€ ê²ƒì€, ì´ê²ƒì´ ë‹¨ìˆœíˆ ë§¤ìš° ê°•ë ¥í•œ ë¶„ê¸° ì‹¤ì ì— ê·¸ì¹˜ì§€ ì•ŠëŠ”ë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì´ëŠ” ë˜í•œ ì¡´ìŠ¨ì•¤ë“œì¡´ìŠ¨ì´ ê°€ì†í™”ëœ ì„±ì¥ ì‚¬ì´í´ì— ì§„ì…í–ˆë‹¤ëŠ” ì‹ í˜¸ì´ì ì§€í‘œì´ë©°, ìš°ë¦¬ëŠ” ì´ëŸ¬í•œ ì„±ì¥ì´ ì´ë²ˆ 10ë…„ì˜ ë‚˜ë¨¸ì§€ ê¸°ê°„ ë™ì•ˆ ì§€ì†ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜¬ë°”ë¥¸ ë°©í–¥ìœ¼ë¡œ ë‚˜ì•„ê°€ê³  ìˆìŠµë‹ˆë‹¤. íˆ¬ììë“¤ì´ ì¡´ìŠ¨ì•¤ë“œì¡´ìŠ¨ì´ ì ê·¹ì ì¸ í¬íŠ¸í´ë¦¬ì˜¤ ê´€ë¦¬ìë¼ëŠ” ì ì„ ë³´ê³  ê¸°ë»í•  ê²ƒì´ë¼ê³  í™•ì‹ í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Joseph Wolk: Executive VP & CFO Yes. Alex, maybe just to build on Joaquin's comments. Thanks for the question. So there was 2 other parts that I thought I heard from you. This is not a precursor to anything else. We look at what we have now and the clarity of our portfolio, 3 strongholds in innovative medicine, serving unmet needs with transformational innovation that elevates the standard of care in oncology, neuroscience and immunology. And likewise, now in MedTech, where we have market-leading positions, cutting-edge technology that is improving care for patients in surgery, eye health and cardiovascular. So we're going to be real pleased with the portfolio, and we think Orthopedics is set up for success going forward based on their profile and their ability to compete against other singularly focused Orthopaedics companies. With respect to guidance revisions, so as we mentioned in the scripted commentary, this will take 18 to 24 months. So anything we say about 2026 will likely include the Orthopaedics business in our outlooks. We would expect maybe some material developments in middle of next year, but we commit to keeping this audience particularly advised on a timely basis should anything material unfold.</td><td>**Joseph Wolk:** ë„¤, ì•Œë ‰ìŠ¤. í˜¸ì•„í‚¨ì˜ ë§ì— ë§ë¶™ì—¬ì„œ ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ë‹¤ë¥¸ ë‘ ê°€ì§€ ë¶€ë¶„ì— ëŒ€í•´ì„œë„ ë§ì”€í•˜ì‹  ê²ƒ ê°™ì€ë°ìš”. ì´ê²ƒì€ ë‹¤ë¥¸ ì–´ë–¤ ê²ƒì˜ ì „ì¡°ê°€ ì•„ë‹™ë‹ˆë‹¤. ìš°ë¦¬ëŠ” í˜„ì¬ ë³´ìœ í•˜ê³  ìˆëŠ” ê²ƒê³¼ í¬íŠ¸í´ë¦¬ì˜¤ì˜ ëª…í™•ì„±ì„ ì‚´í´ë³´ê³  ìˆìŠµë‹ˆë‹¤. í˜ì‹  ì˜ì•½í’ˆ ë¶„ì•¼ì—ì„œ 3ê°œì˜ í•µì‹¬ ì˜ì—­ - ì¢…ì–‘í•™, ì‹ ê²½ê³¼í•™, ë©´ì—­í•™ì—ì„œ ì¹˜ë£Œ í‘œì¤€ì„ ëŒì–´ì˜¬ë¦¬ëŠ” í˜ì‹ ì ì¸ ë³€í™”ë¥¼ í†µí•´ ë¯¸ì¶©ì¡± ì˜ë£Œ ìˆ˜ìš”ë¥¼ í•´ê²°í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ˆì°¬ê°€ì§€ë¡œ ë©”ë“œí…Œí¬(MedTech) ë¶„ì•¼ì—ì„œë„ ìˆ˜ìˆ , ì•ˆê³¼, ì‹¬í˜ˆê´€ ì˜ì—­ì—ì„œ í™˜ì ì¹˜ë£Œë¥¼ ê°œì„ í•˜ëŠ” ìµœì²¨ë‹¨ ê¸°ìˆ ë¡œ ì‹œì¥ì„ ì„ ë„í•˜ëŠ” ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤. í¬íŠ¸í´ë¦¬ì˜¤ì— ëŒ€í•´ ë§¤ìš° ë§Œì¡±í•  ê²ƒì´ë©°, ì •í˜•ì™¸ê³¼ ì‚¬ì—…ë¶€ëŠ” ê·¸ë“¤ì˜ í”„ë¡œí•„ê³¼ ë‹¤ë¥¸ ì •í˜•ì™¸ê³¼ ì „ë¬¸ ê¸°ì—…ë“¤ê³¼ ê²½ìŸí•  ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ì„ ë°”íƒ•ìœ¼ë¡œ í–¥í›„ ì„±ê³µí•  ìˆ˜ ìˆëŠ” ê¸°ë°˜ì„ ê°–ì¶”ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. <br><br>ê°€ì´ë˜ìŠ¤ ìˆ˜ì •ê³¼ ê´€ë ¨í•´ì„œëŠ”, ì•ì„œ ì¤€ë¹„ëœ ë°œì–¸ì—ì„œ ì–¸ê¸‰í–ˆë“¯ì´ 18ê°œì›”ì—ì„œ 24ê°œì›”ì´ ì†Œìš”ë  ì˜ˆì •ì…ë‹ˆë‹¤. ë”°ë¼ì„œ 2026ë…„ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ëŠ” ë‚´ìš©ì—ëŠ” ì •í˜•ì™¸ê³¼ ì‚¬ì—…ì´ ì „ë§ì— í¬í•¨ë  ê°€ëŠ¥ì„±ì´ ë†’ìŠµë‹ˆë‹¤. ë‚´ë…„ ì¤‘ë°˜ ì •ë„ì— ì¼ë¶€ ì¤‘ìš”í•œ ì§„ì „ì´ ìˆì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ì§€ë§Œ, ì¤‘ìš”í•œ ì‚¬ì•ˆì´ ì „ê°œë  ê²½ìš° ì´ ìë¦¬ì— ê³„ì‹  ë¶„ë“¤ê»˜ ì ì‹œì— ì•Œë ¤ë“œë¦¬ê² ë‹¤ê³  ì•½ì†ë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question today is coming from Danielle Antalffy from UBS.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ UBSì˜ ë‹¤ë‹ˆì—˜ ì•ˆíƒˆí”¼ë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Danielle Antalffy: UBS Investment Bank, Research Division Just a question on, Joe, your commentary around potential margins post the Ortho spin. 75 bps, I don't want to get too greedy, but that feels a little light to me. So just curious about why given the mix of the business, it's high-growth cardio, surgical, which I think should be relatively high margin and vision, feels like maybe it could be a little bit more than that. So I just want to make sure I understand the puts and takes to that 75 bps number, appreciating that's just a very early target.</td><td>**Danielle Antalffy:** ì¡°, ì •í˜•ì™¸ê³¼ ë¶„ì‚¬ ì´í›„ ì ì¬ì  ë§ˆì§„ì— ëŒ€í•œ ê·€í•˜ì˜ ì–¸ê¸‰ì— ëŒ€í•´ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. 75bpë¼ê³  í•˜ì…¨ëŠ”ë°, ë„ˆë¬´ ìš•ì‹¬ì„ ë¶€ë¦¬ê³  ì‹¶ì§€ëŠ” ì•Šì§€ë§Œ ì¡°ê¸ˆ ë‚®ê²Œ ëŠê»´ì§‘ë‹ˆë‹¤. ì‚¬ì—… êµ¬ì„±ì„ ê³ ë ¤í•  ë•Œ, ê³ ì„±ì¥ ì‹¬í˜ˆê´€, ìˆ˜ìˆ  ë¶€ë¬¸ì€ ìƒëŒ€ì ìœ¼ë¡œ ë†’ì€ ë§ˆì§„ì„ ê°€ì§ˆ ê²ƒìœ¼ë¡œ ìƒê°ë˜ê³  ë¹„ì „ ë¶€ë¬¸ë„ ë§ˆì°¬ê°€ì§€ì¸ë°, 75bpë³´ë‹¤ëŠ” ì¡°ê¸ˆ ë” ë†’ì„ ìˆ˜ ìˆì„ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ 75bp ìˆ˜ì¹˜ì— ëŒ€í•œ í”ŒëŸ¬ìŠ¤ ìš”ì¸ê³¼ ë§ˆì´ë„ˆìŠ¤ ìš”ì¸ë“¤ì„ ì œëŒ€ë¡œ ì´í•´í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ë¬¼ë¡  ì´ê²ƒì´ ì•„ì§ ì´ˆê¸° ëª©í‘œë¼ëŠ” ì ì€ ì´í•´í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Joseph Wolk: Executive VP & CFO Yes. Thanks, Danielle. That's an insightful question. And I think it really depends on the time period by which you're measuring. If we were just to take 2025, you're absolutely right. It would be probably closer to 100 bps, both on top and bottom or margin improvement. What I would say is we looked out a couple of years, given this will take a couple of years to go through the process. And as Abiomed, Shockwave and the other businesses have higher growth profiles, margin improvements initiatives that are already underway under Tim's leadership, it will have a more muted impact as it goes forward. So I think on today's math, you're probably closer to being right. It's okay. I don't consider it greedy. Tim might, but I don't. And -- but I think as you look out a little bit further with some of the stronger profile businesses from a financial perspective, it will have more of a muted impact.</td><td>**Joseph Wolk:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, ë‹¤ë‹ˆì—˜. ì •ë§ í†µì°°ë ¥ ìˆëŠ” ì§ˆë¬¸ì´ë„¤ìš”. ì´ëŠ” ì–´ë–¤ ê¸°ê°„ì„ ê¸°ì¤€ìœ¼ë¡œ ì¸¡ì •í•˜ëŠëƒì— ë”°ë¼ ë‹¬ë¼ì§„ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë§Œì•½ 2025ë…„ë§Œì„ ê¸°ì¤€ìœ¼ë¡œ í•œë‹¤ë©´, ë§ì”€í•˜ì‹  ê²Œ ë§ìŠµë‹ˆë‹¤. ë§¤ì¶œê³¼ ìˆ˜ìµ ëª¨ë‘ì—ì„œ, ë˜ëŠ” ë§ˆì§„ ê°œì„  ì¸¡ë©´ì—ì„œ 100bpì— ë” ê°€ê¹Œìš¸ ê²ƒì…ë‹ˆë‹¤.<br><br>ì œê°€ ë§ì”€ë“œë¦¬ê³  ì‹¶ì€ ê²ƒì€ ì´ ê³¼ì •ì´ ëª‡ ë…„ì— ê±¸ì³ ì§„í–‰ë  ê²ƒì´ê¸° ë•Œë¬¸ì— ëª‡ ë…„ ì•ì„ ë‚´ë‹¤ë´¤ë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  Abiomed, Shockwave ë° ê¸°íƒ€ ì‚¬ì—…ë“¤ì´ ë” ë†’ì€ ì„±ì¥ í”„ë¡œí•„ì„ ê°€ì§€ê³  ìˆê³ , íŒ€ì˜ ë¦¬ë”ì‹­ í•˜ì— ì´ë¯¸ ì§„í–‰ ì¤‘ì¸ ë§ˆì§„ ê°œì„  ì´ë‹ˆì…”í‹°ë¸Œë“¤ì´ ìˆì–´ì„œ, ì•ìœ¼ë¡œ ê°ˆìˆ˜ë¡ ê·¸ ì˜í–¥ì€ ë” ì™„í™”ë  ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ í˜„ì¬ ê³„ì‚°ìœ¼ë¡œëŠ” ì•„ë§ˆ ë‹¹ì‹  ë§ì´ ë” ë§ì„ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ê´œì°®ìŠµë‹ˆë‹¤. ì €ëŠ” ê·¸ê²ƒì„ ìš•ì‹¬ì´ë¼ê³  ìƒê°í•˜ì§€ ì•Šì•„ìš”. íŒ€ì€ ê·¸ëŸ´ì§€ë„ ëª¨ë¥´ì§€ë§Œ, ì €ëŠ” ì•„ë‹™ë‹ˆë‹¤. í•˜ì§€ë§Œ ì¬ë¬´ì  ê´€ì ì—ì„œ ë” ê°•ë ¥í•œ í”„ë¡œí•„ì„ ê°€ì§„ ì‚¬ì—…ë“¤ì„ ì¡°ê¸ˆ ë” ì¥ê¸°ì ìœ¼ë¡œ ë³´ë©´, ê·¸ ì˜í–¥ì€ ìƒë‹¹íˆ ì™„í™”ë  ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Tim Schmid: Executive VP & Worldwide Chairman of MedTech Yes. And Danielle, maybe just building on Joe's comments as I'm sure there'll be a lot of questions on this topic, and we'd like to try and get them out of the way so we can focus on the broader business. But I wanted to highlight why this makes sense for Johnson & Johnson MedTech. And as you've heard from Joaquin and Joe, this is all about our commitment to continuous portfolio optimization and value creation. And as you know, we've been on a journey over the last couple of several years to really aggressively move our portfolio into higher-growth markets and adding attractive assets such as Abiomed and Shockwave in high-growth markets like cardiovascular are good examples of the bold moves we already made. This decision to separate Ortho is the next major step in that direction. Ortho is a great business, but frankly, one that participates, as you know, in lower growth markets. This is all about shrinking to grow faster for MedTech. And last time I looked, you're not rewarding size, but really rather best-in-class performance, and that's the path that we're on. As you already have heard, we expect the separation would increase our top line growth and margins following the completion. And this allows us in MedTech to really to focus on the businesses that will remain, which is our priorities of Cardiovascular, Surgery and Vision.</td><td>**Tim Schmid:** ë„¤, ë‹¤ë‹ˆì—˜, ì¡°ì˜ ì˜ê²¬ì— ë§ë¶™ì—¬ì„œ ë§ì”€ë“œë¦¬ìë©´, ì´ ì£¼ì œì— ëŒ€í•´ ë§ì€ ì§ˆë¬¸ë“¤ì´ ìˆì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ëŠ”ë°, ì´ëŸ° ì§ˆë¬¸ë“¤ì„ ë¨¼ì € ì •ë¦¬í•´ì„œ ë” ë„“ì€ ì‚¬ì—… ì „ë°˜ì— ì§‘ì¤‘í•  ìˆ˜ ìˆë„ë¡ í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ê²ƒì´ ì™œ Johnson & Johnson MedTechì—ê²Œ ì˜ë¯¸ê°€ ìˆëŠ”ì§€ ê°•ì¡°í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. í˜¸ì•„í‚¨ê³¼ ì¡°ë¡œë¶€í„° ë“¤ìœ¼ì…¨ë“¯ì´, ì´ëŠ” ëª¨ë‘ ì§€ì†ì ì¸ í¬íŠ¸í´ë¦¬ì˜¤ ìµœì í™”ì™€ ê°€ì¹˜ ì°½ì¶œì— ëŒ€í•œ ìš°ë¦¬ì˜ ì•½ì†ê³¼ ê´€ë ¨ì´ ìˆìŠµë‹ˆë‹¤. <br><br>ì•„ì‹œë‹¤ì‹œí”¼, ìš°ë¦¬ëŠ” ì§€ë‚œ ëª‡ ë…„ê°„ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ê³ ì„±ì¥ ì‹œì¥ìœ¼ë¡œ ì ê·¹ì ìœ¼ë¡œ ì´ë™ì‹œí‚¤ëŠ” ì—¬ì •ì„ ê±¸ì–´ì™”ìŠµë‹ˆë‹¤. ì‹¬í˜ˆê´€ê³¼ ê°™ì€ ê³ ì„±ì¥ ì‹œì¥ì—ì„œ Abiomedì™€ Shockwave ê°™ì€ ë§¤ë ¥ì ì¸ ìì‚°ë“¤ì„ ì¶”ê°€í•œ ê²ƒì€ ìš°ë¦¬ê°€ ì´ë¯¸ ì·¨í•œ ê³¼ê°í•œ í–‰ë³´ì˜ ì¢‹ì€ ì‚¬ë¡€ë“¤ì…ë‹ˆë‹¤. ì •í˜•ì™¸ê³¼ ì‚¬ì—…ë¶€ë¥¼ ë¶„ë¦¬í•˜ê¸°ë¡œ í•œ ì´ë²ˆ ê²°ì •ì€ ê·¸ ë°©í–¥ìœ¼ë¡œ ë‚˜ì•„ê°€ëŠ” ë‹¤ìŒ ì£¼ìš” ë‹¨ê³„ì…ë‹ˆë‹¤. ì •í˜•ì™¸ê³¼ëŠ” í›Œë¥­í•œ ì‚¬ì—…ì´ì§€ë§Œ, ì†”ì§íˆ ë§ì”€ë“œë¦¬ë©´ ì•„ì‹œë‹¤ì‹œí”¼ ì„±ì¥ë¥ ì´ ë‚®ì€ ì‹œì¥ì— ì°¸ì—¬í•˜ê³  ìˆëŠ” ì‚¬ì—…ì…ë‹ˆë‹¤. ì´ëŠ” ëª¨ë‘ ë©”ë“œí…Œí¬ê°€ ë” ë¹ ë¥´ê²Œ ì„±ì¥í•˜ê¸° ìœ„í•´ ê·œëª¨ë¥¼ ì¶•ì†Œí•˜ëŠ” ê²ƒì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. ì œê°€ ë§ˆì§€ë§‰ìœ¼ë¡œ í™•ì¸í–ˆì„ ë•Œ, ì—¬ëŸ¬ë¶„ì€ ê·œëª¨ê°€ ì•„ë‹ˆë¼ ì‹¤ì œë¡œëŠ” ë™ê¸‰ ìµœê³ ì˜ ì„±ê³¼ì— ë³´ìƒì„ ì£¼ê³  ê³„ì‹œë©°, ê·¸ê²ƒì´ ë°”ë¡œ ìš°ë¦¬ê°€ ê°€ê³  ìˆëŠ” ê¸¸ì…ë‹ˆë‹¤.<br><br>ì´ë¯¸ ë“¤ìœ¼ì…¨ê² ì§€ë§Œ, ë¶„ë¦¬ ì™„ë£Œ í›„ ë§¤ì¶œ ì„±ì¥ë¥ ê³¼ ë§ˆì§„ì´ ì¦ê°€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ë¥¼ í†µí•´ ë©”ë“œí…Œí¬ì—ì„œëŠ” ë‚¨ê²Œ ë  ì‚¬ì—…ë“¤, ì¦‰ ìš°ë¦¬ì˜ ìš°ì„ ìˆœìœ„ì¸ ì‹¬í˜ˆê´€, ìˆ˜ìˆ , ê·¸ë¦¬ê³  ë¹„ì „ ì‚¬ì—…ì— ì •ë§ë¡œ ì§‘ì¤‘í•  ìˆ˜ ìˆê²Œ ë©ë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Chairman: Thank you. And I -- look, I want to reiterate, as I told you day 1 when I became CEO, that I am fully focused, determined to make our MedTech sector the best-in-class MedTech group in the industry. That's a total priority for me. It's a priority for Johnson & Johnson, and we are fully committed to deliver on that, and we are on track to become the best Med Tech sector in the industry.</td><td>**CEO & Chairman:** ê°ì‚¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì œê°€ CEOê°€ ëœ ì²«ë‚ ë¶€í„° ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ì €ëŠ” ìš°ë¦¬ ë©”ë“œí…Œí¬(MedTech) ë¶€ë¬¸ì„ ì—…ê³„ ìµœê³  ìˆ˜ì¤€ì˜ ë©”ë“œí…Œí¬ ê·¸ë£¹ìœ¼ë¡œ ë§Œë“œëŠ” ë° ì „ì ìœ¼ë¡œ ì§‘ì¤‘í•˜ê³  ìˆìœ¼ë©° í™•ê³ í•œ ì˜ì§€ë¥¼ ê°€ì§€ê³  ìˆë‹¤ëŠ” ì ì„ ë‹¤ì‹œ í•œë²ˆ ê°•ì¡°í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ì´ê²ƒì€ ì €ì—ê²Œ ìˆì–´ ìµœìš°ì„  ê³¼ì œì…ë‹ˆë‹¤. ì¡´ìŠ¨ì•¤ë“œì¡´ìŠ¨ì—ê²Œë„ ìš°ì„ ìˆœìœ„ì´ë©°, ìš°ë¦¬ëŠ” ì´ë¥¼ ì‹¤í˜„í•˜ê¸° ìœ„í•´ ì „ì ìœ¼ë¡œ ì „ë…í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” ì—…ê³„ ìµœê³ ì˜ ë©”ë“œí…Œí¬ ë¶€ë¬¸ì´ ë˜ê¸° ìœ„í•œ ê¶¤ë„ì— ì˜¬ë¼ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question today is coming from Chris Schott from JPMorgan.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ JPMorganì˜ Chris Schottë‹˜ê»˜ì„œ ì£¼ì‹  ì§ˆë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Christopher Schott: JPMorgan Chase & Co, Research Division Maybe just a question for Joaquin. There seems like there might be a framework for MFN agreements with the administration that's emerging across the space focused on new launches in Medicaid. Can you just talk about how you're thinking about MFN tariffs, et cetera, and J&J's approach to some of these kind of policy dynamics that are floating around out there?</td><td>**Christopher Schott:** ì‹ ì •ë¶€ì—ì„œ ë©”ë””ì¼€ì´ë“œ ì‹ ê·œ ì¶œì‹œì— ì´ˆì ì„ ë§ì¶˜ ìµœí˜œêµ­ ëŒ€ìš°(MFN) í˜‘ì •ì— ëŒ€í•œ í”„ë ˆì„ì›Œí¬ê°€ ì—…ê³„ ì „ë°˜ì— ê±¸ì³ ë‚˜íƒ€ë‚˜ê³  ìˆëŠ” ê²ƒ ê°™ìŠµë‹ˆë‹¤. MFN ê´€ì„¸ ë“±ì— ëŒ€í•´ ì–´ë–»ê²Œ ìƒê°í•˜ê³  ê³„ì‹œëŠ”ì§€, ê·¸ë¦¬ê³  í˜„ì¬ ë…¼ì˜ë˜ê³  ìˆëŠ” ì´ëŸ¬í•œ ì •ì±… ë™í–¥ë“¤ì— ëŒ€í•œ J&Jì˜ ì ‘ê·¼ ë°©ì‹ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”?</td></tr>
<tr><td>CEO & Chairman: Thank you for the question. We've been talking with this administration with an open dialogue since day 1, even before day 1. And we are always looking as we have done at Johnson & Johnson for common ground to build in the administration priorities that are similar to ours. Priorities like making sure that American patients have access to innovation in an affordable and timely way, priorities like making sure that foreign entities do not free ride on American innovation, making sure that we are able to maintain the overall leadership that this country has in life sciences. And finally, making sure that we continue to invest in manufacturing in this country to build good middle-class jobs. So we are delivering on that. We announced our plan to invest $55 billion in the U.S. in the next 4 years, which essentially is going to make it so that all our advanced medicines that are used in the U.S. are going to be manufactured in the U.S. As far as the discussions, those are ongoing. I don't have anything to share today, but I am optimistic that we are going to land in a place which is going to create common ground between the administration and ourselves.</td><td>**CEO & Chairman:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ì €í¬ëŠ” ì´ë²ˆ í–‰ì •ë¶€ì™€ ì²«ë‚ ë¶€í„°, ì•„ë‹ˆ ì²«ë‚  ì´ì „ë¶€í„° ì—´ë¦° ëŒ€í™”ë¥¼ ë‚˜ëˆ„ì–´ ì™”ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¡´ìŠ¨ì•¤ë“œì¡´ìŠ¨ì—ì„œ í•­ìƒ í•´ì™”ë“¯ì´, ì €í¬ì™€ ìœ ì‚¬í•œ í–‰ì •ë¶€ì˜ ìš°ì„ ìˆœìœ„ë“¤ê³¼ ê³µí†µë¶„ëª¨ë¥¼ ì°¾ê¸° ìœ„í•´ ì§€ì†ì ìœ¼ë¡œ ë…¸ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ë¯¸êµ­ í™˜ìë“¤ì´ í˜ì‹ ì ì¸ ì¹˜ë£Œì œì— í•©ë¦¬ì ì¸ ê°€ê²©ìœ¼ë¡œ ì ì‹œì— ì ‘ê·¼í•  ìˆ˜ ìˆë„ë¡ í•˜ëŠ” ê²ƒ, ì™¸êµ­ ê¸°ì—…ë“¤ì´ ë¯¸êµ­ì˜ í˜ì‹ ì— ë¬´ì„ìŠ¹ì°¨í•˜ì§€ ëª»í•˜ë„ë¡ í•˜ëŠ” ê²ƒ, ì´ ë‚˜ë¼ê°€ ìƒëª…ê³¼í•™ ë¶„ì•¼ì—ì„œ ì „ë°˜ì ì¸ ë¦¬ë”ì‹­ì„ ìœ ì§€í•  ìˆ˜ ìˆë„ë¡ í•˜ëŠ” ê²ƒê³¼ ê°™ì€ ìš°ì„ ìˆœìœ„ë“¤ ë§ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë§ˆì§€ë§‰ìœ¼ë¡œ, ì´ ë‚˜ë¼ì—ì„œ ì œì¡°ì—…ì— ëŒ€í•œ íˆ¬ìë¥¼ ì§€ì†í•˜ì—¬ ì–‘ì§ˆì˜ ì¤‘ì‚°ì¸µ ì¼ìë¦¬ë¥¼ ì°½ì¶œí•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. <br><br>ì €í¬ëŠ” ì´ë¥¼ ì‹¤í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¯¸êµ­ì— 550ì–µ ë‹¬ëŸ¬ë¥¼ íˆ¬ìí•˜ê² ë‹¤ëŠ” ê³„íšì„ ë°œí‘œí–ˆìŠµë‹ˆë‹¤. í–¥í›„ 4ë…„ê°„ ë¯¸êµ­ì—ì„œ ì‚¬ìš©ë˜ëŠ” ëª¨ë“  ì²¨ë‹¨ ì˜ì•½í’ˆì„ ë¯¸êµ­ ë‚´ì—ì„œ ì œì¡°í•˜ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ë…¼ì˜ì™€ ê´€ë ¨í•´ì„œëŠ” í˜„ì¬ ì§„í–‰ ì¤‘ì´ë©°, ì˜¤ëŠ˜ ê³µìœ í•  ìˆ˜ ìˆëŠ” êµ¬ì²´ì ì¸ ë‚´ìš©ì€ ì—†ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ í–‰ì •ë¶€ì™€ ì €í¬ ì‚¬ì´ì— ê³µí†µë¶„ëª¨ë¥¼ ì°¾ì„ ìˆ˜ ìˆëŠ” í•©ì˜ì ì— ë„ë‹¬í•  ê²ƒì´ë¼ê³  ë‚™ê´€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question today is coming from Larry Biegelsen from Wells Fargo.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Wells Fargoì˜ Larry Biegelsenì”¨ë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Larry Biegelsen: Wells Fargo Securities, LLC, Research Division Joe, you talked about the accelerating sales growth in both Innovative Medicine and MedTech next year. Is the 5% plus, I heard you say earlier on a reported or adjusted operational basis? I think FX is a tailwind. How are you thinking about the extra week next year? I guess I'm trying to understand if growth will accelerate next year on an adjusted operational basis, excluding the extra week? And the same for EPS, is that on a reported or operational basis?</td><td>**Larry Biegelsen:** Wells Fargo Securitiesì—ì„œ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. Joe, ë‚´ë…„ì— Innovative Medicineê³¼ MedTech ëª¨ë‘ì—ì„œ ë§¤ì¶œ ì„±ì¥ì´ ê°€ì†í™”ë  ê²ƒì´ë¼ê³  ë§ì”€í•˜ì…¨ëŠ”ë°ìš”. ì•ì„œ ì–¸ê¸‰í•˜ì‹  5% ì´ìƒì´ë¼ëŠ” ìˆ˜ì¹˜ê°€ ë³´ê³  ê¸°ì¤€ì¸ì§€ ì•„ë‹ˆë©´ ì¡°ì •ëœ ìš´ì˜ ê¸°ì¤€ì¸ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ì™¸í™˜ì´ ìˆœí’ ìš”ì¸ìœ¼ë¡œ ì‘ìš©í•  ê²ƒ ê°™ì€ë°ìš”. ë‚´ë…„ ì¶”ê°€ ì£¼ì— ëŒ€í•´ì„œëŠ” ì–´ë–»ê²Œ ìƒê°í•˜ê³  ê³„ì‹ ì§€ìš”? ì¶”ê°€ ì£¼ë¥¼ ì œì™¸í•œ ì¡°ì •ëœ ìš´ì˜ ê¸°ì¤€ìœ¼ë¡œë„ ë‚´ë…„ì— ì„±ì¥ì´ ê°€ì†í™”ë  ê²ƒì¸ì§€ ì´í•´í•˜ë ¤ê³  í•©ë‹ˆë‹¤. EPSë„ ë§ˆì°¬ê°€ì§€ë¡œ ë³´ê³  ê¸°ì¤€ì¸ì§€ ìš´ì˜ ê¸°ì¤€ì¸ì§€ ì•Œê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Joseph Wolk: Executive VP & CFO Yes, Larry, very simply, since consensus is based on reported for both top line as well as EPS, that was the comparator I used. So there is a slight tailwind, as you mentioned, for FX, but I assume -- and I know, Larry, you and your team are very astute at capturing the FX impact. I would assume that's already baked into the 4.6% top line growth that I saw consensus have for 2026, similarly with the earnings. So it is a lift, I would say, across the board, but on a basis by which the analysts yourself included, look at it.</td><td>**Joseph Wolk:** ë„¤, Larry, ì•„ì£¼ ê°„ë‹¨íˆ ë§ì”€ë“œë¦¬ë©´ ì»¨ì„¼ì„œìŠ¤ê°€ ë§¤ì¶œê³¼ ì£¼ë‹¹ìˆœì´ìµ(EPS) ëª¨ë‘ ë³´ê³  ê¸°ì¤€ìœ¼ë¡œ ë˜ì–´ ìˆê¸° ë•Œë¬¸ì— ê·¸ê²ƒì„ ë¹„êµ ê¸°ì¤€ìœ¼ë¡œ ì‚¬ìš©í–ˆìŠµë‹ˆë‹¤. ë§ì”€í•˜ì‹  ëŒ€ë¡œ ì™¸í™˜ì—ì„œ ì•½ê°„ì˜ ìˆœí’ì´ ìˆì§€ë§Œ, Larry, ê·€í•˜ì™€ ê·€í•˜ íŒ€ì´ ì™¸í™˜ ì˜í–¥ì„ íŒŒì•…í•˜ëŠ” ë° ë§¤ìš° ì˜ˆë¦¬í•˜ë‹¤ëŠ” ê²ƒì„ ì•Œê³  ìˆê¸° ë•Œë¬¸ì— ì œê°€ ë³¸ 2026ë…„ ì»¨ì„¼ì„œìŠ¤ ë§¤ì¶œ ì„±ì¥ë¥  4.6%ì— ì´ë¯¸ ë°˜ì˜ë˜ì–´ ìˆë‹¤ê³  ê°€ì •í•©ë‹ˆë‹¤. ìˆ˜ìµ ë¶€ë¶„ë„ ë§ˆì°¬ê°€ì§€ì…ë‹ˆë‹¤. <br><br>ì „ë°˜ì ìœ¼ë¡œ ìƒìŠ¹ ìš”ì¸ì´ë¼ê³  ë§ì”€ë“œë¦¬ê² ì§€ë§Œ, ê·€í•˜ë¥¼ í¬í•¨í•œ ì• ë„ë¦¬ìŠ¤íŠ¸ë“¤ì´ ë³´ëŠ” ê¸°ì¤€ìœ¼ë¡œ ë§ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question today is coming from Asad Haider from Goldman Sachs.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ê³¨ë“œë§Œì‚­ìŠ¤ì˜ ì•„ì‚¬ë“œ í•˜ì´ë”ë‹˜ê»˜ì„œ ì£¼ì…¨ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Asad Haider: Goldman Sachs Group, Inc., Research Division Just a big picture question. You'll be exiting this year in a clear position of strength where a number of headwinds from the STELARA LOE are fading into the background. The base business is strong and you've got new product cycle momentum accelerating through the Innovative Medicines portfolio. And you're also seeing a second half improvement in MedTech. So in that context, and with the announcement of this morning to spin off DePuy, can you just maybe double-click a little bit more on how you're going to be balancing capital allocation priorities to sustain acceleration in Innovative Meds and push MedTech sustainably towards the 5% to 7% ERB targets? And then related, in the Innovative Medicines business, the sales growth acceleration in 2026, like you said, Joe, that's not getting modeled by consensus. So what are the biggest disconnects there that you're able to highlight today specifically for next year?</td><td>**Asad Haider:** í° ê·¸ë¦¼ì—ì„œ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì˜¬í•´ ë§ íšŒì‚¬ëŠ” í™•ì‹¤íˆ ê°•ë ¥í•œ í¬ì§€ì…˜ì—ì„œ ë§ˆë¬´ë¦¬í•˜ê²Œ ë  ê²ƒ ê°™ìŠµë‹ˆë‹¤. STELARA íŠ¹í—ˆë§Œë£Œ(LOE)ë¡œ ì¸í•œ ì—¬ëŸ¬ ì—­í’ë“¤ì´ ë°°ê²½ìœ¼ë¡œ ì‚¬ë¼ì§€ê³  ìˆê³ , ê¸°ë°˜ ì‚¬ì—…ì€ ê²¬ê³ í•˜ë©°, í˜ì‹ ì˜ì•½í’ˆ í¬íŠ¸í´ë¦¬ì˜¤ ì „ë°˜ì—ì„œ ì‹ ì œí’ˆ ì‚¬ì´í´ ëª¨ë©˜í…€ì´ ê°€ì†í™”ë˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ë©”ë“œí…Œí¬ ë¶€ë¬¸ì—ì„œë„ í•˜ë°˜ê¸° ê°œì„ ì„¸ë¥¼ ë³´ì´ê³  ìˆê³ ìš”. <br><br>ì´ëŸ° ìƒí™©ì—ì„œ, ê·¸ë¦¬ê³  ì˜¤ëŠ˜ ì•„ì¹¨ ë°œí‘œëœ DePuy ë¶„ì‚¬ ê³„íšì„ ê³ ë ¤í•  ë•Œ, í˜ì‹ ì˜ì•½í’ˆ ë¶€ë¬¸ì˜ ê°€ì†í™”ë¥¼ ì§€ì†í•˜ê³  ë©”ë“œí…Œí¬ë¥¼ 5~7% ERB ëª©í‘œì¹˜ë¥¼ í–¥í•´ ì§€ì†ê°€ëŠ¥í•˜ê²Œ ì¶”ì§„í•˜ê¸° ìœ„í•œ ìë³¸ë°°ë¶„ ìš°ì„ ìˆœìœ„ë¥¼ ì–´ë–»ê²Œ ê· í˜•ìˆê²Œ ì¡°ì •í•  ê³„íšì¸ì§€ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ê·¸ë¦¬ê³  ê´€ë ¨í•´ì„œ, í˜ì‹ ì˜ì•½í’ˆ ì‚¬ì—…ì—ì„œ 2026ë…„ ë§¤ì¶œ ì„±ì¥ ê°€ì†í™” ë¶€ë¶„ì¸ë°ìš”, ì¡° ë§ì”€í•˜ì‹  ëŒ€ë¡œ ì»¨ì„¼ì„œìŠ¤ì—ì„œ ì´ë¥¼ ë°˜ì˜í•˜ì§€ ëª»í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ ë‚´ë…„ì„ ìœ„í•´ ì˜¤ëŠ˜ êµ¬ì²´ì ìœ¼ë¡œ ê°•ì¡°í•  ìˆ˜ ìˆëŠ” ê°€ì¥ í° ì°¨ì´ì ë“¤ì€ ë¬´ì—‡ì¸ê°€ìš”?</td></tr>
<tr><td>CEO & Chairman: So first, look, we are in a favorable position as far as capital allocation means. We have a number of important opportunities to invest within our pipeline and portfolio. So that is our #1 priority now as far as capital allocation. We're in the middle of the launch, and Tim and Jennifer will discuss about that of major, major blockbuster products. On the Innovative Medicine side, we are launching TREMFYA in inflammatory bowel disease, RYBREVANT and LAZCLUZE in lung cancer, INLEXZO in localized bladder cancer. We continue with the growth of CARVYKTI and SPRAVATO. And we just filed for icotrokinra in plaque psoriasis. So we have a wealth of opportunities to drive significant growth in our pharmaceutical business that Jennifer will describe. Just to give you an idea of the strength of our Pharmaceutical business. Excluding STELARA, our Pharmaceutical business in the third quarter grew a whopping 16%. So that's a very big business, more than $50 billion business growing at 16%. So we have multiple opportunities to drive capital allocation in the Pharmaceutical business as well as in our pipeline there. I mean, we're working on bispecific for prostate cancer, trispecific for multiple myeloma, a wealth of opportunities to drive capital allocation. On the MedTech side, I mean, we're in the middle of major things in the MedTech side. On one hand, we are committed to remain leaders in the electrophysiology segment with the launch of VARIPULSE, our dual energy catheter. We continue to work in improvements in our CARTO System, and we are determined to invest there to remain the leaders as we have been. We are working to expand our heart pumps. You guys all know about the New England Journal of Medicine published publication showing the DANE study in patients with acute myocardial lung infection that had cardiogenic shock that show a 600 days improvement over a 10-year period, impressive breakthrough innovation there. We have a lot of opportunities in Shockwave with the Javelin Peripheral Catheter and the Aero system in coronary that we are launching. And if I move into the second priority, which is our robotic surgery expansion, we are about to file with the FDA in the first half of the year our OTTAVA soft robotic -- soft tissue robotic system. We are also determined to be a major player in robotics I'm always telling you we are determined to be a major player in robotics. So we continue to have opportunities for capital allocation in both businesses. And our priority now is to be able to fuel the growth in our portfolio and our pipeline. We -- as Joe mentioned before, we are in a position, just to be clear, that we do not need large M&A to deliver in the high end of our growth targets. Let me repeat that. We do not need large M&A to deliver in the high end of our growth targets. We are going to be looking at opportunities as we always do, but we are in a position in which our #1 capital priority, it's going to be fuel our pipeline and our portfolio.</td><td>**CEO & Chairman:** ë¨¼ì € ìë³¸ ë°°ë¶„ ì¸¡ë©´ì—ì„œ ì €í¬ëŠ” ìœ ë¦¬í•œ ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤. íŒŒì´í”„ë¼ì¸ê³¼ í¬íŠ¸í´ë¦¬ì˜¤ ë‚´ì—ì„œ íˆ¬ìí•  ìˆ˜ ìˆëŠ” ì¤‘ìš”í•œ ê¸°íšŒë“¤ì´ ë§ì´ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ í˜„ì¬ ìë³¸ ë°°ë¶„ì—ì„œ ì´ê²ƒì´ ì €í¬ì˜ ìµœìš°ì„  ìˆœìœ„ì…ë‹ˆë‹¤. ì €í¬ëŠ” ì£¼ìš” ë¸”ë¡ë²„ìŠ¤í„° ì œí’ˆë“¤ì˜ ì¶œì‹œ í•œê°€ìš´ë° ìˆìœ¼ë©°, ì´ì— ëŒ€í•´ì„œëŠ” Timê³¼ Jenniferê°€ ë…¼ì˜í•  ì˜ˆì •ì…ë‹ˆë‹¤. <br><br>í˜ì‹ ì˜ì•½í’ˆ ë¶€ë¬¸ì—ì„œëŠ” ì—¼ì¦ì„± ì¥ì§ˆí™˜ì— ëŒ€í•œ TREMFYA, íì•”ì— ëŒ€í•œ RYBREVANTì™€ LAZCLUZE, êµ­ì†Œ ë°©ê´‘ì•”ì— ëŒ€í•œ INLEXZOë¥¼ ì¶œì‹œí•˜ê³  ìˆìŠµë‹ˆë‹¤. CARVYKTIì™€ SPRAVATOì˜ ì„±ì¥ë„ ì§€ì†í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  íŒìƒ ê±´ì„ ì— ëŒ€í•œ icotrokinraë¥¼ ë°©ê¸ˆ ì‹ ì²­í–ˆìŠµë‹ˆë‹¤. Jenniferê°€ ì„¤ëª…í•˜ê² ì§€ë§Œ, ì €í¬ ì œì•½ ì‚¬ì—…ì—ì„œ ìƒë‹¹í•œ ì„±ì¥ì„ ê²¬ì¸í•  ìˆ˜ ìˆëŠ” í’ë¶€í•œ ê¸°íšŒë“¤ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. STELARAë¥¼ ì œì™¸í•˜ê³  ìš°ë¦¬ ì œì•½ ì‚¬ì—…ì˜ ê°•ë ¥í•¨ì„ ë§ì”€ë“œë¦¬ë©´, 3ë¶„ê¸°ì— ë¬´ë ¤ 16% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. 500ì–µ ë‹¬ëŸ¬ê°€ ë„˜ëŠ” ë§¤ìš° í° ì‚¬ì—…ì´ 16% ì„±ì¥í•˜ê³  ìˆëŠ” ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì œì•½ ì‚¬ì—…ê³¼ íŒŒì´í”„ë¼ì¸ ëª¨ë‘ì—ì„œ ìë³¸ ë°°ë¶„ì„ ì¶”ì§„í•  ìˆ˜ ìˆëŠ” ë‹¤ì–‘í•œ ê¸°íšŒê°€ ìˆìŠµë‹ˆë‹¤. ì „ë¦½ì„ ì•” ì¹˜ë£Œë¥¼ ìœ„í•œ ì´ì¤‘íŠ¹ì´í•­ì²´(bispecific), ë‹¤ë°œì„± ê³¨ìˆ˜ì¢…ì„ ìœ„í•œ ì‚¼ì¤‘íŠ¹ì´í•­ì²´(trispecific) ë“± ìë³¸ ë°°ë¶„ì„ ì¶”ì§„í•  ìˆ˜ ìˆëŠ” í’ë¶€í•œ ê¸°íšŒë“¤ì„ ê°œë°œí•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë©”ë“œí…Œí¬ ë¶€ë¬¸ì—ì„œëŠ” ì£¼ìš”í•œ ì‚¬ì—…ë“¤ì„ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. í•œí¸ìœ¼ë¡œëŠ” ë“€ì–¼ ì—ë„ˆì§€ ì¹´í…Œí„°ì¸ VARIPULSE ì¶œì‹œë¥¼ í†µí•´ ì „ê¸°ìƒë¦¬í•™(electrophysiology) ë¶„ì•¼ì—ì„œ ë¦¬ë”ì‹­ì„ ìœ ì§€í•˜ê² ë‹¤ëŠ” ì˜ì§€ë¥¼ ê°–ê³  ìˆìŠµë‹ˆë‹¤. CARTO ì‹œìŠ¤í…œì˜ ê°œì„  ì‘ì—…ì„ ì§€ì†í•˜ê³  ìˆìœ¼ë©°, ê¸°ì¡´ì˜ ë¦¬ë”ì‹­ì„ ìœ ì§€í•˜ê¸° ìœ„í•´ ì´ ë¶„ì•¼ì— íˆ¬ìë¥¼ ê³„ì†í•  ê²ƒì…ë‹ˆë‹¤. ì‹¬ì¥ íŒí”„ ì‚¬ì—… í™•ì¥ì—ë„ ë…¸ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ëŸ¬ë¶„ë„ ì•„ì‹œê² ì§€ë§Œ, ë‰´ì‰ê¸€ëœë“œ ì˜í•™ì €ë„(New England Journal of Medicine)ì— ë°œí‘œëœ DANE ì—°êµ¬ ê²°ê³¼ê°€ ìˆìŠµë‹ˆë‹¤. ê¸‰ì„± ì‹¬ê·¼ê²½ìƒ‰ìœ¼ë¡œ ì¸í•œ ì‹¬ì¸ì„± ì‡¼í¬ í™˜ìë“¤ì„ ëŒ€ìƒìœ¼ë¡œ í•œ ì´ ì—°êµ¬ì—ì„œ 10ë…„ ê¸°ê°„ ë™ì•ˆ 600ì¼ì˜ ê°œì„  íš¨ê³¼ë¥¼ ë³´ì—¬ì¤€ ê²ƒì€ ì •ë§ ì¸ìƒì ì¸ í˜ì‹ ì  ì„±ê³¼ì…ë‹ˆë‹¤. <br><br>Shockwaveì—ì„œë„ ë§ì€ ê¸°íšŒê°€ ìˆìŠµë‹ˆë‹¤. Javelin ë§ì´ˆ ì¹´í…Œí„°(Peripheral Catheter)ì™€ ê´€ìƒë™ë§¥ìš© Aero ì‹œìŠ¤í…œì„ ì¶œì‹œí•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ë‘ ë²ˆì§¸ ìš°ì„ ìˆœìœ„ì¸ ë¡œë´‡ ìˆ˜ìˆ  í™•ì¥ìœ¼ë¡œ ë„˜ì–´ê°€ë©´, ì˜¬í•´ ìƒë°˜ê¸°ì— FDAì— OTTAVA ì—°ì¡°ì§ ë¡œë´‡ ì‹œìŠ¤í…œ(soft tissue robotic system)ì„ ì‹ ì²­í•  ì˜ˆì •ì…ë‹ˆë‹¤. ì €í¬ëŠ” ë¡œë³´í‹±ìŠ¤ ë¶„ì•¼ì—ì„œë„ ì£¼ìš” í”Œë ˆì´ì–´ê°€ ë˜ê² ë‹¤ëŠ” í™•ê³ í•œ ì˜ì§€ë¥¼ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. í•­ìƒ ë§ì”€ë“œë¦¬ê³  ìˆë“¯ì´, ì €í¬ëŠ” ë¡œë³´í‹±ìŠ¤ì—ì„œ ì£¼ìš” í”Œë ˆì´ì–´ê°€ ë˜ê¸°ë¡œ ê²°ì‹¬í–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ë‘ ì‚¬ì—… ì˜ì—­ ëª¨ë‘ì—ì„œ ìë³¸ ë°°ë¶„ì˜ ê¸°íšŒë¥¼ ì§€ì†ì ìœ¼ë¡œ ê°–ê³  ìˆìŠµë‹ˆë‹¤. <br><br>í˜„ì¬ ì €í¬ì˜ ìš°ì„ ìˆœìœ„ëŠ” í¬íŠ¸í´ë¦¬ì˜¤ì™€ íŒŒì´í”„ë¼ì¸ì˜ ì„±ì¥ì— ì—°ë£Œë¥¼ ê³µê¸‰í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì¡°ê°€ ì•ì„œ ì–¸ê¸‰í–ˆë“¯ì´, ëª…í™•íˆ ë§ì”€ë“œë¦¬ë©´ ì €í¬ëŠ” ì„±ì¥ ëª©í‘œì˜ ìƒìœ„ êµ¬ê°„ì„ ë‹¬ì„±í•˜ê¸° ìœ„í•´ ëŒ€ê·œëª¨ M&Aê°€ í•„ìš”í•˜ì§€ ì•Šì€ ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤. ë‹¤ì‹œ í•œë²ˆ ê°•ì¡°í•˜ê² ìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì„±ì¥ ëª©í‘œì˜ ìƒìœ„ êµ¬ê°„ì„ ë‹¬ì„±í•˜ê¸° ìœ„í•´ ëŒ€ê·œëª¨ M&Aê°€ í•„ìš”í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. <br><br>ë¬¼ë¡  í•­ìƒ ê·¸ë˜ì™”ë“¯ì´ ê¸°íšŒë¥¼ ì‚´í´ë³¼ ê²ƒì´ì§€ë§Œ, í˜„ì¬ ì €í¬ì˜ ìµœìš°ì„  ìë³¸ ë°°ë¶„ ìˆœìœ„ëŠ” íŒŒì´í”„ë¼ì¸ê³¼ í¬íŠ¸í´ë¦¬ì˜¤ì— ì—°ë£Œë¥¼ ê³µê¸‰í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Joseph Wolk: Executive VP & CFO Yes. I think, Asad, the only thing I would add to that is just the number of smaller deals we do that don't make headlines on the day of the transaction. I think 60 over the last 2 years. And those lead to products like INLEXZO, which we acquired in 2019 for a couple of hundred million dollars and through really passion for their craft as well as passion for meeting patients' unmet needs. Dr. Chris Coty, Dr. Charles Drake were able to find -- and their teams were able to find a bladder cancer treatment that is revolutionary. Nothing has been new in the last few decades with respect to not only ease for the patient, but also ease for the administrating physician. It's deals like that. We look at next year's product for icotrokinra, where we're expecting, again, a couple of hundred million dollar investment will turn out to be a $1 billion platform for us because that's where our competitive advantage lies is the scientific expertise that we're able to recognize early on, bringing forth a label that is most expansive, most complete and in record time.</td><td>**Joseph Wolk:** ë„¤, ì•„ì‚¬ë“œ, ì œê°€ ë§ë¶™ì´ê³  ì‹¶ì€ ê²ƒì€ ê±°ë˜ ë‹¹ì¼ í—¤ë“œë¼ì¸ì„ ì¥ì‹í•˜ì§€ ì•ŠëŠ” ì†Œê·œëª¨ ë”œë“¤ì˜ ìˆ˜ì…ë‹ˆë‹¤. ì§€ë‚œ 2ë…„ê°„ 60ê±´ ì •ë„ì˜€ì£ . ì´ëŸ° ê±°ë˜ë“¤ì´ INLEXZO ê°™ì€ ì œí’ˆìœ¼ë¡œ ì´ì–´ì§‘ë‹ˆë‹¤. ì´ ì œí’ˆì€ 2019ë…„ ìˆ˜ì–µ ë‹¬ëŸ¬ì— ì¸ìˆ˜í•œ ê²ƒì¸ë°, ì •ë§ ìì‹ ë“¤ì˜ ì „ë¬¸ ë¶„ì•¼ì— ëŒ€í•œ ì—´ì •ê³¼ í™˜ìë“¤ì˜ ë¯¸ì¶©ì¡± ì˜ë£Œ ìˆ˜ìš”ë¥¼ í•´ê²°í•˜ë ¤ëŠ” ì—´ì •ì„ í†µí•´ì„œ ë§ì´ì£ . í¬ë¦¬ìŠ¤ ì½”í‹° ë°•ì‚¬ì™€ ì°°ìŠ¤ ë“œë ˆì´í¬ ë°•ì‚¬, ê·¸ë¦¬ê³  ê·¸ë“¤ì˜ íŒ€ì´ í˜ì‹ ì ì¸ ë°©ê´‘ì•” ì¹˜ë£Œë²•ì„ ì°¾ì•„ë‚¼ ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ì§€ë‚œ ìˆ˜ì‹­ ë…„ê°„ í™˜ìì˜ í¸ì˜ì„±ë¿ë§Œ ì•„ë‹ˆë¼ íˆ¬ì—¬í•˜ëŠ” ì˜ì‚¬ì˜ í¸ì˜ì„± ì¸¡ë©´ì—ì„œë„ ìƒˆë¡œìš´ ê²ƒì´ ì „í˜€ ì—†ì—ˆê±°ë“ ìš”. ë°”ë¡œ ì´ëŸ° ë”œë“¤ì´ ì¤‘ìš”í•œ ê²ë‹ˆë‹¤. ë‚´ë…„ ì•„ì´ì½”íŠ¸ë¡œí‚¤ë‚˜ ì œí’ˆì„ ë³´ë©´, ë‹¤ì‹œ í•œë²ˆ ìˆ˜ì–µ ë‹¬ëŸ¬ íˆ¬ìê°€ ì €í¬ì—ê²ŒëŠ” 10ì–µ ë‹¬ëŸ¬ í”Œë«í¼ìœ¼ë¡œ ì „í™˜ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ì €í¬ì˜ ê²½ìŸ ìš°ìœ„ê°€ ìˆëŠ” ë¶€ë¶„ì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì¡°ê¸°ì— ì¸ì‹í•  ìˆ˜ ìˆëŠ” ê³¼í•™ì  ì „ë¬¸ì„±ì„ ë°”íƒ•ìœ¼ë¡œ ê°€ì¥ ê´‘ë²”ìœ„í•˜ê³  ì™„ì „í•˜ë©° ê¸°ë¡ì ì¸ ì‹œê°„ ë‚´ì— ë¼ë²¨ì„ ì¶œì‹œí•  ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ ë§ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Jennifer Taubert: Executive VP & Worldwide Chairman of Innovative Medicine Thanks, and good morning, everybody. So I'd love to double down on the fact that it really was a great quarter in 3Q and those numbers that for 90% of our business, we actually grew 16%. And that's really driven by 11 key brands that grew double digits, brands like DARZALEX, ERLEADA, SPRAVATO, CARVYKTI and so on as well as the strength that we're seeing in our new launches. And most notable there is TREMFYA in Crohn's disease and ulcerative colitis with 40% growth, that is 4-0. And so we've got a lot of strength in the business right now. Those growth drivers that are growing double digits are not only now and just this year, these really are our growth drivers throughout the rest of the decade as well as the pipeline assets that are coming in and the great growth that we're seeing and most notably TREMFYA. If we take a look versus your models in the areas where we have even -- where we're even more bullish, a few areas to note. So first is TREMFYA. And we think that there's a lot of strength with TREMFYA already. We're seeing in ulcerative colitis about 50% share of the IL-23s, and this was actually before we got the subcutaneous induction dose, which we just got approval for. We're seeing really, really strong uptake there. And I think things bode real well for TREMFYA. As a reminder, for STELARA, about 75% of STELARA sales were in Crohn's and ulcerative colitis, so in IBD. We think that, that's entirely likely or may even be stronger for TREMFYA. So we think that there's a lot of growth opportunity there. We believe SPRAVATO there is a bit of a disconnect. We are more bullish there as well as we continue to expand into new treatment centers as we continue to expand globally, that product is offering so much value for patients with treatment-resistant depression. I'll throw in RYBREVANT LAZCLUZE for non-small cell lung cancer. We're anxiously anticipating our launch of the subcutaneous dosage form. We think that there is a lot of runway there as a $5 billion-plus asset. We're also anticipating new data coming out in head and neck cancer and also colorectal cancer. So great growth. Joaquin and Joe mentioned INLEXZO, formerly known as TARIS. And we just got approval and are in the process of launching for bladder cancer. This is one of our next $5 billion-plus assets. And last but not least, icotrokinra, which we have filed and are also in the midst of showing new data, both in psoriasis as well as in ulcerative colitis. And so when we take a look at the business, both now as well as these future growth drivers, we've got a lot of bullishness there. And so those are really the major areas for disconnection.</td><td>**Jennifer Taubert:** ê°ì‚¬í•©ë‹ˆë‹¤. ëª¨ë“  ë¶„ë“¤ê»˜ ì¢‹ì€ ì•„ì¹¨ì…ë‹ˆë‹¤. 3ë¶„ê¸°ê°€ ì •ë§ í›Œë¥­í•œ ë¶„ê¸°ì˜€ë‹¤ëŠ” ì ì„ ë‹¤ì‹œ í•œë²ˆ ê°•ì¡°í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ì „ì²´ ì‚¬ì—…ì˜ 90%ê°€ ì‹¤ì œë¡œ 16% ì„±ì¥í–ˆë‹¤ëŠ” ìˆ˜ì¹˜ë¥¼ ë§ì”€ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ì´ëŠ” DARZALEX, ERLEADA, SPRAVATO, CARVYKTI ë“±ê³¼ ê°™ì´ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ê¸°ë¡í•œ 11ê°œ í•µì‹¬ ë¸Œëœë“œì™€ ì‹ ì œí’ˆ ì¶œì‹œì—ì„œ ë³´ì´ê³  ìˆëŠ” ê°•ì„¸ì— ì˜í•´ ì£¼ë„ë˜ì—ˆìŠµë‹ˆë‹¤. <br><br>ê·¸ ì¤‘ì—ì„œë„ ê°€ì¥ ì£¼ëª©í•  ë§Œí•œ ê²ƒì€ í¬ë¡ ë³‘ê³¼ ê¶¤ì–‘ì„± ëŒ€ì¥ì—¼ ì ì‘ì¦ì—ì„œ TREMFYAê°€ 40% ì„±ì¥ì„ ê¸°ë¡í•œ ê²ƒì…ë‹ˆë‹¤. 4ì™€ 0, ì¦‰ 40%ì…ë‹ˆë‹¤. í˜„ì¬ ìš°ë¦¬ ì‚¬ì—…ì—ëŠ” ë§ì€ ê°•ì ë“¤ì´ ìˆìŠµë‹ˆë‹¤. ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ë³´ì´ê³  ìˆëŠ” ì´ëŸ¬í•œ ì„±ì¥ ë™ë ¥ë“¤ì€ ì˜¬í•´ë§Œì´ ì•„ë‹ˆë¼ í–¥í›„ 10ë…„ê°„ ì§€ì†ë  ìš°ë¦¬ì˜ í•µì‹¬ ì„±ì¥ ë™ë ¥ì´ë©°, íŒŒì´í”„ë¼ì¸ ìì‚°ë“¤ê³¼ í•¨ê»˜ ìš°ë¦¬ê°€ ë³´ê³  ìˆëŠ” í›Œë¥­í•œ ì„±ì¥ì„¸, íŠ¹íˆ TREMFYAì˜ ì„±ì¥ì´ ê·¸ë ‡ìŠµë‹ˆë‹¤. <br><br>ì—¬ëŸ¬ë¶„ì˜ ëª¨ë¸ê³¼ ë¹„êµí•´ì„œ ìš°ë¦¬ê°€ ë”ìš± ë‚™ê´€ì ìœ¼ë¡œ ë³´ëŠ” ì˜ì—­ë“¤ì´ ëª‡ ê°€ì§€ ìˆìŠµë‹ˆë‹¤. ë¨¼ì € TREMFYAì…ë‹ˆë‹¤. TREMFYAëŠ” ì´ë¯¸ ìƒë‹¹í•œ ê°•ì„¸ë¥¼ ë³´ì´ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ê¶¤ì–‘ì„± ëŒ€ì¥ì—¼ì—ì„œ IL-23 ê³„ì—´ ì•½ë¬¼ ì¤‘ ì•½ 50%ì˜ ì ìœ ìœ¨ì„ ì°¨ì§€í•˜ê³  ìˆëŠ”ë°, ì´ëŠ” ìµœê·¼ ìŠ¹ì¸ë°›ì€ í”¼í•˜ ìœ ë„ ìš©ë²•(subcutaneous induction dose) ì´ì „ì˜ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ì´ ë¶€ë¶„ì—ì„œ ì •ë§ ê°•ë ¥í•œ ì±„íƒë¥ ì„ ë³´ê³  ìˆê³ , TREMFYAì˜ ì „ë§ì´ ë§¤ìš° ë°ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì°¸ê³ ë¡œ STELARAì˜ ê²½ìš°, ë§¤ì¶œì˜ ì•½ 75%ê°€ í¬ë¡ ë³‘ê³¼ ê¶¤ì–‘ì„± ëŒ€ì¥ì—¼, ì¦‰ IBDì—ì„œ ë‚˜ì™”ìŠµë‹ˆë‹¤. TREMFYAì˜ ê²½ìš° ì´ ë¹„ìœ¨ì´ ë™ì¼í•˜ê±°ë‚˜ ë” ë†’ì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ë”°ë¼ì„œ ê·¸ ë¶„ì•¼ì—ì„œ ìƒë‹¹í•œ ì„±ì¥ ê¸°íšŒê°€ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. <br><br>SPRAVATOì˜ ê²½ìš° ì‹œì¥ì—ì„œ ì•½ê°„ì˜ ê´´ë¦¬ê°€ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì €í¬ëŠ” ë” ë‚™ê´€ì ì…ë‹ˆë‹¤. ìƒˆë¡œìš´ ì¹˜ë£Œì„¼í„°ë¡œ ê³„ì† í™•ì¥í•˜ê³  ê¸€ë¡œë²Œ ì§„ì¶œì„ ì§€ì†í•˜ë©´ì„œ, ì´ ì œí’ˆì€ ì¹˜ë£Œì €í•­ì„± ìš°ìš¸ì¦ í™˜ìë“¤ì—ê²Œ ì—„ì²­ë‚œ ê°€ì¹˜ë¥¼ ì œê³µí•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ë¹„ì†Œì„¸í¬íì•” ì¹˜ë£Œì œì¸ RYBREVANT LAZCLUZEë„ ì–¸ê¸‰í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. í”¼í•˜ì£¼ì‚¬ ì œí˜•ì˜ ì¶œì‹œë¥¼ ê°„ì ˆíˆ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. 50ì–µ ë‹¬ëŸ¬ ì´ìƒì˜ ìì‚°ìœ¼ë¡œì„œ ìƒë‹¹í•œ ì„±ì¥ ì—¬ë ¥ì´ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. ë‘ê²½ë¶€ì•”ê³¼ ëŒ€ì¥ì•”ì—ì„œë„ ìƒˆë¡œìš´ ë°ì´í„°ê°€ ë‚˜ì˜¬ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì •ë§ í›Œë¥­í•œ ì„±ì¥ì„¸ì£ . í˜¸ì•„í‚¨ê³¼ ì¡°ê°€ ì–¸ê¸‰í•œ INLEXZOëŠ” ì´ì „ì— TARISë¡œ ì•Œë ¤ì¡Œë˜ ì œí’ˆì¸ë°, ë°©ê¸ˆ ìŠ¹ì¸ì„ ë°›ì•˜ê³  ë°©ê´‘ì•” ì¹˜ë£Œì œë¡œ ì¶œì‹œ ê³¼ì •ì— ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì€ ìš°ë¦¬ì˜ ì°¨ì„¸ëŒ€ 50ì–µ ë‹¬ëŸ¬ ì´ìƒ ê·œëª¨ ìì‚° ì¤‘ í•˜ë‚˜ì…ë‹ˆë‹¤. <br><br>ë§ˆì§€ë§‰ìœ¼ë¡œ icotrokinraê°€ ìˆëŠ”ë°, ì´ë¯¸ ì‹ ì²­ì„œë¥¼ ì œì¶œí–ˆê³  ê±´ì„ ê³¼ ê¶¤ì–‘ì„± ëŒ€ì¥ì—¼ ëª¨ë‘ì—ì„œ ìƒˆë¡œìš´ ë°ì´í„°ë¥¼ ë³´ì—¬ì£¼ëŠ” ê³¼ì •ì— ìˆìŠµë‹ˆë‹¤. <br><br>í˜„ì¬ ì‚¬ì—…ê³¼ ì´ëŸ¬í•œ ë¯¸ë˜ ì„±ì¥ ë™ë ¥ë“¤ì„ ì¢…í•©í•´ì„œ ë³´ë©´, ìš°ë¦¬ëŠ” ìƒë‹¹íˆ ë‚™ê´€ì ì…ë‹ˆë‹¤. ì´ê²ƒë“¤ì´ ë°”ë¡œ ê´´ë¦¬ê°ì„ í•´ì†Œí•  ìˆ˜ ìˆëŠ” ì£¼ìš” ì˜ì—­ë“¤ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Tim Schmid: Executive VP & Worldwide Chairman of MedTech Aside, maybe just building on Jennifer and Joaquin's comments for MedTech, a couple of things that I'd really highlight. Joaquin mentioned our continued confidence and commitment to winning over the long term in electrophysiology. We had a standout quarter and what really marked it was our continued improvement, especially here in the U.S., which will continue to be the largest and most attractive market. We saw a doubling of our growth rate in this quarter, and we continue to build momentum. Vision, which we haven't touched on also, which had a standout quarter, 6.1% growth, 14% growth in the IOL category with significant share gains against our major competitors there. And then surgery, our largest business, around 3.3% growth, but really bolstered by strong performance in wound closure at 7% and biosurgery. And once again, that launch of OTTAVA next year is going to really bolster our performance there. And then I think also what made us more proud and excited about this quarter versus last is that we had performance across the board. Ortho, back to growth with significant improvements in spine, knees, trauma and border.</td><td>**Tim Schmid:** MedTech ë¶€ë¬¸ì— ëŒ€í•œ Jenniferì™€ Joaquinì˜ ì˜ê²¬ì— ë§ë¶™ì—¬ì„œ, ëª‡ ê°€ì§€ ê°•ì¡°í•˜ê³  ì‹¶ì€ ì ë“¤ì´ ìˆìŠµë‹ˆë‹¤. Joaquinì´ ì–¸ê¸‰í–ˆë“¯ì´ ì „ê¸°ìƒë¦¬í•™(electrophysiology) ë¶„ì•¼ì—ì„œ ì¥ê¸°ì ìœ¼ë¡œ ìŠ¹ë¦¬í•  ê²ƒì´ë¼ëŠ” ì§€ì†ì ì¸ í™•ì‹ ê³¼ ì˜ì§€ë¥¼ ê°–ê³  ìˆìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸°ëŠ” ì •ë§ ë›°ì–´ë‚œ ì„±ê³¼ë¥¼ ê±°ë’€ëŠ”ë°, íŠ¹íˆ ê°€ì¥ í¬ê³  ë§¤ë ¥ì ì¸ ì‹œì¥ì´ ë  ë¯¸êµ­ì—ì„œì˜ ì§€ì†ì ì¸ ê°œì„ ì´ ë‘ë“œëŸ¬ì¡ŒìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸°ì— ì„±ì¥ë¥ ì´ ë‘ ë°°ë¡œ ì¦ê°€í–ˆê³ , ê³„ì†í•´ì„œ ëª¨ë©˜í…€ì„ êµ¬ì¶•í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì•„ì§ ì–¸ê¸‰í•˜ì§€ ì•Šì•˜ë˜ Vision ë¶€ë¬¸ë„ ë›°ì–´ë‚œ ë¶„ê¸°ë¥¼ ë³´ëƒˆëŠ”ë°, 6.1% ì„±ì¥ì„ ê¸°ë¡í–ˆê³ , IOL ì¹´í…Œê³ ë¦¬ì—ì„œëŠ” 14% ì„±ì¥í•˜ë©° ì£¼ìš” ê²½ìŸì‚¬ë“¤ ëŒ€ë¹„ ìƒë‹¹í•œ ì‹œì¥ ì ìœ ìœ¨ ì¦ê°€ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ì˜ ìµœëŒ€ ì‚¬ì—…ì¸ ìˆ˜ìˆ  ë¶€ë¬¸ì€ ì•½ 3.3% ì„±ì¥ì„ ê¸°ë¡í–ˆëŠ”ë°, ì´ëŠ” ìƒì²˜ ë´‰í•© ë¶€ë¬¸ì˜ 7% ì„±ì¥ê³¼ ë°”ì´ì˜¤ìˆ˜ìˆ  ë¶€ë¬¸ì˜ ê°•ë ¥í•œ ì‹¤ì ì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‹¤ì‹œ í•œ ë²ˆ ë§ì”€ë“œë¦¬ì§€ë§Œ, ë‚´ë…„ OTTAVA ì¶œì‹œê°€ ì´ ë¶€ë¬¸ì˜ ì‹¤ì ì„ í¬ê²Œ ë’·ë°›ì¹¨í•  ê²ƒì…ë‹ˆë‹¤. <br><br>ë˜í•œ ì´ë²ˆ ë¶„ê¸°ì—ì„œ ì§€ë‚œ ë¶„ê¸°ë³´ë‹¤ ë”ìš± ìë‘ìŠ¤ëŸ½ê³  ê¸°ëŒ€ë˜ëŠ” ì ì€ ì „ ë¶€ë¬¸ì— ê±¸ì³ ì¢‹ì€ ì„±ê³¼ë¥¼ ê±°ë‘ì—ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì •í˜•ì™¸ê³¼ ë¶€ë¬¸ì´ ë‹¤ì‹œ ì„±ì¥ì„¸ë¡œ ëŒì•„ì„°ê³ , ì²™ì¶”, ë¬´ë¦, ì™¸ìƒ ë° ê²½ê³„ ì˜ì—­ì—ì„œ ìƒë‹¹í•œ ê°œì„ ì„ ë³´ì˜€ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Darren Snellgrove: Vice President of Investor Relations Thanks, Tim. And just before we take the next question, we will actually run a little bit longer than the 60 minutes we planned, just given the announcement that we had leading to longer script remarks.</td><td>**Darren Snellgrove:** ê°ì‚¬í•©ë‹ˆë‹¤, íŒ€. ë‹¤ìŒ ì§ˆë¬¸ì„ ë°›ê¸° ì „ì— ë§ì”€ë“œë¦¬ë©´, ì˜¤ëŠ˜ ë°œí‘œ ë‚´ìš©ìœ¼ë¡œ ì¸í•´ ìŠ¤í¬ë¦½íŠ¸ ë°œì–¸ì´ ê¸¸ì–´ì§„ ê´€ê³„ë¡œ ì˜ˆì •ëœ 60ë¶„ë³´ë‹¤ ì¡°ê¸ˆ ë” ê¸¸ê²Œ ì§„í–‰ë  ì˜ˆì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question is coming from Shagun Singh from RBC.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ RBCì˜ Shagun Singhë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Shagun Singh Chadha: RBC Capital Markets, Research Division Joaquin and Joe, congratulations on all the operational progress at J&J. I think a key message that I'm hearing is the acceleration in sales growth. And in your prepared comments, you did indicate the higher end of the 5% to 7%. I guess my question is -- and a lot of your businesses are growing very impressively in the double digits. So what gets you to exceed those levels? And as we think about 2026, why is 5% a good number given that you have easy comps? Could you do better? And what would drive that?</td><td>**Shagun Singh Chadha:** RBC ìºí”¼í„¸ ë§ˆì¼“ ë¦¬ì„œì¹˜ ë¶€ë¬¸ì—ì„œ ì§ˆë¬¸ë“œë¦½ë‹ˆë‹¤. í˜¸ì•„í‚¨ê³¼ ì¡°, J&Jì˜ ëª¨ë“  ìš´ì˜ ì§„ì „ì— ëŒ€í•´ ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. ì œê°€ ë“£ê³  ìˆëŠ” í•µì‹¬ ë©”ì‹œì§€ëŠ” ë§¤ì¶œ ì„±ì¥ì˜ ê°€ì†í™”ì¸ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì¤€ë¹„ëœ ë°œì–¸ì—ì„œ 5%ì—ì„œ 7% ë²”ìœ„ì˜ ìƒë‹¨ì„ ì–¸ê¸‰í•˜ì…¨ëŠ”ë°ìš”. ì œ ì§ˆë¬¸ì€ - ë§ì€ ì‚¬ì—… ë¶€ë¬¸ë“¤ì´ ë‘ ìë¦¿ìˆ˜ë¡œ ë§¤ìš° ì¸ìƒì ì¸ ì„±ì¥ì„ ë³´ì´ê³  ìˆëŠ”ë° - ë¬´ì—‡ì´ ì´ëŸ¬í•œ ìˆ˜ì¤€ì„ ë„˜ì–´ì„œê²Œ í•  ìˆ˜ ìˆì„ê¹Œìš”? ê·¸ë¦¬ê³  2026ë…„ì„ ìƒê°í•´ë³´ë©´, ë¹„êµ ê¸°ì¤€ì´ ë‚®ì€ ìƒí™©ì—ì„œ ì™œ 5%ê°€ ì ì ˆí•œ ìˆ˜ì¹˜ì¼ê¹Œìš”? ë” ì¢‹ì€ ì„±ê³¼ë¥¼ ë‚¼ ìˆ˜ ìˆì§€ ì•Šì„ê¹Œìš”? ê·¸ë¦¬ê³  ê·¸ê²ƒì„ ì´ë„ëŠ” ë™ë ¥ì€ ë¬´ì—‡ì´ ë ê¹Œìš”?</td></tr>
<tr><td>Joseph Wolk: Executive VP & CFO Yes, Shagun, thanks for the recognition. It's a great job by the entire Johnson & Johnson team across the globe. I think towards the 5% to 7%, obviously, we made that commitment back in 2023. We've seen significant progress with our portfolio. We've added some acquisitions that fortify that number. We are striving for something better than that. Don't misconstrue our ambitions here. What I would say for next year, specifically, we are still going to face significant erosion with respect to STELARA. There will be additional discounting in the Innovative Medicine portfolio. And we will still have the Orthopaedics business, and we will continue to make progress with electrophysiology going back to market leadership with the PFA platform. So there's things that we will obviously look to improve upon those numbers. But when I glimpsed at your models for '26, I did see a clear disconnect, and I'll provide more details when it comes to January. But we feel very confident in not just how we're going to conclude 2025, not just the backdrop for 2026, but really the balance of the decade, as Joaquin has said, both on media interviews as well on today's call, this is a new era of growth, accelerated growth for Johnson & Johnson. And we feel very good about not just our in-market portfolio, but all the new products within our pipeline that will come to launch over the next 1 to 2 years.</td><td>**Joseph Wolk:** ë„¤, Shagun, ì¸ì •í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì „ ì„¸ê³„ Johnson & Johnson íŒ€ ì „ì²´ê°€ ì •ë§ í›Œë¥­í•œ ì„±ê³¼ë¥¼ ê±°ë‘ì—ˆìŠµë‹ˆë‹¤. 5%ì—ì„œ 7% ëª©í‘œì™€ ê´€ë ¨í•´ì„œëŠ”, ì €í¬ê°€ 2023ë…„ì— ê·¸ ì•½ì†ì„ í–ˆê³ , í¬íŠ¸í´ë¦¬ì˜¤ì—ì„œ ìƒë‹¹í•œ ì§„ì „ì„ ë³´ì˜€ìŠµë‹ˆë‹¤. ê·¸ ìˆ˜ì¹˜ë¥¼ ê°•í™”í•˜ëŠ” ëª‡ ê°€ì§€ ì¸ìˆ˜ë„ ì¶”ê°€í–ˆê³ ìš”. ì €í¬ëŠ” ê·¸ë³´ë‹¤ ë” ë‚˜ì€ ì„±ê³¼ë¥¼ ìœ„í•´ ë…¸ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ì˜ ì•¼ì‹¬ì„ ì˜ëª» í•´ì„í•˜ì§€ ë§ˆì‹œê¸° ë°”ëë‹ˆë‹¤.<br><br>ë‚´ë…„ì— ëŒ€í•´ êµ¬ì²´ì ìœ¼ë¡œ ë§ì”€ë“œë¦¬ë©´, ì €í¬ëŠ” ì—¬ì „íˆ STELARAì™€ ê´€ë ¨í•´ì„œ ìƒë‹¹í•œ ì¹¨ì‹ì— ì§ë©´í•  ê²ƒì…ë‹ˆë‹¤. í˜ì‹ ì˜ì•½í’ˆ í¬íŠ¸í´ë¦¬ì˜¤ì—ì„œ ì¶”ê°€ì ì¸ í• ì¸ë„ ìˆì„ ê²ƒì´ê³ ìš”. ê·¸ë¦¬ê³  ì—¬ì „íˆ ì •í˜•ì™¸ê³¼ ì‚¬ì—…ì´ ìˆì„ ê²ƒì´ë©°, PFA í”Œë«í¼ì„ í†µí•´ ì „ê¸°ìƒë¦¬í•™ ë¶„ì•¼ì—ì„œ ì‹œì¥ ë¦¬ë”ì‹­ìœ¼ë¡œ ë³µê·€í•˜ë©´ì„œ ê³„ì† ì§„ì „ì„ ì´ë£° ê²ƒì…ë‹ˆë‹¤. ë¬¼ë¡  ì´ëŸ¬í•œ ìˆ˜ì¹˜ë“¤ì„ ê°œì„ í•  ìˆ˜ ìˆëŠ” ë¶€ë¶„ë“¤ì´ ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ 26ë…„ì— ëŒ€í•œ ì—¬ëŸ¬ë¶„ì˜ ëª¨ë¸ë“¤ì„ ì‚´í´ë³´ë‹ˆ ëª…í™•í•œ ê´´ë¦¬ê°€ ìˆë‹¤ëŠ” ê²ƒì„ í™•ì¸í–ˆê³ , 1ì›”ì— ë” ìì„¸í•œ ë‚´ìš©ì„ ì œê³µí•˜ê² ìŠµë‹ˆë‹¤. <br><br>ì €í¬ëŠ” 2025ë…„ì„ ì–´ë–»ê²Œ ë§ˆë¬´ë¦¬í• ì§€ë¿ë§Œ ì•„ë‹ˆë¼ 2026ë…„ì˜ ë°°ê²½, ê·¸ë¦¬ê³  ì‹¤ì œë¡œëŠ” í–¥í›„ 10ë…„ ì „ì²´ì— ëŒ€í•´ ë§¤ìš° í™•ì‹ í•˜ê³  ìˆìŠµë‹ˆë‹¤. í˜¸ì•„í‚¨ì´ ë¯¸ë””ì–´ ì¸í„°ë·°ì™€ ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ì„œ ë§í–ˆë“¯ì´, ì´ê²ƒì€ Johnson & Johnsonì˜ ìƒˆë¡œìš´ ì„±ì¥ ì‹œëŒ€, ê°€ì†í™”ëœ ì„±ì¥ì˜ ì‹œëŒ€ì…ë‹ˆë‹¤. <br><br>ì €í¬ëŠ” í˜„ì¬ ì‹œì¥ì— ì¶œì‹œëœ í¬íŠ¸í´ë¦¬ì˜¤ë¿ë§Œ ì•„ë‹ˆë¼ í–¥í›„ 1-2ë…„ ë‚´ì— ì¶œì‹œë  íŒŒì´í”„ë¼ì¸ ë‚´ì˜ ëª¨ë“  ì‹ ì œí’ˆë“¤ì— ëŒ€í•´ì„œë„ ë§¤ìš° ê¸ì •ì ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question is coming from Terence Flynn from Morgan Stanley.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ëª¨ê±´ìŠ¤íƒ ë¦¬ì˜ í…Œë ŒìŠ¤ í”Œë¦°ìœ¼ë¡œë¶€í„° ë‚˜ì™”ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Terence Flynn: Morgan Stanley, Research Division Great. Congrats on all the progress. This one is for John. I know at our health care conference, you talked about some upcoming data you're going to have for your anti-tau antibody, which is in Phase II. Just I was wondering if you could help frame that data for us, what you're hoping to see there? And could that trial actually be used to support an accelerated approval? Or will you need a Phase III?</td><td>**Terence Flynn:** ëª¨ë“  ì§„ì „ì— ëŒ€í•´ ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. ì¡´ì—ê²Œ ë“œë¦¬ëŠ” ì§ˆë¬¸ì…ë‹ˆë‹¤. ì €í¬ í—¬ìŠ¤ì¼€ì–´ ì»¨í¼ëŸ°ìŠ¤ì—ì„œ 2ìƒ ì§„í–‰ ì¤‘ì¸ í•­íƒ€ìš° í•­ì²´(anti-tau antibody)ì— ëŒ€í•œ í–¥í›„ ë°ì´í„°ì— ëŒ€í•´ ë§ì”€í•´ ì£¼ì…¨ëŠ”ë°ìš”. ê·¸ ë°ì´í„°ë¥¼ ì–´ë–»ê²Œ í•´ì„í•´ì•¼ í• ì§€, ê·¸ë¦¬ê³  ê·¸ê³³ì—ì„œ ë¬´ì—‡ì„ ê¸°ëŒ€í•˜ê³  ê³„ì‹ ì§€ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ê·¸ë¦¬ê³  í•´ë‹¹ ì„ìƒì‹œí—˜ì´ ì‹¤ì œë¡œ ì‹ ì†ìŠ¹ì¸(accelerated approval)ì„ ë’·ë°›ì¹¨í•˜ëŠ” ë° ì‚¬ìš©ë  ìˆ˜ ìˆì„ê¹Œìš”? ì•„ë‹ˆë©´ 3ìƒì´ í•„ìš”í• ê¹Œìš”?</td></tr>
<tr><td>John Reed: Executive Vice President of Innovative Medicine, R&D Thanks, Terence. We expect to have the data on the Phase II study in-house within this year and would then be in a position to share those at a medical congress sometime first half of next year. The endpoints in that study include, first and foremost, cognitive endpoints that are traditionally used for regulatory approvals for medicines in terms of looking for effects and efficacy in Alzheimer's. But in addition, we'll also have important neuroimaging data looking at tau spread using PET imaging. So that will be an important piece of the data as well. And based on the quality of those data, that will be a decision-making point for us in terms of go/no-go. We have designed our antibody to attack a specific epitope in tau that's differentiated from what some others have exploited and feel confident in the ability to prevent the spread of tau based on the preclinical data. But of course, the data will be the data as we say, when we get the clinical results. So we'll be eagerly awaiting those results and look forward to communicating in the fullness of time.</td><td>**John Reed:** ì˜¬í•´ ì•ˆì— 2ìƒ ì—°êµ¬ ë°ì´í„°ë¥¼ í™•ë³´í•  ì˜ˆì •ì´ë©°, ë‚´ë…„ ìƒë°˜ê¸° ì¤‘ ì˜í•™ í•™íšŒì—ì„œ í•´ë‹¹ ê²°ê³¼ë¥¼ ê³µìœ í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì´ë²ˆ ì—°êµ¬ì˜ ì£¼ìš” í‰ê°€ì§€í‘œëŠ” ë¬´ì—‡ë³´ë‹¤ë„ ì•Œì¸ í•˜ì´ë¨¸ ì¹˜ë£Œì œì˜ íš¨ê³¼ì™€ ìœ íš¨ì„±ì„ í‰ê°€í•˜ëŠ” ë° ìˆì–´ ê·œì œ ìŠ¹ì¸ì—ì„œ ì „í†µì ìœ¼ë¡œ ì‚¬ìš©ë˜ëŠ” ì¸ì§€ ê¸°ëŠ¥ í‰ê°€ì§€í‘œë“¤ì…ë‹ˆë‹¤. ë˜í•œ PET ì˜ìƒì„ í™œìš©í•œ íƒ€ìš° ë‹¨ë°±ì§ˆ í™•ì‚°ì„ ê´€ì°°í•˜ëŠ” ì¤‘ìš”í•œ ì‹ ê²½ì˜ìƒ ë°ì´í„°ë„ í™•ë³´í•˜ê²Œ ë©ë‹ˆë‹¤. ì´ëŠ” ë§¤ìš° ì¤‘ìš”í•œ ë°ì´í„°ê°€ ë  ê²ƒì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ë°ì´í„°ì˜ í’ˆì§ˆì„ ë°”íƒ•ìœ¼ë¡œ í–¥í›„ ì§„í–‰ ì—¬ë¶€ì— ëŒ€í•œ ì˜ì‚¬ê²°ì •ì„ ë‚´ë¦¬ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ì €í¬ëŠ” ë‹¤ë¥¸ íšŒì‚¬ë“¤ì´ í™œìš©í•œ ê²ƒê³¼ëŠ” ì°¨ë³„í™”ëœ íƒ€ìš°ì˜ íŠ¹ì • ì—í”¼í† í”„(epitope)ë¥¼ ê³µê²©í•˜ë„ë¡ í•­ì²´ë¥¼ ì„¤ê³„í–ˆìœ¼ë©°, ì „ì„ìƒ ë°ì´í„°ë¥¼ ë°”íƒ•ìœ¼ë¡œ íƒ€ìš°ì˜ í™•ì‚°ì„ ë°©ì§€í•  ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ì— ëŒ€í•´ í™•ì‹ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ì €í¬ê°€ í•­ìƒ ë§í•˜ë“¯ì´ ë°ì´í„°ëŠ” ë°ì´í„°ì´ê¸° ë•Œë¬¸ì—, ì„ìƒ ê²°ê³¼ê°€ ë‚˜ì™€ì•¼ ì•Œ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ë„ ê·¸ ê²°ê³¼ë¥¼ ê°„ì ˆíˆ ê¸°ë‹¤ë¦¬ê³  ìˆìœ¼ë©°, ì ì ˆí•œ ì‹œì ì— ì†Œí†µí•  ìˆ˜ ìˆê¸°ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question today is coming from Jayson Bedford from Raymond James.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Raymond Jamesì˜ Jayson Bedfordë¡œë¶€í„° ë‚˜ì™”ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Jayson Bedford: Raymond James & Associates, Inc., Research Division Congrats on the progress. Maybe just a quick one for Joe or Tim. Just trying to gauge the underlying growth in MedTech. It looks like there was a reserve adjustment that helped MedTech growth, perhaps offset by this go-to-market change in energy. Is there a way to quantify the net impact of these adjustments as it relates to the, what, 5.7% adjusted operational growth in MedTech?</td><td>**Jayson Bedford:** ì¶•í•˜ë“œë¦½ë‹ˆë‹¤, ì§„ì „ì´ ìˆìœ¼ì…¨ë„¤ìš”. Joeë‚˜ Timì—ê²Œ ê°„ë‹¨í•œ ì§ˆë¬¸ í•˜ë‚˜ë§Œ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. MedTechì˜ ê¸°ì € ì„±ì¥ë¥ ì„ íŒŒì•…í•´ë³´ë ¤ê³  í•˜ëŠ”ë°ìš”. MedTech ì„±ì¥ì— ë„ì›€ì´ ëœ ì¶©ë‹¹ê¸ˆ ì¡°ì •ì´ ìˆì—ˆë˜ ê²ƒ ê°™ê³ , ì•„ë§ˆë„ ì—ë„ˆì§€ ë¶€ë¬¸ì˜ ì‹œì¥ì§„ì¶œ ë°©ì‹ ë³€í™”ë¡œ ìƒì‡„ëœ ë¶€ë¶„ì´ ìˆì„ ê²ƒ ê°™ìŠµë‹ˆë‹¤. MedTechì˜ 5.7% ì¡°ì • ìš´ì˜ ì„±ì¥ë¥ ê³¼ ê´€ë ¨í•´ì„œ ì´ëŸ¬í•œ ì¡°ì •ë“¤ì˜ ìˆœ ì˜í–¥ì„ ì •ëŸ‰í™”í•  ìˆ˜ ìˆëŠ” ë°©ë²•ì´ ìˆì„ê¹Œìš”?</td></tr>
<tr><td>Tim Schmid: Executive VP & Worldwide Chairman of MedTech Yes, I'm happy to take one. We do not believe that the one you're referring to has any significant materiality and shouldn't impact, we would say, moderate, certainly not material from an overall performance perspective.</td><td>**Tim Schmid:** ë„¤, ê¸°êº¼ì´ ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë§ì”€í•˜ì‹  ê±´ì— ëŒ€í•´ì„œëŠ” ì¤‘ìš”í•œ ì‹¤ì§ˆì  ì˜í–¥ì€ ì—†ë‹¤ê³  ë³´ê³  ìˆìœ¼ë©°, ì „ì²´ì ì¸ ì„±ê³¼ ê´€ì ì—ì„œ ë³¼ ë•Œ ì˜í–¥ì„ ì£¼ì§€ ì•Šì„ ê²ƒìœ¼ë¡œ íŒë‹¨í•©ë‹ˆë‹¤. ë³´í†µ ìˆ˜ì¤€ì´ë¼ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆê³ , í™•ì‹¤íˆ ì¤‘ëŒ€í•œ ì˜í–¥ì€ ì•„ë‹™ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question is coming from Vamil Divan from Guggenheim Securities.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ êµ¬ê²í•˜ì„ ì‹œíë¦¬í‹°ì¦ˆì˜ ë°”ë°€ ë””ë°˜ë‹˜ê»˜ì„œ ì£¼ì‹  ì§ˆë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Vamil Divan: Guggenheim Securities, LLC, Research Division If I could on INLEXZO, really a 2-part question. So one is sort of the near-term uptake. Just curious if you can comment on sort of what initial feedback is from doctors and it is this buy-and-bill model. Just curious if you're seeing doctors already sort of step in and purchase the product or are they waiting for the permanent J-code? And then second is more of a longer-term question on this is just what should we expect in terms of updates, both clinical data-wise or regulatory-wise in the next, say, 12 to 18 months to just expand the addressable population here to other patients with bladder cancer and also outside the U.S. I think we were getting excited about the outlook for this product. But just I know before you mentioned that there's a big disconnect between your internal expectations and where consensus is. And I think that suggests you guys think this will be a sort of $2 billion-plus product by 2028. So just trying to get a sense of how you expect to build from the initial launch to that level.</td><td>**Vamil Divan:** INLEXZOì— ëŒ€í•´ ë‘ ë¶€ë¶„ìœ¼ë¡œ ë‚˜ëˆ„ì–´ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì²« ë²ˆì§¸ëŠ” ë‹¨ê¸°ì ì¸ ë„ì… í˜„í™©ì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. ì˜ì‚¬ë“¤ì˜ ì´ˆê¸° ë°˜ì‘ê³¼ buy-and-bill ëª¨ë¸ì— ëŒ€í•´ ì–´ë–»ê²Œ ë³´ê³  ê³„ì‹ ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ì˜ì‚¬ë“¤ì´ ì´ë¯¸ ì œí’ˆì„ êµ¬ë§¤í•˜ê³  ìˆëŠ”ì§€, ì•„ë‹ˆë©´ ì˜êµ¬ J-codeë¥¼ ê¸°ë‹¤ë¦¬ê³  ìˆëŠ”ì§€ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”?<br><br>ë‘ ë²ˆì§¸ëŠ” ë³´ë‹¤ ì¥ê¸°ì ì¸ ì§ˆë¬¸ì¸ë°, í–¥í›„ 12~18ê°œì›” ë‚´ì— ì„ìƒ ë°ì´í„°ë‚˜ ê·œì œ ì¸¡ë©´ì—ì„œ ì–´ë–¤ ì—…ë°ì´íŠ¸ë¥¼ ê¸°ëŒ€í•  ìˆ˜ ìˆì„ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ë‹¤ë¥¸ ë°©ê´‘ì•” í™˜ìë“¤ê³¼ ë¯¸êµ­ ì™¸ ì§€ì—­ìœ¼ë¡œ ëŒ€ìƒ í™˜ìêµ°ì„ í™•ëŒ€í•˜ëŠ” ë¶€ë¶„ì—ì„œ ë§ì…ë‹ˆë‹¤. ì´ ì œí’ˆì˜ ì „ë§ì— ëŒ€í•´ ê¸°ëŒ€ê°€ í¬ê±°ë“ ìš”. í•˜ì§€ë§Œ ì´ì „ì— ë§ì”€í•˜ì‹  ëŒ€ë¡œ ë‚´ë¶€ ê¸°ëŒ€ì¹˜ì™€ ì»¨ì„¼ì„œìŠ¤ ê°„ì— í° ì°¨ì´ê°€ ìˆë‹¤ê³  í•˜ì…¨ëŠ”ë°ìš”. ì´ëŠ” 2028ë…„ê¹Œì§€ 20ì–µ ë‹¬ëŸ¬ ì´ìƒì˜ ì œí’ˆì´ ë  ê²ƒìœ¼ë¡œ ë³´ê³  ê³„ì‹ ë‹¤ëŠ” ì˜ë¯¸ë¡œ í•´ì„ë©ë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ˆê¸° ì¶œì‹œë¶€í„° ê·¸ ìˆ˜ì¤€ê¹Œì§€ ì–´ë–»ê²Œ ì„±ì¥ì‹œì¼œ ë‚˜ê°ˆ ê³„íšì¸ì§€ ì•Œê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Jennifer Taubert: Executive VP & Worldwide Chairman of Innovative Medicine Sure. Thanks so much for the question. So yes, we did just get approval for INLEXZO, and the teams are out in full launch mode. And we have a lot of confidence that this is one of our $5 billion-plus assets for Johnson & Johnson. The receptivity has been very strong. We like to say that this product was really designed by urologists for urologists and really is addressing a high unmet need. There hasn't been much advances in the way of bladder cancer for a very, very long time. And so in the initial launch, it's in BCG unresponsive, high-risk non-muscle invasive bladder cancer, and we've been able to demonstrate the highest complete response rates without a need for reinduction. And over half of responders are still cancer-free at 1 year. And so really, really transformational results. The product was designed to seamlessly fit into urology practice and be relatively speaking, easy on the patient compared to other therapies and like I said, seamlessly work into practice. And so, so far, the response from clinicians has been very positive for our executive committee. We actually had one of our top investigators come and spend time with us last week and show us on models, their demonstration and talk about why he's so excited about it, both as a clinician as well as for his patients. So we've already had a number of insertions based on the high level of unmet need. But as you note, we're also anticipating the J-code for reimbursement come April of next year. So we think that, that will be an important catalyst for uptake as is normal and common in routine buy-and-bill type products. So we're excited about that. John, maybe you want to talk a little bit particularly about SunRISe-3 and what's coming as well as TAR-210.</td><td>**Jennifer Taubert:** ë„¤, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ë§ì”€í•˜ì‹  ëŒ€ë¡œ INLEXZO ìŠ¹ì¸ì„ ë°©ê¸ˆ ë°›ì•˜ê³ , íŒ€ë“¤ì´ ë³¸ê²©ì ì¸ ì¶œì‹œ ëª¨ë“œë¡œ í™œë™í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ì œí’ˆì´ ì¡´ìŠ¨ì•¤ì¡´ìŠ¨ì˜ 50ì–µ ë‹¬ëŸ¬ ì´ìƒ ìì‚° ì¤‘ í•˜ë‚˜ê°€ ë  ê²ƒì´ë¼ê³  í™•ì‹ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì‹œì¥ ë°˜ì‘ì´ ë§¤ìš° ê¸ì •ì ì…ë‹ˆë‹¤. ì €í¬ëŠ” ì´ ì œí’ˆì´ ë¹„ë‡¨ê¸°ê³¼ ì˜ì‚¬ë“¤ì— ì˜í•´, ë¹„ë‡¨ê¸°ê³¼ ì˜ì‚¬ë“¤ì„ ìœ„í•´ ì„¤ê³„ë˜ì—ˆë‹¤ê³  ë§í•˜ê³¤ í•˜ëŠ”ë°, ì‹¤ì œë¡œ ë†’ì€ ë¯¸ì¶©ì¡± ì˜ë£Œ ìˆ˜ìš”ë¥¼ í•´ê²°í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë°©ê´‘ì•” ë¶„ì•¼ì—ì„œëŠ” ì •ë§ ì˜¤ë«ë™ì•ˆ í° ì§„ì „ì´ ì—†ì—ˆê±°ë“ ìš”.<br><br>ì´ˆê¸° ì¶œì‹œëŠ” BCG ë¬´ë°˜ì‘ì„± ê³ ìœ„í—˜ ë¹„ê·¼ì¹¨ìŠµì„± ë°©ê´‘ì•”ì„ ëŒ€ìƒìœ¼ë¡œ í•˜ê³  ìˆìœ¼ë©°, ì¬ìœ ë„ ìš”ë²• ì—†ì´ë„ ê°€ì¥ ë†’ì€ ì™„ì „ ë°˜ì‘ë¥ ì„ ì…ì¦í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ì‘ë‹µìì˜ ì ˆë°˜ ì´ìƒì´ 1ë…„ í›„ì—ë„ ì—¬ì „íˆ ì•”ì´ ì—†ëŠ” ìƒíƒœë¥¼ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì •ë§ë¡œ í˜ì‹ ì ì¸ ê²°ê³¼ë¼ê³  í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ ì œí’ˆì€ ë¹„ë‡¨ê¸°ê³¼ ì§„ë£Œì— ì›í™œí•˜ê²Œ í†µí•©ë˜ë„ë¡ ì„¤ê³„ë˜ì—ˆìœ¼ë©°, ë‹¤ë¥¸ ì¹˜ë£Œë²•ë“¤ê³¼ ë¹„êµí–ˆì„ ë•Œ í™˜ìì—ê²Œ ìƒëŒ€ì ìœ¼ë¡œ ë¶€ë‹´ì´ ì ê³ , ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´ ì§„ë£Œ ê³¼ì •ì— ë§¤ë„ëŸ½ê²Œ ì ìš©ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì§€ê¸ˆê¹Œì§€ ì„ìƒì˜ë“¤ë¡œë¶€í„° ì €í¬ ê²½ì˜ì§„ì— ëŒ€í•œ ë°˜ì‘ì´ ë§¤ìš° ê¸ì •ì ì…ë‹ˆë‹¤. <br><br>ì‹¤ì œë¡œ ì§€ë‚œì£¼ì—ëŠ” ì €í¬ì˜ ì£¼ìš” ì—°êµ¬ì ì¤‘ í•œ ë¶„ì´ ì§ì ‘ ë°©ë¬¸í•˜ì…”ì„œ ëª¨ë¸ì„ í†µí•´ ì‹œì—°ì„ ë³´ì—¬ì£¼ì‹œê³ , ì„ìƒì˜ë¡œì„œ ê·¸ë¦¬ê³  í™˜ìë“¤ì„ ìœ„í•´ì„œ ì™œ ì´ë ‡ê²Œ ê¸°ëŒ€í•˜ê³  ê³„ì‹œëŠ”ì§€ì— ëŒ€í•´ ì„¤ëª…í•´ ì£¼ì…¨ìŠµë‹ˆë‹¤. ì¶©ì¡±ë˜ì§€ ì•Šì€ ë†’ì€ ì˜ë£Œ ìˆ˜ìš”ë¡œ ì¸í•´ ì´ë¯¸ ì—¬ëŸ¬ ê±´ì˜ ì‹œìˆ ì´ ì´ë£¨ì–´ì¡ŒìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ë§ì”€í•˜ì‹  ë°”ì™€ ê°™ì´, ë‚´ë…„ 4ì›” ê¸‰ì—¬ ì ìš©ì„ ìœ„í•œ J-codeë„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì´ê²ƒì´ ì¼ë°˜ì ì¸ êµ¬ë§¤-ì²­êµ¬(buy-and-bill) ë°©ì‹ ì œí’ˆì—ì„œ í”íˆ ë³¼ ìˆ˜ ìˆëŠ” ì¤‘ìš”í•œ ë„ì… ì´‰ì§„ ìš”ì¸ì´ ë  ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì´ ë¶€ë¶„ì— ëŒ€í•´ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. John, SunRISe-3ì™€ í–¥í›„ ê³„íš, ê·¸ë¦¬ê³  TAR-210ì— ëŒ€í•´ì„œë„ ì¢€ ë” ìì„¸íˆ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>John Reed: Executive Vice President of Innovative Medicine, R&D Yes. Thank you so much for the question. We have a broad development program underway with several Phase III studies to address the non-muscle invasive bladder cancer population, high risk. That's about half of all the non-muscle invasive bladder cancer patients. And our studies include both the patients who are BCG experienced in the first approval that was for BCG nonresponsive. We also have studies in BCG relapsed. And then we also have head-to-head frontline studies against BCG. So really covering a broad landscape there. And just to remember that there are about 600,000 patients every year who are newly diagnosed with bladder cancer. 75% of those have the non-muscle invasive localized and then another 20% have localized, but it is muscle invasive. There, too, we're also doing studies. And in fact, at the ESMO conference in a couple of days, we'll present data where in the neoadjuvant context, we've used INLEXZO in combination with our PD-1 antibody, cetrelimab, and we'll report the data there showing that we're able to render a much higher percentage of patients completely free of any evidence of disease that you can find histologically or by other methods, what's called pathological complete response and therefore, boding for better outcomes for these patients who already have muscle-invasive disease and are having surgery to remove their bladder as a result of that risk. So really see a broad opportunity for INLEXZO, particularly in the non-muscle invasive across all lines of therapy. In that high-risk non-muscle invasive, which is about half of all of those patients as well as in some populations of patients with the muscle invasive as well. And then I would just give a shout out that, that's not going to be a one-trick pony for us. We have TAR-210 coming rapidly on the heels. This is a next-generation device that releases instead of a chemotherapy, a targeted therapy or erdafitinib drug that inhibits a receptor tyrosine kinase that is commonly mutated in bladder cancers. It's actually the most common genetic mutation that occurs in bladder cancers. And there, we've seen response rates, complete response rates north of 90%. And our next-generation device for that releases the medicine at a steady rate, not just for 3 weeks like INLEXZO, but for 3 months. So more to come. Really excited about this platform for addressing the great unmet need of bladder cancer.</td><td>**John Reed:** ë„¤, ì§ˆë¬¸í•´ ì£¼ì…”ì„œ ì •ë§ ê°ì‚¬í•©ë‹ˆë‹¤. ì €í¬ëŠ” ê³ ìœ„í—˜ ë¹„ê·¼ì¹¨ìŠµì„± ë°©ê´‘ì•” í™˜ìêµ°ì„ ëŒ€ìƒìœ¼ë¡œ ì—¬ëŸ¬ 3ìƒ ì—°êµ¬ë¥¼ í¬í•¨í•œ ê´‘ë²”ìœ„í•œ ê°œë°œ í”„ë¡œê·¸ë¨ì„ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì „ì²´ ë¹„ê·¼ì¹¨ìŠµì„± ë°©ê´‘ì•” í™˜ìì˜ ì•½ ì ˆë°˜ì— í•´ë‹¹í•©ë‹ˆë‹¤. ì €í¬ ì—°êµ¬ì—ëŠ” ì²« ë²ˆì§¸ ìŠ¹ì¸ì´ BCG ë¬´ë°˜ì‘ í™˜ìë¥¼ ëŒ€ìƒìœ¼ë¡œ í–ˆë˜ BCG ê²½í—˜ í™˜ìë“¤ì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë˜í•œ BCG ì¬ë°œ í™˜ìë¥¼ ëŒ€ìƒìœ¼ë¡œ í•œ ì—°êµ¬ë„ ì§„í–‰í•˜ê³  ìˆê³ ìš”. ê·¸ë¦¬ê³  BCGì™€ì˜ ì •ë©´ ëŒ€ê²° 1ì°¨ ì¹˜ë£Œ ì—°êµ¬ë„ ìˆìŠµë‹ˆë‹¤. ì •ë§ ê´‘ë²”ìœ„í•œ ì˜ì—­ì„ ë‹¤ë£¨ê³  ìˆëŠ” ì…ˆì´ì£ .<br><br>ê·¸ë¦¬ê³  ë§¤ë…„ ì•½ 60ë§Œ ëª…ì˜ í™˜ìê°€ ë°©ê´‘ì•”ìœ¼ë¡œ ìƒˆë¡­ê²Œ ì§„ë‹¨ë°›ëŠ”ë‹¤ëŠ” ì ë„ ê¸°ì–µí•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. ê·¸ ì¤‘ 75%ëŠ” ê·¼ìœ¡ ë¹„ì¹¨ìŠµì„± êµ­ì†Œí™” ìƒíƒœì´ê³ , ë˜ ë‹¤ë¥¸ 20%ëŠ” êµ­ì†Œí™”ë˜ì–´ ìˆì§€ë§Œ ê·¼ìœ¡ ì¹¨ìŠµì„±ì…ë‹ˆë‹¤. ì´ ì˜ì—­ì—ì„œë„ ì €í¬ê°€ ì—°êµ¬ë¥¼ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ ë©°ì¹  í›„ ESMO ì»¨í¼ëŸ°ìŠ¤ì—ì„œ ìˆ˜ìˆ  ì „ ë³´ì¡°ìš”ë²•(neoadjuvant) ìƒí™©ì—ì„œ INLEXZOë¥¼ ì €í¬ PD-1 í•­ì²´ì¸ cetrelimabê³¼ ë³‘ìš©í•œ ë°ì´í„°ë¥¼ ë°œí‘œí•  ì˜ˆì •ì…ë‹ˆë‹¤. <br><br>ì´ ë°ì´í„°ì—ì„œëŠ” ì¡°ì§í•™ì ìœ¼ë¡œë‚˜ ë‹¤ë¥¸ ë°©ë²•ìœ¼ë¡œë„ ì§ˆë³‘ì˜ ì¦ê±°ë¥¼ ì „í˜€ ì°¾ì„ ìˆ˜ ì—†ëŠ” ì™„ì „í•œ ìƒíƒœ, ì¦‰ ë³‘ë¦¬í•™ì  ì™„ì „ ê´€í•´(pathological complete response)ë¥¼ ë‹¬ì„±í•˜ëŠ” í™˜ì ë¹„ìœ¨ì„ í›¨ì”¬ ë†’ì¼ ìˆ˜ ìˆë‹¤ëŠ” ê²°ê³¼ë¥¼ ë³´ê³ í•  ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ë¯¸ ê·¼ìœ¡ ì¹¨ìŠµì„± ì§ˆí™˜ì„ ì•“ê³  ìˆì–´ì„œ ê·¸ ìœ„í—˜ìœ¼ë¡œ ì¸í•´ ë°©ê´‘ ì œê±° ìˆ˜ìˆ ì„ ë°›ì•„ì•¼ í•˜ëŠ” í™˜ìë“¤ì—ê²Œ ë” ë‚˜ì€ ê²°ê³¼ë¥¼ ê¸°ëŒ€í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. INLEXZOì˜ ê´‘ë²”ìœ„í•œ ê¸°íšŒë¥¼ ë³´ê³  ìˆìŠµë‹ˆë‹¤. íŠ¹íˆ ëª¨ë“  ì¹˜ë£Œ ë¼ì¸ì— ê±¸ì¹œ ë¹„ê·¼ì¹¨ìŠµì„± ë°©ê´‘ì•”ì—ì„œ ë§ì´ì£ . ê³ ìœ„í—˜ ë¹„ê·¼ì¹¨ìŠµì„± í™˜ìêµ°ì€ ì „ì²´ í™˜ìì˜ ì•½ ì ˆë°˜ì„ ì°¨ì§€í•˜ë©°, ê·¼ì¹¨ìŠµì„± ë°©ê´‘ì•”ì˜ ì¼ë¶€ í™˜ìêµ°ì—ì„œë„ ê¸°íšŒê°€ ìˆìŠµë‹ˆë‹¤.<br><br>ê·¸ë¦¬ê³  ê°•ì¡°í•˜ê³  ì‹¶ì€ ê²ƒì€ ì´ê²ƒì´ ìš°ë¦¬ì—ê²Œ ì¼íšŒì„± ì„±ê³µì‘ì´ ì•„ë‹ˆë¼ëŠ” ì ì…ë‹ˆë‹¤. TAR-210ì´ ë¹ ë¥´ê²Œ ë’¤ë”°ë¥´ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” í™”í•™ìš”ë²• ëŒ€ì‹  í‘œì ì¹˜ë£Œì œì¸ ì—ë¥´ë‹¤í”¼í‹°ë‹™(erdafitinib)ì„ ë°©ì¶œí•˜ëŠ” ì°¨ì„¸ëŒ€ ë””ë°”ì´ìŠ¤ì…ë‹ˆë‹¤. ì´ ì•½ë¬¼ì€ ë°©ê´‘ì•”ì—ì„œ í”íˆ ëŒì—°ë³€ì´ê°€ ë°œìƒí•˜ëŠ” ìˆ˜ìš©ì²´ í‹°ë¡œì‹  í‚¤ë‚˜ì œ(receptor tyrosine kinase)ë¥¼ ì–µì œí•©ë‹ˆë‹¤. ì‹¤ì œë¡œ ë°©ê´‘ì•”ì—ì„œ ë°œìƒí•˜ëŠ” ê°€ì¥ í”í•œ ìœ ì „ì  ëŒì—°ë³€ì´ì…ë‹ˆë‹¤. ì—¬ê¸°ì„œ ìš°ë¦¬ëŠ” 90%ë¥¼ ë„˜ëŠ” ë°˜ì‘ë¥ , ì™„ì „ë°˜ì‘ë¥ ì„ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì°¨ì„¸ëŒ€ ê¸°ê¸°ëŠ” INLEXZOì²˜ëŸ¼ 3ì£¼ê°€ ì•„ë‹ˆë¼ 3ê°œì›” ë™ì•ˆ ì•½ë¬¼ì„ ì¼ì •í•œ ì†ë„ë¡œ ë°©ì¶œí•©ë‹ˆë‹¤. ì•ìœ¼ë¡œ ë” ë§ì€ ì†Œì‹ì´ ìˆì„ ì˜ˆì •ì…ë‹ˆë‹¤. ë°©ê´‘ì•”ì˜ í° ë¯¸ì¶©ì¡± ì˜ë£Œ ìˆ˜ìš”ë¥¼ í•´ê²°í•˜ëŠ” ì´ í”Œë«í¼ì— ëŒ€í•´ ì •ë§ ê¸°ëŒ€ê°€ í½ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question is coming from Matt Miksic from Barclays.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ë°”í´ë ˆì´ì¦ˆì˜ Matt Miksicë¡œë¶€í„° ë‚˜ì™”ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Matthew Miksic: Barclays Bank PLC, Research Division So just a couple of follow-ups. One on just the sequential strength in the quarter, a little bit unusual for a summer quarter. So how much of that do you feel like is the -- I'm speaking of MedTech mostly here, even though pharma was pretty strong also. But just the sequential improvements from -- do you think the market feels stronger? Or was this predominantly you sort of leaning back into competition in some of your core med tech markets? And then just a follow-up on all the discussion about the spin, just if we should think of holding on to MedTech, concentrating on the key businesses that you mentioned, also open the door to sort of, I guess, loosen up the capital structure and balance sheet in such a way to start adding to some of those areas as you get closer to or through the spin?</td><td>**Matthew Miksic:** ëª‡ ê°€ì§€ í›„ì† ì§ˆë¬¸ì´ ìˆìŠµë‹ˆë‹¤. ë¨¼ì € ì´ë²ˆ ë¶„ê¸°ì˜ ìˆœì°¨ì  ê°•ì„¸ì— ëŒ€í•´ì„œì¸ë°, ì—¬ë¦„ ë¶„ê¸°ì¹˜ê³ ëŠ” ë‹¤ì†Œ ì´ë¡€ì ì´ì—ˆìŠµë‹ˆë‹¤. ì£¼ë¡œ ë©”ë“œí…Œí¬(MedTech)ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ëŠ” ê²ƒì´ì§€ë§Œ, ì œì•½ ë¶€ë¬¸ë„ ê½¤ ê°•í–ˆìŠµë‹ˆë‹¤. ìˆœì°¨ì  ê°œì„ ì´ ì–¼ë§ˆë‚˜ ì‹œì¥ì´ ë” ê°•í•´ì¡Œë‹¤ê³  ëŠë¼ì‹œëŠ” ê±´ì§€, ì•„ë‹ˆë©´ ì£¼ë¡œ í•µì‹¬ ë©”ë“œí…Œí¬ ì‹œì¥ì—ì„œ ê²½ìŸì— ë‹¤ì‹œ ì ê·¹ì ìœ¼ë¡œ ë‚˜ì„œì‹  ê²°ê³¼ì¸ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìŠ¤í•€ì˜¤í”„ì— ëŒ€í•œ ëª¨ë“  ë…¼ì˜ì— ëŒ€í•œ í›„ì† ì§ˆë¬¸ì¸ë°ìš”, MedTechì„ ë³´ìœ í•˜ë©´ì„œ ë§ì”€í•˜ì‹  í•µì‹¬ ì‚¬ì—…ì— ì§‘ì¤‘í•˜ëŠ” ê²ƒìœ¼ë¡œ ìƒê°í•´ì•¼ í• ì§€, ê·¸ë¦¬ê³  ì´ê²ƒì´ ì–´ë–¤ ë©´ì—ì„œëŠ” ìë³¸ êµ¬ì¡°ì™€ ëŒ€ì°¨ëŒ€ì¡°í‘œë¥¼ ìœ ì—°í•˜ê²Œ ë§Œë“¤ì–´ì„œ ìŠ¤í•€ì˜¤í”„ì— ê°€ê¹Œì›Œì§€ê±°ë‚˜ ì§„í–‰í•˜ë©´ì„œ ê·¸ëŸ° ì˜ì—­ë“¤ì— íˆ¬ìë¥¼ ëŠ˜ë ¤ê°ˆ ìˆ˜ ìˆëŠ” ë¬¸ì„ ì—´ì–´ì£¼ëŠ” ê²ƒì¸ì§€ìš”?</td></tr>
<tr><td>Joseph Wolk: Executive VP & CFO Matt, thank you for the question. Let me take the first one. What was really attractive about this quarter and built on the tremendous performance in the second quarter was the solid performances across all businesses. And so where you saw that sequential improvement, if you'll recall, our ortho business struggled in the first and second quarter. We saw a nice improvement in Q2. Q3, we returned that business to growth with tremendous performances in categories like hips with 5.1%, knees 5.6%, strong performance in trauma and actually returning to growth in spine. And so Ortho was a major competitor or a major contributor to that performance. And then, of course, we had continued tremendous performances in our fastest-growing category in cardiovascular, solid performances in surgery and acceleration within vision, as I mentioned earlier, driven by our performance primarily in the intraocular space.</td><td>**Joseph Wolk:** ì´ë²ˆ ë¶„ê¸°ì—ì„œ ì •ë§ ë§¤ë ¥ì ì´ì—ˆë˜ ì ê³¼ 2ë¶„ê¸°ì˜ ë›°ì–´ë‚œ ì„±ê³¼ë¥¼ ë°”íƒ•ìœ¼ë¡œ í•œ ê²ƒì€ ëª¨ë“  ì‚¬ì—… ë¶€ë¬¸ì—ì„œì˜ ê²¬ê³ í•œ ì‹¤ì ì´ì—ˆìŠµë‹ˆë‹¤. ìˆœì°¨ì  ê°œì„ ì„ ë³´ì‹  ë¶€ë¶„ì—ì„œ, ê¸°ì–µí•˜ì‹œê² ì§€ë§Œ ì €í¬ ì •í˜•ì™¸ê³¼ ì‚¬ì—…ì´ 1ë¶„ê¸°ì™€ 2ë¶„ê¸°ì— ì–´ë ¤ì›€ì„ ê²ªì—ˆìŠµë‹ˆë‹¤. 2ë¶„ê¸°ì— ì¢‹ì€ ê°œì„ ì„ ë³´ì˜€ê³ , 3ë¶„ê¸°ì—ëŠ” ì´ ì‚¬ì—…ì„ ì„±ì¥ìœ¼ë¡œ ë˜ëŒë ¸ìŠµë‹ˆë‹¤. ê³ ê´€ì ˆ 5.1%, ë¬´ë¦ 5.6%ì™€ ê°™ì€ ì¹´í…Œê³ ë¦¬ì—ì„œ ë›°ì–´ë‚œ ì„±ê³¼ë¥¼ ê±°ë‘ì—ˆê³ , ì™¸ìƒ ë¶„ì•¼ì—ì„œë„ ê°•í•œ ì‹¤ì ì„ ë³´ì˜€ìœ¼ë©° ì‹¤ì œë¡œ ì²™ì¶” ë¶€ë¬¸ë„ ì„±ì¥ìœ¼ë¡œ ëŒì•„ì„°ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì •í˜•ì™¸ê³¼ ì‚¬ì—…ì´ ì´ëŸ¬í•œ ì„±ê³¼ì— ì£¼ìš”í•œ ê¸°ì—¬ë¥¼ í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¬¼ë¡  ì‹¬í˜ˆê´€ ë¶„ì•¼ì—ì„œëŠ” ê°€ì¥ ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠ” ì¹´í…Œê³ ë¦¬ì—ì„œ ì§€ì†ì ìœ¼ë¡œ ë›°ì–´ë‚œ ì„±ê³¼ë¥¼ ê±°ë‘ì—ˆê³ , ìˆ˜ìˆ  ë¶„ì•¼ì—ì„œëŠ” ê²¬ê³ í•œ ì‹¤ì ì„ ë³´ì˜€ìœ¼ë©°, ì•ì„œ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´ ì•ˆê³¼ ë¶„ì•¼ì—ì„œëŠ” ê°€ì†í™”ëœ ì„±ì¥ì„ ì´ë¤˜ìŠµë‹ˆë‹¤. ì´ëŠ” ì£¼ë¡œ ì•ˆë‚´ë Œì¦ˆ ì˜ì—­ì—ì„œì˜ ìš°ìˆ˜í•œ ì„±ê³¼ì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Chairman: Thank you. And overall, as we discussed at the beginning of this call, our focus and priority within MedTech is around our 3 areas, which are Vision, Cardiovascular, in which we already have acquired a number of companies and also robotic surgery, where we are focusing on being able to submit our OTTAVA soft tissue robotic system to the FDA in the first half of 2026. We'll continue to look for opportunities there in order to enhance our portfolio and be able to make our MedTech group the best MedTech group in the industry, which is a clear goal for me and for Johnson & Johnson.</td><td>**CEO & Chairman:** ê°ì‚¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì „ë°˜ì ìœ¼ë¡œ ì´ë²ˆ í†µí™” ì´ˆë°˜ì— ë…¼ì˜í–ˆë“¯ì´, MedTech ë‚´ì—ì„œ ì €í¬ì˜ ì§‘ì¤‘ ë¶„ì•¼ì™€ ìš°ì„ ìˆœìœ„ëŠ” 3ê°œ ì˜ì—­ì…ë‹ˆë‹¤. ë°”ë¡œ Vision, Cardiovascular - ì´ë¯¸ ì—¬ëŸ¬ íšŒì‚¬ë“¤ì„ ì¸ìˆ˜í•œ ë¶„ì•¼ì´ì£  - ê·¸ë¦¬ê³  ë¡œë´‡ ìˆ˜ìˆ  ë¶„ì•¼ì…ë‹ˆë‹¤. ë¡œë´‡ ìˆ˜ìˆ ì—ì„œëŠ” 2026ë…„ ìƒë°˜ê¸°ì— OTTAVA ì—°ì¡°ì§ ë¡œë´‡ ì‹œìŠ¤í…œì„ FDAì— ì œì¶œí•˜ëŠ” ê²ƒì— ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì €í¬ëŠ” í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ê°•í™”í•˜ê³  MedTech ê·¸ë£¹ì„ ì—…ê³„ ìµœê³ ì˜ MedTech ê·¸ë£¹ìœ¼ë¡œ ë§Œë“¤ê¸° ìœ„í•´ ê³„ì†í•´ì„œ ê¸°íšŒë¥¼ ëª¨ìƒ‰í•  ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ì €ì™€ Johnson & Johnsonì˜ ëª…í™•í•œ ëª©í‘œì…ë‹ˆë‹¤.</td></tr>
<tr><td>Darren Snellgrove: Vice President of Investor Relations We have time for one last question.</td><td>**Darren Snellgrove:** ë§ˆì§€ë§‰ ì§ˆë¬¸ì„ í•˜ë‚˜ ë” ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our final question today is coming from David Risinger from Leerink.</td><td>**Operator:** ì˜¤ëŠ˜ ë§ˆì§€ë§‰ ì§ˆë¬¸ì€ ë¦¬ì–´ë§í¬ì˜ ë°ì´ë¹„ë“œ ë¦¬ì‹±ê±°ë‹˜ê»˜ì„œ ì£¼ì‹¤ ì˜ˆì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>David Risinger: Leerink Partners LLC, Research Division Congrats on the performance. So my question is on icotrokinra. I'm curious about how you plan to position it relative to TREMFYA given the similar indications for the 2 therapies.</td><td>**David Risinger:** Leerink Partners LLC, Research Divisionì˜ ì‹¤ì ì— ëŒ€í•´ ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. ì œ ì§ˆë¬¸ì€ ì´ì½”íŠ¸ë¡œí‚¤ë‚˜ì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. ë‘ ì¹˜ë£Œì œê°€ ìœ ì‚¬í•œ ì ì‘ì¦ì„ ê°€ì§€ê³  ìˆëŠ” ìƒí™©ì—ì„œ TREMFYA ëŒ€ë¹„ ì´ì½”íŠ¸ë¡œí‚¤ë‚˜ë¥¼ ì–´ë–»ê²Œ í¬ì§€ì…”ë‹í•  ê³„íšì¸ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Jennifer Taubert: Executive VP & Worldwide Chairman of Innovative Medicine Great. Thanks. And we are really excited about the opportunity for icotrokinra and see this as one of our next big $5 billion-plus brands. And so why are we excited about it? So we believe it's really going to set the new standard of care in the treatment of plaque psoriasis, and that will be the first indication, unprecedented combination of complete skin clearance and a favorable safety profile with the simplicity of an oral pill. We're really, really confident in what we've seen. And so not only are we studying it versus other orals, we're actually studying it head-to-head versus STELARA. And no oral agents have been able to really compete with that combination of both biologic-like efficacy and that known safety profile. And so we're really bullish. If you take a look at the market, despite today's treatments, there's still less than 30% of eligible patients who have moderate to severe psoriasis who are receiving advanced treatments. And so we think there is a significant market expansion opportunity to be able to bring patients into advanced therapies into that frontline setting. So we think there's a opportunity there. We think as we move closer to the launches with the way the profiles are differentiating, there will be a unique and distinct position for icotrokinra and also a distinct and unique position for TREMFYA that will allow us to have both really continued significant growth on both assets, particularly given the high level of unmet need in the market. So more to come on that. I'm not going to give away everything on the positioning, but we think that there are really distinct places that they're going to play. Ico is going to be a really significant asset for us, and you can see how well TREMFYA is doing with the 40% growth that we achieved this quarter.</td><td>**Jennifer Taubert:** ì •ë§ ê°ì‚¬í•©ë‹ˆë‹¤. ì €í¬ëŠ” ì´ì½”íŠ¸ë¡œí‚¤ë‚˜(icotrokinra)ì˜ ê¸°íšŒì— ëŒ€í•´ ë§¤ìš° í¥ë¶„í•˜ê³  ìˆìœ¼ë©°, ì´ë¥¼ ë‹¤ìŒ 50ì–µ ë‹¬ëŸ¬ ì´ìƒ ê·œëª¨ì˜ ì£¼ìš” ë¸Œëœë“œ ì¤‘ í•˜ë‚˜ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì™œ ì´ë ‡ê²Œ ê¸°ëŒ€í•˜ê³  ìˆì„ê¹Œìš”? ì €í¬ëŠ” ì´ ì•½ë¬¼ì´ íŒìƒ ê±´ì„  ì¹˜ë£Œì˜ ìƒˆë¡œìš´ í‘œì¤€ì„ ì œì‹œí•  ê²ƒì´ë¼ê³  ë¯¿ê³  ìˆìœ¼ë©°, ì´ê²ƒì´ ì²« ë²ˆì§¸ ì ì‘ì¦ì´ ë  ê²ƒì…ë‹ˆë‹¤. ì™„ì „í•œ í”¼ë¶€ ê°œì„ ê³¼ ìš°ìˆ˜í•œ ì•ˆì „ì„± í”„ë¡œíŒŒì¼, ê·¸ë¦¬ê³  ê²½êµ¬ìš© ì•Œì•½ì˜ ê°„í¸í•¨ì´ë¼ëŠ” ì „ë¡€ ì—†ëŠ” ì¡°í•©ì„ ì œê³µí•©ë‹ˆë‹¤. ì§€ê¸ˆê¹Œì§€ í™•ì¸í•œ ê²°ê³¼ì— ëŒ€í•´ ì •ë§ë¡œ í™•ì‹ í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ê·¸ë˜ì„œ ì €í¬ëŠ” ë‹¤ë¥¸ ê²½êµ¬ìš© ì•½ë¬¼ë“¤ê³¼ì˜ ë¹„êµ ì—°êµ¬ë¿ë§Œ ì•„ë‹ˆë¼, ì‹¤ì œë¡œ ìŠ¤í…”ë¼ë¼(STELARA)ì™€ì˜ ì§ì ‘ ë¹„êµ ì—°êµ¬ë„ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì§€ê¸ˆê¹Œì§€ ì–´ë–¤ ê²½êµ¬ìš© ì•½ë¬¼ë„ ìƒë¬¼í•™ì  ì œì œ ìˆ˜ì¤€ì˜ íš¨ëŠ¥ê³¼ ì…ì¦ëœ ì•ˆì „ì„± í”„ë¡œíŒŒì¼ì˜ ì¡°í•©ì„ ì œëŒ€ë¡œ êµ¬í˜„í•˜ì§€ ëª»í–ˆìŠµë‹ˆë‹¤. ì •ë§ ë‚™ê´€ì ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì‹œì¥ì„ ì‚´í´ë³´ë©´, í˜„ì¬ì˜ ì¹˜ë£Œë²•ë“¤ì—ë„ ë¶ˆêµ¬í•˜ê³  ì¤‘ë“±ë„ì—ì„œ ì¤‘ì¦ ê±´ì„ ì„ ì•“ê³  ìˆëŠ” ì ê²© í™˜ì ì¤‘ 30% ë¯¸ë§Œë§Œì´ ì§„ë³´ëœ ì¹˜ë£Œë¥¼ ë°›ê³  ìˆëŠ” ìƒí™©ì…ë‹ˆë‹¤. ë”°ë¼ì„œ í™˜ìë“¤ì„ ì§„ë³´ëœ ì¹˜ë£Œë²•ìœ¼ë¡œ, íŠ¹íˆ 1ì°¨ ì¹˜ë£Œ í™˜ê²½ìœ¼ë¡œ ëŒì–´ë“¤ì¼ ìˆ˜ ìˆëŠ” ìƒë‹¹í•œ ì‹œì¥ í™•ì¥ ê¸°íšŒê°€ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤.<br><br>ì¶œì‹œê°€ ê°€ê¹Œì›Œì§€ë©´ì„œ í”„ë¡œíŒŒì¼ë“¤ì´ ì°¨ë³„í™”ë˜ëŠ” ë°©ì‹ì„ ë³´ë©´, ì•„ì´ì½”íŠ¸ë¡œí‚¤ë‚˜(icotrokinra)ëŠ” ë…íŠ¹í•˜ê³  ëšœë ·í•œ í¬ì§€ì…˜ì„ ê°€ì§ˆ ê²ƒì´ê³ , TREMFYA ì—­ì‹œ êµ¬ë³„ë˜ê³  ë…íŠ¹í•œ í¬ì§€ì…˜ì„ í™•ë³´í•  ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ë‘ ìì‚° ëª¨ë‘ì—ì„œ ì§€ì†ì ì´ê³  ìƒë‹¹í•œ ì„±ì¥ì„ ì´ì–´ê°ˆ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. íŠ¹íˆ ì‹œì¥ì—ì„œ ì¶©ì¡±ë˜ì§€ ì•Šì€ ë‹ˆì¦ˆê°€ ë†’ì€ ìˆ˜ì¤€ì´ë¼ëŠ” ì ì„ ê³ ë ¤í•˜ë©´ ë”ìš± ê·¸ë ‡ìŠµë‹ˆë‹¤. ì´ì— ëŒ€í•´ì„œëŠ” ì¶”í›„ ë” ìì„¸íˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í¬ì§€ì…”ë‹ì— ëŒ€í•´ ëª¨ë“  ê²ƒì„ ê³µê°œí•  ìˆ˜ëŠ” ì—†ì§€ë§Œ, ì´ ë‘ ì œí’ˆì´ ì •ë§ ëšœë ·í•˜ê²Œ êµ¬ë¶„ë˜ëŠ” ì˜ì—­ì—ì„œ ì—­í• ì„ í•  ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. IcoëŠ” ì €í¬ì—ê²Œ ì •ë§ ì¤‘ìš”í•œ ìì‚°ì´ ë  ê²ƒì´ë©°, ì´ë²ˆ ë¶„ê¸°ì— ë‹¬ì„±í•œ 40% ì„±ì¥ë¥ ì„ ë³´ì‹œë©´ TREMFYAê°€ ì–¼ë§ˆë‚˜ ì˜í•˜ê³  ìˆëŠ”ì§€ ì•„ì‹¤ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>John Reed: Executive Vice President of Innovative Medicine, R&D David, keep your eyes open. We have more publications coming out on our icotrokinra data, 2 back-to-back papers in press at the New England Journal of Medicine, describing the placebo-controlled studies and then a paper in press at the Lancet showing our head-to-head against the leading TYK2 inhibitor in psoriasis. So exciting times for that really novel targeted oral peptide for the autoimmune diseases where the IL-23 class plays.</td><td>**John Reed:** í˜ì‹ ì˜í•™ ì—°êµ¬ê°œë°œ ë‹´ë‹¹ ë¶€ì‚¬ì¥ ë°ì´ë¹„ë“œ, ê³„ì† ì£¼ëª©í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. ì €í¬ ì´ì½”íŠ¸ë¡œí‚¤ë‚˜ ë°ì´í„°ì— ëŒ€í•œ ì¶”ê°€ ë…¼ë¬¸ë“¤ì´ ê³§ ë°œí‘œë  ì˜ˆì •ì…ë‹ˆë‹¤. ë‰´ì‰ê¸€ëœë“œ ì˜í•™ì €ë„(New England Journal of Medicine)ì— ì—°ì†ìœ¼ë¡œ 2í¸ì˜ ë…¼ë¬¸ì´ ê²Œì¬ ì˜ˆì •ì¸ë°, ìœ„ì•½ ëŒ€ì¡° ì—°êµ¬ë“¤ì„ ë‹¤ë£¬ ë…¼ë¬¸ê³¼ ê±´ì„ ì—ì„œ ì£¼ìš” TYK2 ì–µì œì œì™€ì˜ ì§ì ‘ ë¹„êµ ì—°êµ¬ë¥¼ ë‹¤ë£¬ ëœì‹¯(Lancet) ë…¼ë¬¸ì´ ìˆìŠµë‹ˆë‹¤. IL-23 ê³„ì—´ì´ ì‘ìš©í•˜ëŠ” ìê°€ë©´ì—­ì§ˆí™˜ì„ ìœ„í•œ ì´ ì •ë§ í˜ì‹ ì ì¸ í‘œì  ê²½êµ¬ í©íƒ€ì´ë“œì— ìˆì–´ì„œ ë§¤ìš° í¥ë¯¸ì§„ì§„í•œ ì‹œê¸°ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Darren Snellgrove: Vice President of Investor Relations Thanks, David, and thanks to everyone for your questions and interest in J&J. Please reach out to the Investor Relations team with any remaining questions you have. I will now turn the call over to Joaquin for some brief closing remarks.</td><td>**Darren Snellgrove:** ê°ì‚¬í•©ë‹ˆë‹¤, David. ê·¸ë¦¬ê³  J&Jì— ëŒ€í•œ ì§ˆë¬¸ê³¼ ê´€ì‹¬ì„ ë³´ì—¬ì£¼ì‹  ëª¨ë“  ë¶„ë“¤ê»˜ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ì¶”ê°€ ì§ˆë¬¸ì´ ìˆìœ¼ì‹œë©´ íˆ¬ìì ê´€ê³„íŒ€ì— ì–¸ì œë“ ì§€ ì—°ë½í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. ì´ì œ ê°„ë‹¨í•œ ë§ˆë¬´ë¦¬ ë§ì”€ì„ ìœ„í•´ Joaquinì—ê²Œ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>CEO & Chairman: Thank you all of you for joining the call today. As you heard, we have had a very strong third quarter. We have sharpened focus around our 6 priority areas of oncology, immunology, neuroscience, cardiovascular, surgery and vision, and we are in a period of accelerated growth with innovation and pioneering treatments that are going to transform lives. Thank you for your interest in Johnson & Johnson, and enjoy the rest of your day.</td><td>**CEO & Chairman:** ì˜¤ëŠ˜ ì½œì— ì°¸ì—¬í•´ ì£¼ì‹  ëª¨ë“  ë¶„ë“¤ê»˜ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´ 3ë¶„ê¸° ì‹¤ì ì´ ë§¤ìš° ê°•ë ¥í–ˆìŠµë‹ˆë‹¤. ì¢…ì–‘í•™, ë©´ì—­í•™, ì‹ ê²½ê³¼í•™, ì‹¬í˜ˆê´€, ìˆ˜ìˆ , ê·¸ë¦¬ê³  ì‹œë ¥ ë¶„ì•¼ë¼ëŠ” 6ê°œ ìš°ì„  ì˜ì—­ì— ì§‘ì¤‘ë„ë¥¼ ë†’ì˜€ìœ¼ë©°, ì‚¶ì„ ë³€í™”ì‹œí‚¬ í˜ì‹ ì ì´ê³  ì„ êµ¬ì ì¸ ì¹˜ë£Œë²•ë“¤ê³¼ í•¨ê»˜ ê°€ì†í™”ëœ ì„±ì¥ ì‹œê¸°ì— ìˆìŠµë‹ˆë‹¤. ì¡´ìŠ¨ì•¤ë“œì¡´ìŠ¨ì— ëŒ€í•œ ê´€ì‹¬ì— ê°ì‚¬ë“œë¦¬ë©°, ë‚¨ì€ í•˜ë£¨ ì¢‹ì€ ì‹œê°„ ë³´ë‚´ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Thank you. This concludes today's Johnson & Johnson's Third Quarter 2025 Earnings Conference Call. You may now disconnect.</td><td>**Operator:** ê°ì‚¬í•©ë‹ˆë‹¤. ì´ê²ƒìœ¼ë¡œ ì˜¤ëŠ˜ ì¡´ìŠ¨ì•¤ì¡´ìŠ¨ì˜ 2025ë…„ 3ë¶„ê¸° ì‹¤ì  ì»¨í¼ëŸ°ìŠ¤ ì½œì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ì´ì œ ì—°ê²°ì„ ëŠìœ¼ì…”ë„ ë©ë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;">Here's a summary of the key points from the earnings call transcript in Korean:<br><br>â€¢ ì£¼ìš” ì „ëµì  ë³€í™”:<br>- ì •í˜•ì™¸ê³¼ ì‚¬ì—…ë¶€(DePuy Synthes) ë¶„ì‚¬ ê³„íš ë°œí‘œ<br>- í–¥í›„ 18-24ê°œì›” ë‚´ ì™„ë£Œ ì˜ˆì •<br>- ë¶„ì‚¬ í›„ J&Jì˜ ì„±ì¥ë¥ ê³¼ ë§ˆì§„ ê°œì„  ì „ë§<br><br>â€¢ ì‹¤ì  í•˜ì´ë¼ì´íŠ¸:<br>- í˜ì‹ ì˜ì•½í’ˆ ë¶€ë¬¸ STELARA ì œì™¸ ì‹œ 16% ì„±ì¥<br>- ë©”ë“œí…Œí¬ ë¶€ë¬¸ ì „ë°˜ì  ì„±ì¥ì„¸ (ì‹¬í˜ˆê´€, ìˆ˜ìˆ , ì•ˆê³¼ ë“±)<br>- 11ê°œ ì£¼ìš” ë¸Œëœë“œì—ì„œ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ë¥  ë‹¬ì„±<br><br>â€¢ í–¥í›„ ì „ë§:<br>- 2026ë…„ê¹Œì§€ 5% ì´ìƒì˜ ë§¤ì¶œ ì„±ì¥ ì˜ˆìƒ<br>- ëŒ€ê·œëª¨ M&A ì—†ì´ë„ ë†’ì€ ì„±ì¥ ëª©í‘œ ë‹¬ì„± ê°€ëŠ¥<br>- ì‹ ì œí’ˆ íŒŒì´í”„ë¼ì¸ì„ í†µí•œ ì§€ì†ì  ì„±ì¥ ë™ë ¥ í™•ë³´<br><br>â€¢ ë¦¬ìŠ¤í¬/ê¸°íšŒ ìš”ì¸:<br>- STELARA íŠ¹í—ˆ ë§Œë£Œì— ë”°ë¥¸ ì˜í–¥ ì§€ì†<br>- ì‹ ì œí’ˆ ì¶œì‹œì™€ íŒŒì´í”„ë¼ì¸ ê°•í™”ë¡œ ì„±ì¥ ëª¨ë©˜í…€ ìœ ì§€<br>- ì •ë¶€ ì •ì±…(ì•½ê°€ ë“±)ì— ëŒ€í•œ ì§€ì†ì  ëŒ€ì‘ í•„ìš”</p>
    <hr style="margin:50px 0;">
    
</body></html>